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Abstract 
Epigenetics and post-translational modifications (PTMs) are processes which 
contribute to the activation and deactivation of tumour development and cancer cell 
proliferation. ENCODE is a database incorporating all of the found modifications 
lying on the genome. Currently, a huge gap in the literature exists which proves that 
histone modifications are significantly underrepresented within cancer research. This 
gap is due to the lack of methods available for analysis of clinical samples. 
Chromatin immunoprecipitation (ChIP) is a vastly used technique however, it holds 
many limitations. This thesis describes a protocol which can be used to successfully 
identify the presence of PTMs of proteins from samples containing as little as 1,000-
10,000 cells. By using carrier cells from d.melanogaster, target cells can be input into 
the solution and immunoprecipitated side by side. Results showed that by treating 
carriers with UV light in specific conditions, it is possible to inhibit the PCR 
amplification of the carrier cells 200 fold while still retaining carrier qualities. The 
treated cells were tested for their carrier and inhibition abilities where, it was proved 
that a successful ChIP can be carried out after treatment. Carrier cell inhibition 
provides an opportunity for subsequent analysis via high throughput sequencing, in 
turn producing more reliable and in depth results. This protocol could aid in the 
identification of new drug targets during pharmaceutical drug development. 
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1. Introduction 
1.1 Epigenetics 
1.1.1 The Nucleosome 
The human genome project launched in 1990, 13 years later researchers had 
sequenced the 3 billion base pairs in all 23 diploid chromosomes. These 3 billion 
base pairs are found within all of the 50 trillion cells which form the human 
body.  Each base pair is known to be 0.34 nanometers long, therefore each cell 
contains about 2 meters of ravelled DNA. With 50 trillion cells each encompassing 
around 2 meters of DNA, the human DNA component is long enough to stretch to 
the Sun and back more than 300 times. An intelligent packaging system, known as 
the nucleosome, was first imaged by Klug et al. in 1980, it comprises 2 copies each 
of the core histone proteins; H2A, H2B, H3 and H4. Together, these proteins 
constitute the histone octamer by which 147 base pairs of DNA is wrapped (Lugar et 
al. 1997). DNA is wrapped 1 ¾ times around the octamer in a left-handed turn, kept 
in place by histone H1, also known as the ‘linker’ histone. The idea of a ‘linker’ 
histone acting as the locking complex between the core octamer and DNA was 
recognized initially by Varshavshy et al. (1976). To add to the complexity of the 
packaging system, an arginine and lysine rich tail is located at the N-terminus of the 
core histones. While these tails may not largely impact the nucleosome structure 
they play a significant role in signalling, this role is interchangeable depending on the 
type and location of modification. 
Not only is the nucleosome considered a packaging molecule accommodating 100 
trillion meters of DNA within the human body, it also bares the capacity to covalently 
bind with chemical groups, in turn resulting in reversible changes to gene 
expression. By supporting or suppressing chromatin compaction the nucleosome 
can control promoter and enhancer access and moderate regulator binding. In 
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addition, the nucleosome can be used as a regulator with the accumulation of certain 
proteins which can also dictate the fate of regulator binding and gene expression. 
Histone modifications are molecular changes to the histone, the most notable being 
methylation, acetylation and phosphorylation. The ‘epigenetic code’ is a continuation 
of post translation modifications through mitosis to daughter cells (Turner 2000). This 
epigenetic code has many layers, initially the modification is put into place via 
enzymes, most of which are specific to a modification, i.e. KATs are enzymes which 
target lysine residues to acetylate, the acetylation domain is known as a ‘writer’. 
Since these modifications are dynamic, ‘erasers’ exist which remove this 
modification, i.e. HDACs remove the acetyl group on an acetylated histone residue. 
And finally, the readers, are domains on the effectors which provide an accessible 
area to accommodate this modified residue, i.e. the methylation of lysine 3 on 
histone 9 provides a surface area specific for the binding of the protein HP1 (Yun et 
al. 2011) 
1.1.2 Acetylation 
Histones have been thought to play a significant role in signalling since before the 
nucleosome was first imaged (Klug et al. 1980). Pogo et al. (1966) recognised the 
positive correlation between histone acetylation and RNA synthesis by using 
phytohemaglutinin (PHA), a protein isolated from the red kidney bean. They 
concluded that acetylation alters the fine structure of chromatin, therefore loosening 
the grip of the negatively charged DNA allowing for more fluent binding of 
transcription factors (Jiang et al. 2011). Di-acetylation is the double acetylation of a 
residue, the addition of each acetyl group will incur a resulting increase in negative 
charge on the nucleosome structure making the DNA more accessible.  
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Histone acetylation is a dynamic and reversible reaction which can be catalysed by 
enzymes known as histone acetyltransferases (HATs). There are 2 main HAT 
groups, GNAT and MYST. The MYST family of proteins are highly conserved 
throughout human and yeast entities, they comprise of 5 main proteins: Moz, Qkf, 
Mof, TIP60 and Hbo (Thomas and Voss 2007, Zhang et al. 2014). The GNAT 
enzyme family is a huge group of enzymes named after the founding GCN5 enzyme 
(GCN5-related N-acetyltransferase), over 10,000 have been identified throughout all 
kingdoms (Vetting et al. 2004).  
Histone acetylation can also be reversed by histone deacetylases (HDACs), the 
deacetylation of histones is just as important for gene regulation as acetylation. 
There are currently 18 known HDACs in mammalian cells which have been grouped 
in to class I, II, III and IV, characterised this way because of their similarities to 
various yeast proteins (summarised in Delcuve et al. 2012). Class I, II and IV are all 
part of the classical HDAC family and are zinc (Zn2+) dependant. Class III however, 
consists of seven Sir2 (sirtuin) proteins with NAD+ dependant reactions. HATs and 
HDACs work in partnership to control the levels of histone acetylation in the cell 
nucleus.  
The second line of regulation is in what is known to be the ‘readers’, they are 
domains within proteins which specifically identify and bind to modified residues. 
Although the HAT and HDAC enzymes catalyse the acetyl transfer reactions, 
another domain can be found in most HATs which recognises the residue which 
needs to be acetylated, thereby ensuring a secure acetylation pattern.  
Generally, but not exclusively, acetylation targets lysine residues, however Tweedie-
Cullen et al. (2012) identified 58 never-before-described modifications including 
acetylation and di-acetylation of serine’s and threonine’s. In a publication entitled 
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“Histone acetylation and epigenetic code” (Turner 2000) lysine acetylation was 
named as being the most common, well understood and significant amongst all the 
post translational modifications.  
1.1.3 Methylation 
Histone methylation was first described 40 years ago by Murray (1964) and, along 
with acetylation, first identified as a post translation modification by Allfrey et al. later 
in 1964. Since its discovery vast research has elucidated numerous biological 
functions, mechanisms and molecular interactions by which histone methylation can 
occur. Histone methylation, unlike acetylation, does not have a direct effect on 
chromatin structure, i.e. DNA-histone affinity is left unchanged because methyl 
groups are neutrally charged. Another difference between methylation and 
acetylation is that lysine residues are capable of being methylated multiple times, in 
a mono-, di- and tri-methylated state. The main two residues affected by methylation 
are lysine and arginine; histidine methylation also occurs but is less common and not 
as well understood. Methylation is a broadly studied histone modification, despite 
this there is no definitive outcome which can summarise its effects. For example, tri-
methylation of lysine 27 on histone 3 (H3K27me3) is associated with gene silencing, 
H3K4me3 however, is known to be linked with active transcription (Cao et al. 2002, 
Bernstein et al. 2005).  
Methylation has two lines of regulation: firstly, the histone tail residue must be 
methylated. There are numerous enzymes involved in the methylation and 
demethylation of both arginine and lysine, each with a different purpose. 
Methyltransferases are enzymes which catalyse the relocation of one methyl group 
from the donor, usually S-adenosyl-L-methionine (SAM), to a substrate. There are 
currently thought to be 208 proteins with the potential to act as a catalyst for this 
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reaction (Petrossian and Clarke 2011). KMTs or lysine methyltransferases are lysine 
specific transfer enzymes, most KMTs carry a SET domain which is the fundamental 
factor when signalling to the lysine on the histone tail (Dillon et al. 2005). 8 families 
of KMT have been identified, all except one contain a SET domain (Feng et al. 
2002).  
Until the identification of histone demethylases by Shi et al. (2004), histone 
methylation was considered to be a permanent post-translational modification where, 
in order to remove the modification the histone tails were cut or the entire histone 
was replaced. Shi et al. (2004) identified the first demethylase known as Lysine-
specific Demethylase 1 (KDM1), a flavin adenine dinucleotide (FAD)-dependant 
amine oxide reaction (Cloos et al. 2008). However, this enzyme family require a 
protonated methyl ε-ammonium group to catalyse this reaction, since trimethylated 
lysines do not hold this additional hydrogen atom this family is only suitable for the 
demethylation of mono- and di- methylated lysines. Further research discovered a 
subfamily of enzymes from 2-oxoglutarate (2OG) enzymes are capable of 
demethylating trimethylated histone residues via a hydroxylation reaction. This 
subgroup of the 2OG enzymes contains a JmjC catalytic domain and produces the 
demethylation action with Fe (II) and α-ketoglutarate (αKG) as cofactors (Klose et al. 
2006). The third demethylation family, Petidylarginine deiminase 4, PADI4, doesn’t 
demethylate arginine in the typical manor, but deimminates the methyl-arginine to 
citrulline thereby removing the methyl group (Cuthbert et al. 2004).  
The second line of regulation are the recognition domains, or ‘readers’ found within 
the methyl transfer enzymes. The outcomes associated with histone methylation are 
pre-determined according the domain associated with that region. Once the proteins 
are bound they produce a signal calling for enhancers, promoters and other 
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effectors, thereby regulating transcription. The domains required for lysine or 
arginine interaction differ, methylated lysine residues are recognised by with 
Chromo-, Plant Homeo-, Malignant Brain Tumour- (MBT) and Tudor-domains. 
Similarly the domain family associated with arginine binding are the bromodomains, 
whereas phosphorylationis recognised by the 14-3-3 containing proteins (Izzo and 
Scneider 2011).  
1.2 Examples of Well Studied Histone Modifications 
Many histone modifications have been identified throughout the genome, each 
having a resulting effect on gene regulation and expression. In brief, the methylation 
of lysine 9 on histone 3 (H3K9me) is a heterochromatin mark (Bannister et al. 2001). 
In contrast to H3K9me and H3K9me3, acetylation of lysine 9-histone 3 (H3K9ac) and 
lysine 4 (H3K4ac) will provide a hallmark note of gene activation (Tjeertes et al. 
2009). The methylation of lysine 4 on histone 3 (H3K4me) is uniformly known as an 
active chromatin marker (Flanagan et al. 2005). Acetylation of lysine 56 on histone 3 
(H3K56ac) has also been suggested to be required for repair of DNA breaks during 
replication (Yuan et al. 2009). 
Heterochromatin Protein 1 (HP1) selectively binds to H3K9me, it is the protein 
responsible for mediating gene silencing at heterochromatin (Fischle et al. 2005). 
The chromo domain located in HP1 recognises the methyl group on K9 as a ‘marker’ 
for binding. Methylation is catalysed by the SET domain within the Histone-lysine N-
methyltransferase, SUV39H1 (Aagaard et al. 2000). Once SUV39H1 methylates the 
residue it signals for HP1 to bind where it is used as a transcriptional repressor.  
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1.2.1 Histone Crosstalk 
Histone crosstalk is a mechanism by which histone modifications are enzymatically 
put into place and in turn have impact upon other potential modifications. An 
example of how this can occur is by substrate competition, catalyst inhibition, and by 
interfering with the space around it (Turner 2000). Histone crosstalk plays a 
fundamental part in gene regulation for example, cross talk occurs between 
H3S10ph and H3K9me1/2/3 during M phase. As previously mentioned, 
H3K9me1/2/3 are all uniform marks of heterochromatin, during M phase of the cell 
cycle certain heterochromatin marks have to be removed, therefore displacing the 
HP1 protein. Since the protein is already bound to the methyl marker a reaction must 
occur in order to dissociate this complex. Phosphorylation of Serine 10 on histone 3 
(H3S10ph) is the mechanism by which HP1 can be removed. The kinase enzyme 
Aurora B is activated by factors within the chromosomal passenger complex (CPC), 
once active Aurora B has the catalytic capacity to phosphorylate H3S10. A study by 
Fischle et al. (2005) identified that phosphorylation of H3S10 inhibited the binding 
capacity of HP1 to H3K9me3. By mutating 3 aromatic amino acids in the 
chromodomain of HP1 Fischle et al. produced evidence that H3S10ph is the sole 
inhibitor of the HP1 chromodomain-H3K9me3 complex. Furthermore, they also found 
that H3S10 is not present during interphase of the cell cycle explaining how the HP1-
H3K9me3 complex is restored during this time. By initiating H3S10ph, chromatin can 
keep its form and such modification can be passed on to daughter cells, if the 
mechanism were to merely remove the methylation from site it would mean a high 
risk methylation reformation when the cell comes through the other side of M phase, 
therefore leaving chromatin open for replication errors, and consequently, 
detrimental effects upon the organism. 
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1.3 Chromatin Immunopreciptation  
In 1978 Vaughn Jackson (Jackson 1978) published a paper identifying what would 
become a ground breaking technique in molecular biology. Chromatin 
immunoprecipitation is a comparative technique using antibodies to bind to proteins 
on specific locations in the genome, it assesses where in the genome histone 
modifications occur and where non-histone proteins bind. The chromatin 
immunoprecipitation (ChIP) protocol has since been used for the mapping of 
numerous post-translational modifications. Modification and manipulation of the ChIP 
protocol have enabled more effective nucleosome digestion, use with small cell 
numbers and with or without protein cross-linking (Jackson 1978, Hebbes 1988, 
Gilmour and Lis 1985, O’Neil et al. 2006); it has also been used in conjunction with 
other techniques, e.g. Microarray (ChIP-chip); this partnership creates a more global 
view of DNA- protein binding (Lee et al. 2006).  
Firstly, chromatin must be extracted, there are various ways in which this can be 
achieved. The native ChIP (NChIP) chromatin preparation involves the breakdown of 
cells via homogenisation and nucleosome digestion with micrococcal nucleases 
(O’Neil and Turner 2003). X-ChIP chromatin preparation is a method using 
formaldehyde as a cross-linking agent prior to nucleosome fragmentation via 
sonication (Jackson 1978); cross-linking can also be achieved by exposure to a UV 
source (Gilmour and Lis 1985). Other successful methods are worth mentioning to 
demonstrate the versatility of ChIP, Bauer et al. (2002) used a combination of 
formaldehyde cross linking followed by micrococcal nuclease digestion. Secondly, by 
binding antibodies to proteins found on the genome it is possible to isolate protein-
bound DNA regions. Once again, there are various methods for immunoprecipitation 
depending on the chromatin preparation protocol used. Beads are bound to 
antibodies, introduction of the antibody-bound-beads to the chromatin gives the 
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opportunity for the antibodies to bind to their complimentary modifications. The 
output chromatin, or ‘pull-down’, can be taken on for further analysis with q-PCR, 
microarray and high throughput sequencing.  
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Figure 1.1 A figure to illustrate the main steps involved in carrier-ChIP for both native and formaldehyde 
crosslinked chromatin preparation 
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1.3.1 Native Chromatin Immunoprecipitation (N-ChIP) 
Unlike X-ChIP, the native chromatin immunoprecipitation (N-ChIP) technique as first 
published by Hebbes et al. (1988) does not require any cross-linking. It is therefore 
only effective on histone proteins or other proteins that bind DNA with extremely high 
affinity. Nucleosome digestion or fragmentation is achieved using the enzyme 
micrococcal nuclease (MNase), polynucleosomal strands become mono-, di- and tri-
nucleosomal segments or variably (yet reproducibly) bigger (concentration and 
duration dependant). The nuclease family are a group of enzymes which cut the 
phosphodeister bonds between nucleotides in a DNA or RNA sequence. MNase 
specifically is a ribo-, deribo-, endo-, exonuclease enzyme isolated from 
Staphylococcus aureus, which cuts chromatin at the linker strands between 
nucleosomes (Heins et al. 1966).  
N-ChIP holds many advantages in identifying histone modifications compared to 
other ChIP techniques. N-ChIP provides a higher antibody specificity as micrococcal 
nuclease digestion is not as harsh as sonication (the fragmentation method used in 
X-ChIP) and does not chemically modify the histone tail as fixation does. Enzymatic 
fragmentation will leave the histone tails intact allowing for more efficient antibody 
binding, whereas when sonication is used to fragment the nucleosome, histone tails 
are damaged leading to fewer tails to bind to and in turn, decreased pulldown 
efficiency. In addition, DNA and protein output can be analysed leading to a more 
efficient precipitation; moreover, output DNA can be analysed without the use of 
PCR amplification (O’Neil and Turner 2003). However it has a major disadvantage, 
due to the nature of the protocol it is not possible to analyse non-histone proteins 
because non-histone proteins do not exert the same affinity to the post-translation 
modification as histones, therefore another technique is needed for these non-
histone proteins. Additionally, the nucleosomes have the ability to rearrange during 
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nuclease digestion which can cause detrimental effects on further analysis. 
Furthermore, nuclease digestion is known to be somewhat selective potentially 
causing bias in the input chromatin. 
1.3.2 Cross-linked Chromatin Immunoprecipitation 
Cross-linked chromatin immunoprecipitation (X-ChIP) was the first method of ChIP to 
be developed, Jackson (1978) initially identified the use of formaldehyde as the 
optimal cross-linking agent. Due to the small size (just four atoms) and simple 
molecular structure it is easy for the formaldehyde (CH2O, otherwise known as 
methanal) to infiltrate the cell, following absorption covalent bonds are formed 
between proteins, DNA, RNA etc (Sunderland et al., 2008). The small size of the 
formaldehyde molecule means that only residues that are in close proximity to one 
another can be cross-linked, hence why it is the chosen chemical for protein-protein 
interactions, fig. 1.1. This theory has been utilised and broadly studied in order to 
bring about a more refined X-ChIP protocol. Cross-linking can also be achieved by 
using UV radiation, Gilmour and Lis (1985) used this technology as an alternative to 
the carcinogen formaldehyde, their results showed a cross-linking productivity of one 
protein molecule per 60kb. Following this, nucleosome fragmentation is achieved 
using sonication, a process which uses high energy sound waves to break down the 
nucleosomes into smaller sequences. However, sonication is not a reproducible way 
of obtaining fragmented chromatin, due to the erratic and intermittent use of sounds 
waves chromatin is sheered at unpredictable locations.  
It is commonly known that there are a number of transcription regulatory factors 
(TRFs) that work in combinations to regulate gene expression and regulation. Miura 
et al. (2009) identified a set of transcription regulatory factors (TRFs) and various 
DNA regions which could be involved in combinatorial regulation. More specifically, 
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with the use of X-ChIP they were able to locate the regulatory region downstream 
from the CEBPA gene and confirm its functionality.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
These studies show that X-ChIP by formaldehyde, UV and other cross-linking 
methods is a largely versatile and reliable technique; particularly the use of non-
histone proteins and those who’s binding affinity to DNA is not effective enough for 
the use of N-ChIP. In organisms where native chromatin preparation is not easy, X-
ChIP is the ideal technique due to the complexity of native chromatin preparation. X-
ChIP can also be advantageous during instances where there is not enough cells 
available for N-ChIP, as the number of cells required for X-ChIP is generally less (5 x 
107 – 1 x 108 cells/ N-ChIP vs  >1 x 107  cells/ X-ChIP) (O’Neil and Turner 2003, 
Abcam 2011). Moreover, the use of cross-linking reduces the likelihood of 
nucleosome rearrangement during sonication compared to N-ChIP. Never-the-less, 
cross-linking still has its limitations, the most prominent being the irregular and 
unreproducible way in which the nucleosomes are fragmented during sonication; 
cross-linking may inadvertently fix temporary interactions therefore not giving a true 
image of permanent modifications. Finally, despite the reduced number of cells 
required for X-ChIP compared to N-ChIP, it is still not possible to perform X-ChIP 
with small cell numbers therefore ruling out clinical application. 
1.3.3 Carrier Chromatin Immunoprecipitation (C-ChIP) 
Carrier ChIP is a development of the N-ChIP protocol to allow for the use of small 
cell numbers. As identified in the X-ChIP and N-ChIP sections, a major disadvantage 
of both techniques is that they do not have a clinical application due to the high 
number of cells required to start the experiment. When you consider that a typical 
mouse embryo’s inner cell mass (ICM) consists of ~20 cells (O’Neill et al. 2006) it is 
possible to understand that obtaining the required 107-108 cells is unrealistic. By 
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using cultured SL2 cells from the Drosophila melanogaster (fruit fly) and combining 
them with as little as 100 mammalian cells, the SL2 cells will protect against the loss 
of the mammalian cells through chromatin preparation and act as a carrier 
throughout. 
O’Neill et al. (2006) established this idea of using cultured D.melanogaster cells 
alongside mammalian cells in order to determine epigenetic changes in the early 
embryo. They used this carrier technology to identify and confirm the existence of 
modificated genes in the inner cell mass and embryonic stem cells, a project that 
until the introduction of C-ChIP would not have been possible.  
Carrier ChIP was able to revolutionise the way in which we can look at histone 
modifications, other techniques have been recorded as identified in table 1.1. 
Moreover, researchers are now able to judge the validity of their research which has 
relied solely on cultured cells, made possible by using carrier ChIP as a comparative 
analysis to provide a realistic picture from non-cultured cells. Despite the wide 
application of this technique to many experiments it leaves one fundamental 
weakness. Due to the presence of a large excess of the D.melanogaster cells it is 
not possible to complete the analysis with high throughput sequencing. Analysis of 
C-ChIP chromatin has thus far been limited to PCR analysis and the global 
distribution of the modifications of samples prepared by C-ChIP is not possible. 
1.3.4 Alternative Techniques for Small Cell Number ChIP 
Other ChIP techniques have been published which are specific to the sequencing 
analysis of small cell number samples. Nano-ChIP-Seq uses the same concept as X-
ChIP by initially crosslinking the modifications with formaldehyde, lysing and 
subsequently sonicating to sheer the nucleosomes. IP is achieved using sepharose 
A beads and subsequent incubation with the chosen antibody isolates the target 
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chromatin. Losses during the wash stage are reduced by binding the bead/antibody 
complex to columns.  After IP libraries are prepared in three major steps, firstly, IP 
DNA is primed  with custom primers,  containing a hair pin loop, restriction site 
(BsiVI) and random nonamer sequence for DNA binding, step two involves the 
amplification of the target DNA plus the added restriction site. BciVI, when cut, 
leaves a 3’ adenosine overhang which allows adaptor binding during the final step of 
library preparation followed by quantification by RT-PCR. Although Aldi and 
Bernstein (2011) were able to reduce the number of cells needed for ChIP to as little 
as 10,000 this method still has some limitations. Firstly, the method described has 
used formaldehyde crosslinking and sonication to isolate DNA, similar to that of X-
ChIP, it’s adaptation to NChIP is yet to be proven. In addition, this protocol can only 
be utilised for 10,000 cells when using embryonic stem cells, when using other cell 
types including FACS sorted cells 25,000 cell or more were needed. Indeed, the 
authors quote only a two to three orders of magnitude improvement in terms of the 
numbers of cells required compared to standard ChiP methodology. Furthermore, 
the time taken to perform the whole ChIP protocol including library preparation is 
upwards of five days. Thus, although at the time of publication this method was a 
breakthrough in the field, it can be concluded that a better, more efficient protocol 
could be adapted to eliminate many of these limitations.  
iChIP (index-first ChIP) is a recently developed ChIP technique used for analysis of 
chromatin samples from small cell numbers by Lara-Astiaso et al. (2014). In iChIP, 
the chromatin is isolated by chemical fixation before using a carefully selected 
number of cycles for sonication. Using magnetic beads coated in H3 antibody, the 
chromatin is immobilised allowing for barcoding of individual samples which are then 
pooled together for IP. Sequencing analysis of the pooled samples is made possible 
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as the barcodes are unique to each chromatin sample and can therefore be 
separated upon analysis. This is a very new technique which is yet to be fully 
explored by other researchers. The authors of iChIP have gone into great depth on 
how to optimise various steps to ensure the integrity of the resulting DNA without the 
use of a carrier. The analysis of such small cell numbers without the use of a carrier 
increase loss of DNA to tubes and pipette tips. Using a carrier during chromatin 
preparation significantly reduces these losses, furthermore carrier cells are able to 
increase the reliability and reproducibility of each assay as the amount of chromatin 
in each reaction is careful controlled. 
 
The number of cells recovered from a tumour biopsy can vary depending on the 
biopsy procedure used to recover the sample, type and location of tumour (Rajer and 
Kmet 2005). Although the number of cells retrieved from biopsies in some cases can 
be relatively useable, after the cells have been separated into their relevant groups 
and proportions have been sent for diagnostic purposes, the number of cells left to 
use for research purposes is limited. Although the genetic sequence is mostly a set 
sequence (with the exception of single nucleotide polymorphisms, SNPs, and 
artefacts), epigenetics and PTMs of histones provide a code which regulate factors 
on top of the genome, i.e. transcription factor binding sites. The same is true for non-
histone proteins where PTMs can regulate binding capacity and modify their 
activation motifs etc. To provide an insight into the role of post-translational 
modifications on the mechanisms of tumour growth and survival, including cell 
apoptosis and proliferation, it is important to develop a reliable technique which 
identifies the presence of PTMs. Current techniques, mostly involving chromatin 
immunoprecipitation, hold many limitations and fundamental weaknesses which 
22 
 
raise issues with analysis. Since the number of cells required to initiate the first steps 
in ChIP are too large to enable use with primary clinical samples, current research is 
relying on the generation of new cell lines by cell culture which, by nature, has 
limitations growing exponentially as the passage line number increases. Analysis of 
primary cell PTMs was made possible by the introduction of a carrier, increasing the 
reliability of results and expanding the applications of ChIP to tumour cells after 
FACS separation, but introduces new barriers in analysis by high throughput 
sequencing. This project aimed to provide a new, versatile analysis for the 
identification of PTMs for both histone and non-histone proteins by addressing the 
limitations of the current techniques, thereby expanding the depth of current 
research in PTMs to primary cells from real, clinical samples. 
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Table 1.1 A comparison of the techniques available to identify and compare post-translational modifications of proteins outlining 
the advantages, limitations and sources for each. Table 1.1 also includes a comparision methods used for ChIP analysis. 
Method Advantages Disadvantages Protocol/Source  
Mass Spectrometry (MS) 
Botton Up 
o No prior knowledge of 
the modification site or 
type is needed. 
o Required expensive software and use of 
complicated algorithms. 
o Success rate varies. 
o Short peptides are incompatible with MS 
o Trypsine digests K and R, histones are K 
and R rich therefore creates short 
peptides. 
o Trypsine cleaves mono-, but not di- and 
tri- methylated lysines. 
Arnaudo and Garcia 
2013 
Mass Sepctrometry (MS) 
Middle Up 
o Use with PTMap 
software increases 
reliability and reduces 
false positives. 
o Misidentification of modifications due to: 
isobaric mass shift, sample preparation, 
incorrect database assignments and 
false positives. 
o Can cause methyltransfer within a 
peptide incurring false positives. 
o Loss of modification during sample 
processing. 
o Histone phosphorylation is lost during 
sample. processesing due to being acid 
labile. 
o Heavy isotope labelling required for 
reassurance of correct identification. 
Arnaudo and Garcia 
2013 
µ-ChIP (Micro-ChIP) o Uses samples with as 
little as 10,000 cells. 
o No carrier interference. 
o Requires an amplification step. 
o Expensive equipment and kits. 
o Not enough sample available to use one 
Acevedo et al. 2007 
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o Can be used with 
microarray.  
as an ‘input’. 
o Reduced signal from less cells leads to 
underestimation of protein-DNA 
interaction. 
Fast ChIP o Quicker due to 
shortened antibody 
binding times. 
o Can use multiple 
antibodies to 
simultaneously process 
many samples. 
o Required Chelex-100 to facilitate DNA 
extraction. 
o Only suitable for large cell samples. 
 
Nelson et al. 2006 
Quick and Quantitative 
ChIP(Q2ChIP) 
o Faster protocol by 
reducing timing. 
o Formaldehyde can cause disruptions to 
modifications creating inefficient epitope 
precipitation. 
o Only suitable for samples of a large cell 
number 
Dahl and Collas 2007 
Matrix ChIP o Several samples in one 
plate. 
o Can be automated. 
o Quicker due to 
shortening of steps. 
o Requires Chlenex-100 to facilitate DNA 
extraction. 
o Volume of cells required. 
Flanagin et al. 2008 
Native ChIP (N-ChIP) o No crosslinking 
required. 
o Nucleosomes are cut at 
reproducible lengths 
between the 
nucleosomes.  
o High antibody 
o Not suitable for non-histone proteins. 
o Nucelosome rearrangement . 
o Nuclease digestion can be selective. 
o Volume of cells required. 
O’Neil and Turner 2003 
Hebbes et al. 1988 
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specificity. 
o DNA and protein output 
can be analysed, 
therefore more efficient 
precipitation. 
o Analysis can be 
achieved without PCR. 
Formaldehyde Crosslinked 
ChIP 
o Applicable to non-
histone proteins. 
o Good for organisms 
where chromatin is 
difficult to prepare. 
o Histone tails can be damaged during 
sonication causing issues with antibody 
binding. 
o Fragmentation by sonication is not 
reproducible. 
o Volume of cells required. 
o Formaldehyde can cause disruptions to 
modifications creating inefficient epitope 
precipitation. 
Jackson 1978 
UV Crosslinked ChIP o Applicable to non-
histone proteins. 
Good for organisms where 
chromatin is difficult to 
prepare. 
o Histone tails can be damaged during 
sonication causing issues with antibody 
binding. 
o Fragmentation by sonication is not 
reproducible. 
o Volume of cells required. 
Gilmour and Lis 1985 
Carrier ChIP (C-ChIP) o Can be used with 
samples of a small cell 
number. 
o Applicable with both 
crosslinked and native 
chromatin therefore, 
o Carrier cells cause background ‘noise’ 
during high throughput sequencing. 
O’Neil et al. 2006 
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histone and non-
histone proteins. 
ChIP-chip  
(ChIP with microarray 
analysis) 
o Provides a whole 
genome analysis. 
o Broad applications. 
o High quantity whole genome micro-array 
platforms are expensive. 
o Experimental process is long. 
o Challenging to troubleshoot. 
o Requires the use of replicate samples to 
account for experimental ‘noise’. 
o Use of algorithms. 
Lee et al. 2006 
ChIP by sequencing 
analysis (ChIP-Seq) 
o Higher resolution than 
ChIP-chip. 
o Fewer artefacts. 
o Large coverage of 
analysis. 
o Analyses all input sample so not to be 
used as analysis for C-ChIP. 
o N-ChIP and X-ChIP analysis require 
large cell numbers. 
o Doesn’t view whole genome. 
Park 2009 
Nano-ChIP-Seq o Can analyse as few as 
10,000 cells. 
o High throughput 
sequencing is possible. 
o Duration can be up to 5 days 
o 10,000 is only applicable to ESC, other 
cell types require higher quantities. 
Adli and Bernstein 2011 
iChIP o Can reduce the number 
of cells required to just 
500 cells. 
o Can be analysed with 
high throughput 
sequencing. 
o Requires the use of a specialised 
barcoding system. 
o Cells can cause detrimental effects to 
the quality of the chromatin. 
Lara-Astiaso et al. 2014 
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1.4 Aims and Objectives 
1.4.1 Primary Aims 
The main focus of this experiment was to identify a novel way of coupling carrier 
chromatin immunoprecipitation (C-ChIP), a procedure for immunoprecipitating 
chromatin from small numbers of cells, to next generations sequencing (C-ChIP-
seq). This requires the development of techniques that will suppress the 
amplification of carrier DNA when constructing sequencing libraries.  
1.4.2 Objectives 
In order to achieve this aim 3 objectives were identified. 
1. To develop a protocol by which the DNA of carrier cells can be fragmented 
by UV light so as to supress its amplification, while still allowing the 
preparation of chromatin suitable for ChIP. Ensuring that the number of 
output cells (number of cells recovered after treatment) is not reduced so 
much that it hinders further experimental  
2. Identify parameters for the use of crosslinked ChIP with carrier cells (a 
technique not previously attempted). 
3. Perform chromatin immunoprecipitation assay on both crosslinked and 
native chromatin assessing the rate of inhibition induced by UV treated 
cells before and after the creation of DNA libraries.  
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2. Materials and Methods 
2.1 Materials 
Primer sets used (See appendix for position within the sequence) 
Name Sequence Company 
DM GapDH Forward AGCGAACTGAAACTGAACGA Invitrogen 
DM GapDH R142 ACGGAGGCGCCCTTAT Invitrogen 
DM GapDH R221 GAAACGACCGTGAGTCGAG Invitrogen 
DM GapDH R319 CTGGCCCAGTTGATGTTG Invitrogen 
DM GapDH R419 CGAGATGATGACCTTCTTGG Invitrogen 
HS CD74 end F TGCTGCTTCTCTCTCCAGTC Invitrogen 
HS CD74 end R TGTCCAAGGGTGACGAAAGA Invitrogen 
HS CD74 -500F TGCCCCTTCTCTCTGTCTTG Invitrogen 
HS CD74 -500R GCACTAGAGGCCTCAGTTGA Invitrogen 
HS CD74 -1000F CTTGCCAACACAGTCCCATC Invitrogen 
HS CD74 -1000R GTGATCTTTACGGAGGCCCT Invitrogen 
Chromosome 18 
desert F 
ACTCCCCTTTCATGCTTCTG Invitrogen 
Chromosome 18 
desert R 
AGGTCCCAGGACATATCCATT Invitrogen 
HS CD74 F103 AGTGGGCGGAGTGGCCTTCT Invitrogen 
HS CD74 R172 CCCGGCTCGCCTCTTAAAGTCGGTGCT Invitrogen 
HS CD74 R221 CTTCCCGACAGCTCCTGCTTCTCCTCC Invitrogen 
HS CD74 R344 TCGGTGTGCCCTTTCCTGGTGCTCA Invitrogen 
HS CD74 R492 GAGAGGGAGCCGGAGCCCAGAGCA Invitrogen 
DM = Drosophila Melanogaster 
HS = Homo Sapien 
 
Buffers used 
Name Components Concentration Experiment(s) 
1 x TAE Tris 
Acetic Acid 
EDTA 
40 mM 
20 mM 
1 mM 
Agarose gel 
electrophoresis 
0.1 % TE Tris 
EDTA 
1 mM 
0.1 mM 
 
Buffer NB Tris-HCl 
MgCl2 
NaCl 
KCl 
EGTA 
2-mercaptoethanol 
15 mM 
5 mM 
15 mM 
60 mM 
0.1mM 
0.5 mM 
N-ChIP 
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Na Butyrate 
PMSF 
5 mM 
0.1 mM 
Digestion buffer Sucrose 
Tris-HCl 
MgCl2 
CaCl2 
Na Butyrate  
PMSF 
 
0.32 M 
50 mM 
4 mM 
1 mM 
5 mM 
0.1 mM 
N-ChIP 
 
 
 
Lysis buffer (N-
ChIP) 
Tris-HCl 
EDTA 
Na Butyrate 
PMSF 
1 mM 
0.2 mM 
5 mM 
0.2 mM 
N-ChIP 
Incubation buffer NaCl 
Tris-HCl 
Na Butyrate 
EDTA 
PMSF 
50 mM 
20 mM 
20 mM 
5 mM 
0.1 mM 
N-ChIP 
Wash Buffer A Tric-HCl 
EDTA 
Na Butyrate 
NaCl 
PMSF 
50 mM 
10 mM 
5 mM 
50 mM 
0.1 mM 
N-ChIP 
Wash Buffer B Tric-HCl 
EDTA 
Na Butyrate 
NaCl 
PMSF 
50 mM 
10 mM 
5 mM 
100 mM 
0.1 mM 
N-ChIP 
Wash Buffer C Tric-HCl 
EDTA 
Na Butyrate 
NaCl 
PMSF 
50 mM 
10 mM 
5 mM 
150 mM 
0.1 mM 
N-ChIP 
Dilution buffer Triton X-100 
EDTA 
NaCl 
Tris-HCl, pH 8 
Protease inhibitor 
cocktails 
1 % 
2 mM 
150 mM 
20 mM 
X-ChIP 
0.1 M Citrate-
phosphate buffer, 
pH 5 
Citric Acid 
Na2HPO4 
 X-ChIP 
Low salt buffer Triton X-100 1 % X-ChIP 
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SDS 
EDTA 
NaCl 
Tris-HCl, pH 8 
0.1 % 
2 mM   
150 mM 
20 mM 
High salt buffer Triton X-100 
SDS 
EDTA 
NaCl 
Tris-HCl 
1 % 
0.1 % 
2 mM 
500 mM 
20 mM 
X-ChIP 
Elution buffer NaHCO3 
SDS 
100 mM 
1 % 
X-ChIP 
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2.2 Methods  
2.2.1 Cell Culture 
Drosophila melanogaster SL2 cells (Schneider 1972) were cultured at 24 °C, 5 % 
CO2 and routinely split twice weekly in a 1:10 ratio with growth media [500 ml Insect-
Xpress + 5 % Fetal Bovine Serum (FBS) + 1 % Penicillin Streptomycin (Pen Strep)] 
until required when the cells were split 1:3 and allowed to grow overnight. To 
dissociate weakly adherent cells, flask was ‘banged’. Once dislodged the cells were 
washed with PBS (phosphate buffered saline) and resuspended in buffer NB to be 
counted using a haemocytometer.  Cells were resuspended at 2 x 107 cells ml-1. 
Frozen plates were made by pouring water into the contours of the plate between 
each of the wells on both sides and leaving to freeze overnight. Cells to the 
concentration of ~2 x 107 cells/ ml at a volume of 500 µl were transferred into various 
wells on frozen and non-frozen 12-well plates ready for ultra violet treatment. The 
plates were sealed with optical film and kept cool by using frozen plates, storing in 
ice during movement and placing an ice block on one side during UV treatment. The 
cells were treated by placing on a UV transilluminator for 30 minutes; 10 minutes in 
UV conditions, 5 minute submerged in ice followed by 10 minutes in treatment and a 
final 5 minutes submerged in ice. The cells were counted again to assess the level of 
UV-induced damage. 
2.2.2 DNA extraction  
DNA was extracted according to the QIAgen DNA extraction from cultured cells 
protocol. 
The cultured cells were pelleted by centrifuging at 300 x g for 5 minutes. Proteins 
were digested and removed by resuspending the pellet in 200 µl of PBS and 20 µl 
Proteinase K. Cell lysis was achieved using 200 µl Buffer AL, and incubated at 56˚ 
for 10 minutes. To purify the DNA 200 µl of 100% ethanol was added to the solution, 
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mixed, transferred into a mini spin column and centrifuged (6,000 x g, 1 minute). 
Flow through was discarded and washed again with 500 µl of AW1 and AW2 at 
6,000 x g for 1 minute and 20,000 x g for 3 minutes, respectively. DNA was eluted by 
placing the spin column into a new 1.5 ml Eppendorf, pipetting 200 µl of buffer AE 
directly onto the column membrane and centrifuging at 6,000 x g for 1 minute. 
2.2.3 Chromatin immunoprecipitation (ChIP)  
Native Chromatin Immunoprecipitation(N-ChIP) 
The native chromatin immunoprecipitation (N-ChIP) protocol as described by O’Neil 
and Turner (2003) was followed. The cells were washed and resuspended in buffer 
NB to ~2 x 107 cells/ ml. An equal volume of 1 % tween in NB buffer was added and 
cells incubated on ice for 15 minutes with gentle mixing before homogenisation. 
Homogenisation was carried out using a dounce homogeniser with a tight pestle, in 
order to break down the cell membrane, leaving the nucleus exposed. Cells were 
checked under a microscope after every 3-5 strokes to avoid over- homogenisation, 
in turn creating sub-nucleosomal DNA. 
To eliminate debris created by homogenisation the broken cells were centrifuged 
and washed sequentially (~1 x 107/ ml) in 5 % sucrose/buffer NB and digestion 
buffer. A nanospectrometer was used to assess the ƛ 260/280 values and DNA 
concentrations (µg/ µl) of the solutions. In preparation for digestion the pellet was 
resuspended in digestion buffer (0.5 mg/ ml) and divided into 1 ml aliquots. 
Micrococcal nuclease was added at 50 U/ml and incubated at 37 °C for 5 mins. 0.5 
M EDTA was added to the solution (10 µl/ ml) and placed on ice for a further 5 
minutes to stop the reaction. After centrifugation the supernatant was retained and 
kept chilled for further analysis (S1). Finally, the pellet was resuspended in 1 ml lysis 
buffer, and dialysed overnight against 2 L lysis buffer (4 °C). 
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Following dialysis, samples were centrifuged and the supernatant retained (S2). The 
resulting pellet was resuspended into 200 µl lysis buffer (P) and quantified, taking 
particular note of the ƛ 260/280 values and µg/ µl concentrations. During optimisation 
of chromatin preparation the S1, S2 and P samples were visualised on a 1.2 % 
agarose gel in 1 x TAE buffer containing GelRed dye. The purpose of this gel is to 
check chromatin integrity from the size and abundance of fragmented nucleosomes 
after micrococcal nuclease digestion.  For each sample, 1 µg DNA was loaded in a 
final volume of 25 µl containing 0.1 % SDS and loading dye. S1 represents the 
supernatant after micrococcal nuclease digestion and will therefore contain mostly 
mono nucleosomes, S2 is the supernatant collected after overnight dialysis and 
therefore will have mostly di-, and tri-nucleosomes whereas P, or pellet, was the 
soluble portion of the sample resuspended after night dialysis. 
N ChIP- Immunoprecipitation 
For immunoprecipitation (IP), S1 and S2 were combined and the P sample was 
discarded. An initial pre-clear reaction was set up to eliminate unspecific binding 
from both the beads and the chromatin. Per IP, 30 µg – 100 µg of chromatin was 
used (depending on the amount available after chromatin preparation), 50 – 100 µl 
Protein A Sepharose beads, 100 µl 10 x incubation buffer, up to 900 µl with u.p. H2O. 
After rotation at 4 °C for 1 hour an ‘input’ sample was retained as an unbound 
control. The antibody was bound to the chromatin by adding 4 µg to the chromatin 
solution and incubated overnight at 4 °C. Protein A sepharose beads are used to 
immunoprecipitate the antibody bound chromatin overnight at room temperature. 
Chromatin is washed on the beads using gradient salt washes buffer A, buffer B and 
buffer C and finally eluted using 500 µl of 10 x incubation buffer/SDS solution on 
rotation.  
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Crosslinking Chromatin Preparation (X-ChIP) 
The cells were pelleted (centrifuge at 300 x g, 5 minutes) and resuspended in PBS 
(106-7 cells/ ml) at room temperature. The crosslinking was achieved by dropping 
formaldehyde (1 % v/v) into the solution and leaving to rotate for 10 minutes. To 
quench formaldehyde activity 1/10 volume of 2 M glycine was added to the solution 
and centrifuged at 300 x g, 5 minutes, 4 ˚C. Non-target excess compounds were 
removed by washing in PBS. The supernatant was discarded and the pellet 
resuspended in lysis buffer at 5 x 107 cells/ ml. In clean eppendorfs the cells were 
sonicated; 30 seconds on, 30 seconds off for 5-30 cycles. The samples were 
pelleted by centrifuging at 16,000 x g for 10 minutes, 4 ˚C. The resulting pellet was 
discarded and the supernatant was retained overnight at 4 ᵒC.  
X ChIP - Immunoprecipitation 
One chromatin sample should be left un-immunoprecipitated (input sample) for 
further comparison on pull-down and relevant quantification. The other samples were 
diluted with ½ volume of dilution buffer, using a maximum of 1ml for each 
immunoprecipitation (IP).  
To bind the anti-bodies with the magnetic Dyna-beads, the beads were washed 
using citrate-phosphate buffer and resuspended in citrate-phospate buffer + 0.5 % 
Bovine Serum Albumin (BSA), the protein in the BSA blocks non-specific binding of 
protein to the beads. Antibodies were bound using 4 µg of antibody per 15 µl 
Dynabeads, the solution was rotated for 2 hours at 4 ᵒC. 
Any surplus antibodies were washed away with citrate-phosphate buffer, Dynabead-
antibody complex was resuspended in 15 µl citrate-phosphate + 0.5 % BSA per 
immunoprecipitation. 1 ml of chromatin and the Dynabead-antibody complex were 
mixed and left to rotate for 4 hours at 4 ᵒC. 
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The antibody bound chromatin was washed twice each with low and high salt buffer. 
The chromatin was eluted twice using freshly prepared Elution buffer (50 µl) with 15 
minute incubation and rotation at room temperature between each elution.  
Using the antibody-bound chromatin and the input sample, the cross-linking was 
reversed by incubation with 20 mg/ ml of proteinase K at 65 ᵒC, 300rpm overnight.  
2.2.4 DNA Purification 
DNA was extracted from the chromatin using the QIAgen PCR Purification Kit: Five 
volumes Buffer PB was added to one volume DNA in a spin column ready for 
removal via centrifugation. At this point the DNA is bound to the membrane of the 
spin column, and subsequently washed with Buffer PE to ensure all surplus 
fragments are removed. Finally, the DNA can be eluted with Buffer EB. 
2.2.5 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) is a widely used DNA amplification method first 
developed by Nobel Prize winner Dr Kary Mullis in 1984. The primers used were 
specifically designed to create 132 bp, 211 bp, 309 bp and 409 bp amplicons (see 
appendix 1-4). It was anticipated that there would be considerably more DNA 
amplified in the smaller strands, and less amplification as the target size grows. This 
decline is due to the increased accumulation of UV-induced damage in larger. In 
order to significantly reduce amplification of the carrier DNA during library 
preparation, it was important to induce sufficient UV damage within the average size 
of a sequencing library. Drosphila melanogaster primers were designed to the 
housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase (GapDH) encoding 
the enzyme which catalyses the sixth step of glycolysis and therefore highly 
expressed in nearly all animals (Greer et al. 2010). Human primers corresponded to 
the CD74 gene, a gene which is highly expressed in lymphoblastoid cells and 
therefore easy to detect. All primer sequences have been mapped within their gene 
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sequences, see appendix. The optimal PCR settings for these primers were 95°C, 
30 seconds for denaturation; 60 °C, 30 seconds for primer annealing; and 72 °C, 30 
seconds for elongation. A no template negative control is also produced for 
comparison. For evaluation, a 2 % agarose gel electrophoresis was run and 
observed stained with GelRed under a UV light.  
Real-time PCR (RT-PCR)/ q-PCR 
To be able to run the chromatin on the RT-PCR the chromatin must be purified into 
DNA. RT-PCR was set up using 10 µl reaction volume: 8.8 ng DNA, 3 pM reverse 
primer, 3 pM forward primer, 2 x 10-5 M SYBR. 
Real Time-PCR (RT-PCR) is a quantitative technique for the detection of DNA 
molecules using either a probe or SYBR. In this project the SYBR detection 
technique was utilised. SYBR is a double stranded DNA binding dye such that 
fluorescence signal at each cycle is directly proportional to DNA concentration. In 
this experiment 7 point standard curves were constructed from a series of 1:5 (DNA: 
NF H2O) standard DNA. A blank reaction series was also created as a negative 
control for possible contamination.  
2.2.6 Library preparation of ChIP samples 
DNA libraries were prepared using the New England Biolabs NEBNext® ChIP-Seq 
Library Prep Master Mix Set for Illumina kit according to the manufacturer’s 
instructions.  
Library preparation is the process of taking the immunoprecipitated DNA sample and 
manipulating it ready for injection into the DNA sequencer. Firstly, the DNA 
‘overhangs’ need to be repaired; when the DNA is fragmented it is left with 
‘overhang’ where one strand of the DNA is longer than the other, during the first step 
of library preparation this ‘overhang’ is fixed and blunt ends are produced. This is 
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made possible with the introduction of a repair enzyme buffer and a repair enzyme 
during an incubation period of 20 ᵒC for 30 minutes. Following this an ‘A’ tail is added 
to the newly repaired double stranded DNA which provides a station for the docking 
of adaptors in the subsequent steps. dATPs are added to the repaired ends with the 
Klenow fragment (DNA polymerase I extracted from E.coli) (Klenow and Henningsen 
1970). The DNA, dA-Tailing Reaction Buffer and Klenow fragment are incubated for 
30 minutes at 37 ᵒC. Adaptors are added to the 5’ end and the 3’ end of the A-tailed 
DNA, The double stranded adaptors contain the primer-binding sites for library 
amplification and paired end sequencing.  DNA ligase is also used to reform the 
phosphodiester bonds between double stranded DNA. The DNA, ligation reaction 
buffer, adaptor and T4 DNA ligase are incubated for 15 minutes at 20 ᵒC. After each 
incubation period the DNA is bound to magnetic Agencourt® AMPure® beads, 
washed with 80 % ethanol and eluted in 0.1 % TAE. 
PCR amplification increases the abundance of the adapted DNA, this ensures there 
is enough fragmented sample to analyse. Real-time PCR can also be used as well 
as sequencing to assess the relative abundance of the different strands as a 
comparative study.  
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3. Results 
The aim of this project was to establish whether ultraviolet damaged cells could be 
used as a viable carrier in order to create a modified version of the carrier - 
chromatin immunoprecipitation protocol to be used in conjuction with high throughput 
DNA sequencing (ChIP-Seq). To be successful, UV damage must inhibit PCR 
amplification of carrier DNA sufficiently enough that during PCR amplification of the 
ChIP-seq libraries target DNA is amplified and carrier DNA suppressed to such an 
extent as to overcome the initial excess of carrier chromatin.  At the same time, UV 
damage must leave carrier cells and chromatin intact sufficiently to act as a viable 
carrier through all steps of the ChIP procedure.  
During optimisation two experimental methods were used to assess the impact of UV 
treatment upon the cells and their DNA. To view the inflicted damage upon DNA the 
cells were taken through a chromatin preparation protocol after UV treatment. An 
agarose gel electrophoresis was performed after micrococcal nuclease digestion to 
view the productivity of the enzymatic reaction and to assess the level of UV damage 
Figure 3.1 Initial identification of UV limits after micrococcal nuclease digestions 
with lanes 1-3 showing the control sample, 4-6 showing the 10 minute treated 
sample and 7-9 showing the 20 minute treatment sample. 
1 2 7 3 4 5 8 6 9 
S1 S2 
Control 
S1 S1 S2 P P 
10 minute 
treatment 
S2 P 
20 minute 
treatment 
L 
Sub-nucleosomal 
DNA damage 
induced by UV 
radiation 
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inflicted upon the DNA. Secondly, four primer pairs were developed for use with PCR 
to assess the level of inhibition. Using the same forward primer, the reverse primers 
increased in amplicon length from 132 bp, 211 bp, 309 bp and 409 bp. This allowed 
a visual representation of how successful the UV treatment had been in inhibiting 
amplification.  
3.1 Duration of Exposure 
 
In order to identify optimal parameters for the UV treatment of Drosophila 
melanogaster SL2 cells the UV treatment conditions had to be adjusted. Firstly, the 
D.melanogaster cells were counted to the concentration of 2 x 107 cells/ ml and 
aliquoted into 0.5 ml samples in a 12 well plate and subsequent chromatin 
preparation undertaken using native chromatin methods. The first optimal condition 
we established was the duration of treatment. Here, assessment via electrophoresis 
following micrococcal nuclease digestion was used. From this we expected to see an 
1 
4 6 8 2 
Figure 3.2 Picture after micrococcal nuclease digestion when using the frozen 
(lanes 1-3), non-frozen (lanes 4.6) and control sample (lanes 7-9). 
1 9 5 7 3 
S1 S2 
Cooled 
treatment 
S1 S1 S2 P P 
Non-cooled 
treatment 
S2 P 
Control 
L 
Sub-nucleosomal DNA 
damage induced by UV 
radiation 
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increase in the level of damage in proportion to the duration of treatment. The initial 
tests of 10 and 20 minutes (figure 3.1) showed a large subnucleosomal band 
beneath the mononucleosome at the 20 minute treatment sample and a light band at 
the 10 minute treated sample compared with no band for the control (no UV 
treatment), in keeping with anticipated results. These results indicate that 20 minutes 
is too harsh on the cells, resulting in a loss of intact chromatin and an increase in 
subnucleosomal DNA, whereas 10 minutes is not damaging enough, therefore 
another treatment schedule had to be identified.  
3.2 Temperature control  
I investigated methods for reducing the heat of the cells during UV treatment to 
maintain chromatin and cellular integrity as well as inhibiting ongoing DNA repair. A 
20 minute treatment time was used. Temperature of the cells was maintained by 
 Input number of 
cells  
Output number of 
cells 
% destroyed cells 
Cooled plate 12 x 107 / ml 4.14 x 107 / ml 65.5 
Non-cooled plate 12 x 107 / ml 1.375 x 107 / ml 86.25 
Table 3.1 
 
   
Figure 3.3. An electrophoresshowing the difference in amplification inhibition between a 
cooled and non-cooled plate. Lanes 1-4 identify PCR amplification of the control using primer 
pairs to generate 132 bp, 211 bp, 309 bp and 409 bp amplicons, respectively. Lanes 5-8 
show 132 bp, 211 bp, 309 bp and 409 bp, amplicons, respectively from the non-cooled plate. 
Lanes 9-12 from the cooled plate shows amplicons 132 bp, 211 bp, 309 bp and 409 bp, 
respectively. 
 
1 2 3 4 5 6 7 8 9 11 10 12 
Control Non-cooled 
treatment 
Cooled 
treatment 
132 132 132 211 211 211 309 309 309 409 409 409 
Amplicon 
size 
1 kb 
500 bp 
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freezing water in the contours between the wells of the plate before treatment. We 
predicted that temperatures wouldn’t become as high as they previously had and, in 
turn would result in more cells surviving UV treatment. As expected, this added 
temperature control meant a higher number of output cells (table 3.1). There was 
also less DNA damage compared to the previous experiment, as seen in figure 3.2, 
and slightly less PCR inhibition (figure 3.3).  
3.3 Increasing Sample Volume Increases Survival Rate but Reduces DNA 
Damage 
 
It was initially forecast that by increasing the volume of sample in each aliquot from 
0.5 ml (lanes 5-8) to 2.5 ml (lanes 9-12) the heat would distribute across the sample 
more efficiently in turn protecting the cells. With 77.5 % of cells surviving treatment, 
the initial analysis proved to be promising. Furthermore, PCR analysis following 
chromatin preparation (figure 3.4) showed that the 2.5 ml treatment sample had 
protected the DNA and amplification inhibition had been reduced to the point where 
amplicons were almost as abundant as those in the control (lanes 1-4) sample for 
Figure 3.4 A figure showing the level of protection provided by the increased UV treated 
volume. Lanes 1-4 show PCR amplicons 132 bp, 211 bp, 309 bp and 409 bp, respectively from 
the control sample. Lanes 5-8 are amplicons 132 bp, 211 bp, 309 bp and 409 bp, respectively, 
from the 0.5ml treated sample. Lanes 9-12 from the 2.5ml treated sample show 132 bp, 211 
bp, 309 bp and 409 bp amplicons, respectively. 
1 2 3 4 5 7 6 8 9 11 12 10 
Control 
0.5 ml 
treatment 
2.5 ml 
treatment 
Amplicon size 
1 kb 
500 bp 
132 211 309 409 132 211 309 409 211 309 132 409 
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some amplicons, therefore concluding that the increased sample volume does not 
encourage enough DNA damage. 
3.4 Alternating UV treatment with ice proved to be the best temperature 
control. 
Given these results it was clear we had to provide an environment which could keep 
the sample cool while still inflicting optimal damage. A cooler environment for the 
cells during the UV damage period was provided by adopting a new treatment 
schedule. The cells were treated for 10 minutes under the UV lamp, taken off and 
submerged in ice for 5 minutes, followed by a further 10 minutes under a UV lamp 
Figure 3.6 A figure showing the range of inhibition given by the duration of treatment for 10 
minutes under a UV lamp, 5 minutes submerged in ice, 10 minutes back under the UV lamp and 
finally, 5 minutes in ice. Lanes 1-4 display PCR amplification of the control sample, lanes 5-8 show 
the UV treated sample. 
1 2 3 4 5 6 7 8 
1 kb 
500 bp 
Amplicon size 
(bp) 
Control Treated 
132 132 209 209 311 311 411 411 
Figure 3.5 Illustrates the level of UV damage inflicted upon 
the cells after the 10 + 10 UV treatment. Lanes 1, 2 and 3 
represent the S1, S2 and pellet, respectively. 
1 2 3 
Sub-nucleosomal 
DNA damage 
induced by UV 
radiation 
DNA 
Ladder 
43 
 
and finally, 5 minutes in ice. The first electrophoresis after micrococcal nuclease 
digestion showed a band beneath the mononucleosome demonstrating UV damage 
had been inflicted on to the DNA, consistent with our aim to find an intermediate 
treatment (figure 3.5). Further to this we had to also ensure that the cooling time 
between treatments was not allowing for too much repair time and therefore affecting 
the level of inhibition provided by the UV. Figure 3.6 shows a control sample and a 
UV treated sample after PCR amplification of DNA following chromatin preparation. 
The first four lanes show the control sample, lanes five to eight represent the UV 
treated sample. A comparison of the 2 samples clearly identifies a high level of 
inhibition by UV treatment at all sample sizes with only a faint band for amplicons of 
132 bp.  
 
Real-time PCR was used to quantify the rate of inhibition and clarify the results of 
standard PCR. Figure 3.7 demonstrates the success of amplification inhibition 
relative to the control samples. Inhibition for the 132 bp long gene sequence proved 
to be 94 % successful compared with the untreated control sample, the 211 bp 
sequence saw 98.5 % inhibition, with 309 bp it was 99.3 % and 99.5 % inhibition was 
achieved for amplicons 409 bp long. These results show an exponential increase in 
success with the longer amplicon.  
From these results it can be concluded that the required level of inhibition had been 
identified using the following parameters:  
 Duration: 10 minutes under treatment conditions, 5 minutes in ice, 10 minutes 
in treatment and 5 minutes in ice. 
 Temperature: using a pre-frozen 12-well plate with ice between each of the 
wells.  
LC
L 
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 Volume and concentration: cells were pipetted into 0.5 ml aliquots in each well 
at 2 x 107 cells/ ml.  
3.5 Reducing the stability of SL2 cells aids in optimising the sonication step. 
Once the ideal treatment conditions had been ascertained the rest of the protocol 
had to be optimised. During the formaldehyde crosslinking variation of ChIP (X-ChIP) 
the chromatin is fragmented by sonication. Initial experiments using SL2 cells 
showed that after UV treatment the d.melanogaster cells fragmented to the required 
band length only after 30 cycles (30 seconds on, 30 seconds off), figure 3.8. 
However, experiments showed that human lymphoblastoid cells are not as robust, 
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Figure 3.7 A graph to show the level of inhibition delivered by the UV treated SL2 cells during 
real-time PCR where the blue bars demonstrate comparison to the control DNA. 
Figure 3.8 Chromatin sizes after sonication cycles. Lanes 1 and 3 
show 20 cycles and 2 and 4 are 30 cycles. Where a cycle is 30 
seconds on, 30 seconds off. Lanes 1-2 show the control sample and 
3-4 identify the UV treated sample. 
1 2 4 3 
1 kb 
500 bp 
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requiring only around 10 cycles of sonication. I attempted to address this by devising 
measures to destabilise the SL2 cells. An equilibrium in cell stability between the two 
cell lines was established by freezing the SL2 cells post-UV treatment, pre-chromatin 
preparation. Two electrophoresis photos are shown in figure 3.9, the areas 
highlighted by the red box are the required fragment length ascertained from 
samples which were sonicated for 10 cycles. This demonstrates that after freezing 
the SL2 cells for 1 hour, 10 sonication cycles was optimum for both cells lines. 
 
3.6 UV treated cells for use as a carrier during chromatin immunoprecipitation 
After optimisation of chromatin preparation the immunoprecipitation steps were 
followed. Firstly, it was important to prove that the UV treated cells could still be used 
as a viable carrier. A full X-ChIP experiment using the antibodies complimentary to 
RNA polymerase II and H3K4me3 was performed using only SL2 cells. An input 
sample was retained prior to immunoprecipitation to quantify the level of pull down 
by comparison. The results showed good pull down from both the treated and 
untreated cells; furthermore these results also indicated that the UV treated cells 
showed increased pull down compared to the control when using crosslinked 
chromatin (table 3.2). 
Table 
3.2 
To demonstrate the concentration and relative amount of pull down 
of target DNA from samples with treated and untreated carrier cells. 
  Concentration 
(ng/µl) 
% pull down 
 
 
X-ChIP 
Control Input 177  
Control Pol II 15 8.48 
Control H3K4me3 6 3.39 
UV Input 101  
UV Pol II 24 23.76 
UV H3K4me3 22 21.78 
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Next we optimised carrier ChIP. Experiments using the treated SL2 D.melanogaster 
cells as carrier, holding 10,000 and 1,000 human cells were set up for both 
crosslinked chromatin and native chromatin. The data was quantified using real-time 
PCR (figure 3.10) which showed enrichment of the crosslinked chromatin was higher 
in the UV treated cells than that of the untreated sample, in keeping with the rate of 
pull down in table 3.2. However, it should be noted that because the primers used 
are specific for human DNA, the results demonstrate that pull down has been 
achieved from the target LCL cells. This result was seen consistently throughout 
each crosslinked carrier ChIP. Native chromatin immunoprecipitation was also used 
to assess whether there was a difference in pull down between the two types of 
ChIP. N-ChIP demonstrated good powers of antibody affinity providing pull down 
percentages from UV treated cells of 6.47 and 5 % for 10,000 and 1,000 LCL cells, 
respectively. The results from these experiments have proven that UV treated cells 
can be used as a viable carrier for use in C-ChIP.  
Creating DNA libraries is essential to enable next generation sequencing of the 
resulting DNA. Libraries were prepared following the New England BioLabs® Inc 
protocol: Illumina® Library Preparation for the creation of ChIP-Seq libraries. Finally, 
to check the enrichment of the target DNA subsequent analysis by Real Time PCR 
was conducted using primers: H.sapien CD74 -1000, HS CD74 (TSS) (see appendix 
1). 
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3.7 Analysis of library prepared samples 
The DNA samples were prepared for DNA sequencing using the New England 
Biolabs NEBNext® ChIP-Seq Library Prep Master Mix Set for Illumina. Figure 3.11 
shows the relative enrichment of the genes at 1,000 bp upstream the CD74 
transcription start site (TSS) and at the transcription start site relative to the input 
sample (unbound chromatin). Since H3K4me3 is associated with gene activation it 
would be expected to see higher fold enrichment of genes at the transcription start 
site of an active gene as that is where the H3K4me3 binds. In addition to this, 
judging by the results from previous experiments we would also expect to see an 
increased enrichment of these genes in ChIP with a UV-treated carrier in comparison 
to the control. Figure 3.11 visualises the enrichment of the two gene sequences at -
1000 bp and the TSS. As expected the gene sets in the UV treated sample are more 
enriched.  
Figure 3.9 Electrophoresis showing the optimisation of sonication cycles between LCL cells 
and SL2 cells after freezing the SL2 cells post UV treatment. Lanes 1 - 3 show size of 
fragmented SL2 DNA, lanes 5-7 show fragmented LCL DNA after sonication. Samples in 
lanes 1 and 5 were sonicated for 5 cycles, lanes 2 and 6 for 10 cycles and lanes 3 and 7 for 
15 cycles. 
1     2   3     5     7    6     4   
1 kb 
500 bp 
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Figure 3.10 Graph to show the fold enrichment of target DNA during real-time PCR 
amplification using primer sets from the human CD74 gene (see appendix). Shows that 
quantifiable target DNA within each sample is present. 
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Figure 3.11 Real-time PCR analysis of Library Prepared Samples. The graph exhibits the 
relative enrichment genes around the transcription start site (TSS) (blue) and 1000 bp before 
the TSS (red). The graph shows that there is human DNA available for amplification therefore 
human DNA has been pulled down after immunopecipitation. It also shows that after pull 
down using the antibody with an epitope for H3K4me3, more DNA is available from the 
transcription start site than further up in the gene therefore, validating our results.  
Indicates that 10,000 target cells produces statistically significant results with highly enriched 
region at the TSS as predicted. 1,000 cell samples shows less convincing results which could 
indicated sample was boarding the limits of detection. 
49 
 
4. Discussion 
The ENCODE project is a follow up of the human genome project, established in 
2003 upon the completion of the human genome project it set out to provide a better 
understanding of the human body’s responses to health and disease (The ENCODE 
Project Consortium 2004). In terms of epigenetics, ENCODE had provided a 
substantial insight into the impact of DNA modifications and post-translational 
histone modifications. Here however is where problems arise, ENCODE data is 
generated from cell lines where large amounts of starting material are readily 
available. However, the size of clinical samples generally available to study means 
there are significant gaps in the research on histone modifications in cancers, 
tumours and disease research. The National Centre of Biotechnology Information 
‘PubMed’ database (www.NCBI.nlm.nih.gov/pudmed), on 23rd February 2014 
provides 19,969 results in relation to DNA methylation and cancer, histone 
modifications however are largely underrepresented at 1,791 results when searched 
in relation to cancer. Without a reputable procedure to analyse histone modification 
of cancer cells there is little hope of increasing the current understanding of  the 
roles of post-translational modifications of histone and other proteins in cancers and 
tumour cells. Chromatin immunoprecipitation is one of the main sources of 
experimental data for ENCODE protein post-translational modification investigations 
(ENCODE Project Consortium 2011). ChIP is a widely used technique providing a 
tool for identification and interpretation of histone post-translational modifications and 
other DNA-protein interactions. The original and ultimately, most reliable ChIP 
protocols - NChIP and X-ChIP utilise the affinity of the histone to the DNA or 
crosslink the proteins to the DNA prior to chromatin preparation, respectively. The 
large number of cells required to initiate the first steps of these two protocols is the 
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main drawback which have hindered progression of understanding epigenetic 
processes for mammalian cancers, tumour and other immune stresses. Given that 
clinical samples produce significantly less cells than required it is evident that a 
technique is needed to utilise the analysis properties of ChIP-Seq without the need 
for such large quantities of input cells. As summarised in table 1.1 many variations of 
this technique exist, all of these however carry fundamental weaknesses which 
inhibit and sometimes carry the potential to misidentify analysis products. Other ChIP 
techniques which enable the sequencing of ChIP samples from small cell numbers 
have been published. Nano-ChIP-Seq is a technique which has begun to address 
this issue by providing a technique which requires only 10,000 cells as a lower limit 
of detection however, this lower limit applied to embryonic stem cells and was higher 
for other cell types (Adli and Berntstein 2011). We therefore proposed that by 
modifying the carrier-ChIP technique by O’Neil et al. (2006) it would be possible to 
sequence an exponentially smaller volume of immunoprecipitated target cells using a 
carrier. The impact of this new, adapted protocol could see a breakthrough in the 
way in which we are able to view post-translation modifications from a clinical 
perspective giving greater understanding and insight into the epigenetic mechanisms 
of real cancer and tumour cells by being able to analyse a broader range of clinical 
sample.  
4.1 Explanation of the Results 
4.1.1 Optimisation of exposure time induces appropriate damage upon DNA. 
Previous experiments had shown that UV treatment induced more effective damage 
to the cells than exposure to chemicals. Upon this discovery the UV treatment 
conditions had to be optimised in keeping with the project objective of causing 
enough damage to the DNA in order to inhibit PCR amplification, while not inducing 
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so much that the cells can no longer be used as viable carriers, but also to ensure 
the loss of cells after treatment is not so drastic as to hinder further experimental 
use. The most important guideline to establish first was the duration of treatment; the 
initial experiments saw 2 treatments of 10 and 20 minutes with very different results. 
While 10 minutes induced minor damage on the cells with only a faint band beneath 
the mononucleosomes representing DNA damage, 20 minutes proved to induce 
significantly more damage, closer to the range of damage required (Fig 3.1). In a 
comparison to check the effect of UV light on cell survival, cells were counted pre- 
and post-treatment. Although the severity of damage occurring to the 20 minute cells 
was in keeping with the level of damage we anticipated, the percentage of cells 
recovered (31 %) was less than ideal. The natural progression from here would have 
been to moderate the duration of treatment to 15 minutes, indeed this would 
increase the number of cells returning from treatment however, it would have also 
seen a decrease in the level of DNA damage induced to the cells which in turn, 
would decrease the rate of inhibition during PCR amplification. Using the 20 minute 
conditions another idea was pitched which involved better temperature control during 
UV exposure. 
4.1.2 Temperature control using a coolled 12-well plate increases cell volume output. 
During UV treatment the UV light inflicts temperatures onto the cells which are high 
enough to cause a percentage to burst open. From this, an idea emerged which 
gave greater temperature control of the solution containing the cells during UV 
exposure. A 12-well plate containing crevices in which ice was allowed to form 
around the wells was created to assess the difference temperature control could 
have on cell destruction. The sample was then treated using these plates and a non-
cooled control to compare the protection offered by the temperature. As expected, 
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the number of cells returning after treatment increased to a 65.5% loss, which 
although was higher than the previous experiment it was still not within the range 
that was aimed for (table 3.1). Amplification inhibition was seen as in fig. 3.2, 
inevitably the reduction in temperature had a negative impact on the UV’s ability to 
inhibit PCR amplification however the reduction in inhibition was well within 
acceptable limits for this project in comparison to the control sample. This finding 
suggests that although more output cells are still required, the cooler temperature 
helps to protect cells during treatment producing a higher volume of cells returning 
from treatment without abolishing the desired level of inhibition. 
4.1.3 Increasing sample volume absorbs too much UV and reduced DNA damage 
Further experimentation on temperature control to reduce cell death during treatment 
lead to the variation of sample volume (concentration was kept to 2 x 107 cells/ ml at 
all times). It was proposed that the larger sample size would encourage the 
distribution of heat more effectively throughout the sample discouraging cell death 
and therefore bringing back more output cells from treatment. Previous experiments 
had used 0.5 ml aliquots of sample in each well of the plate during treatment, for the 
purpose of this investigation some 2.5 ml samples were also treated. As 
hypothesised the number of cells coming back after treatment had increased to 77.5 
% in the 2.5 ml sample. This huge increase was also reflected in the amount of 
inhibition seen during PCR. It was thought that the buffer (buffer NB) used to treat 
the cells created a protective screen between the cells and UV light, or that the 
increased volume distributed the heat too effectively. The electrophoresis in fig. 3.3 
demonstrates that the level of amplification inhibition given by the 2.5 ml sample was 
on par with that provided by the non-UV treated control, the 0.5 ml sample however, 
continued to provide more desirable results. From this data it is evident that another 
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method of temperature control is required which is in keeping with the objective of 
optimising UV treatment which does not protect the cells as much as the increase in 
sample volume. 
4.1.4 Alternating UV treatment with ice proved to be the best temperature control. 
As demonstrated by these results temperature control is key to the optimisation of 
the UV treatment. With this, a treatment schedule was applied to prevent the cells 
reaching temperatures that would be detrimental to their survival but in keeping with 
the already established ideal inhibition by the 20 minute treated sample. Given that 
the 20 minute schedule was too harsh a revised schedule was adopted which 
involved 10 minutes in UV treatment, 5 minutes submerged in ice, 10 further minutes 
under the UV light with a final 5 minute ice treatment (abbreviated to 10 + 10). Figure 
3.4 shows faint bands at only the 132bp amplicon size for the sample following the 
10 + 10 treatment protocol in comparison to the solid bands given from the control 
for all amplicon sizes. Furthermore, the number of cells coming back from UV 
treatment increased to 63 %, double that of the original experiment.  From this it is 
possible to determine that the inhibition provided by these conditions were on point 
for the desired effects as stated in the objectives section. In summary, the optimal 
UV treatment conditions were sample concentration of 2 x 107 cells/ ml in buffer NB, 
separated into 0.5 ml aliquots in a frozen, 12-well plate at a treatment schedule of 10 
+ 10. 
4.1.5 Reducing the stability of SL2 cells aids in optimising the sonication step. 
Sonication is the mechanism used which produces ultrasonic sound waves at high 
intensity to a solution, as a result powerful vibrations are inflicted onto the cells 
causing them to break and expose the contents of the nucleus. The sound waves 
continue to work by fragmenting the chromatin into variable sizes which are used for 
immunoprecipitation. Preliminary experiments using both D.melanogaster SL2 and 
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H.sapien LCL cell types showed significantly different fragmented sizes when 
sonicated at 5-30 cycles with SL2 cells showing much larger DNA fragments. This 
difference in size suggests that the SL2 cells are more robust than the LCL cells, 
therefore an additional step was implemented resulting in cells of an equal stability.  
A follow up experiment which involved freezing the SL2 cells for 1 hour, post-UV-
treatment and prior to chomatin preparation meant the SL2 cells were destabilised 
enough to create fragments of the same size as the LCL cells during sonication. As 
shown in figure 3.5, the lanes showing 10 cycles for both SL2s and LCLs 
demonstrated an abundance of chromatin between the desired lengths of 250-550 
bp. In conclusion, this data shows that the optimal parameters for using SL2 cells as 
carriers during X-ChIP are freezing the sample post-UV treatment at aliquots of 5 x 
107 cells/ ml per sonication sample.  
4.1.6 UV Treated Cells are a Viable Carrier during Cross Linked Chromatin 
Immunoprecipitation. 
Despite the measures taken to create optimal conditions for variables in the protocol 
so far, it had not yet been proven that the UV treated cells were a viable option for 
use as carriers during ChIP. The first step in achieving objective three, to assess the 
practicality of using UV treated cells as carriers during the ChIP experiments for both 
native and crosslinked chromatin, was to carry out the full protocol using only UV 
treated and control D.melanogaster cells. This was done for the formaldehyde 
crosslinked ChIP experiment where all optimised conditions were implemented. 
Table 3.2 identifies the resulting concentration of chromatin after each ChIP and the 
percentage pull-down relative to the input samples. From this table it is justifiable to 
conclude that the UV treated cells could be used as sustainable carriers. 
Interestingly, table 3.2 shows an increase in the percentage LCL pull-down for the 
sample using UV treated carriers compared with the control sample after 
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formaldehyde crosslinking. Initially, the explanation that UV radiation was inflicting 
enough damage to the cells to initiate DNA repair responses resulting in added 
stress markers on the chromatin was suggested however, there was one vital issue 
with this idea; histone markers H3K4me3 and Pol II have already been identified as 
a markers for active transcription, not DNA damage responses. To further investigate 
thesis theories another C-ChIP experiment could be performed using a completely 
unrelated marker, for example H3K9me. 
4.1.7 Immunoprecipitation of as little as 1,000 Human LCL cells using UV Treated 
Carriers. 
The introduction of C-ChIP in 2006 has led to broader applications of ChIP to 
samples of a small cell number, e.g. clinical samples. O’Neil et al. (2006) reported 
successful pull down and real-time PCR amplification when using carrier ChIP with 
as little as 100 mouse cells. Detection of such small quantities required the use of 
radioactive RT-PCR which uses x-ray light to detect amplicons. However, radioactive 
RT-PCR is only semi-quantitative and therefore it was decided that real-time PCR 
would be a more effective use of resources. Recently, Lara-Astiaso and colleagues 
developed a technique known as iChIP, this was published after the work on this 
thesis had been completed, their method reduced the number of cells required for 
ChIP-Seq by five orders of magnitude to just 500 cells (Lara-Astiaso et al. 2014). 
iChIP is a technique which has become of great interest within our laboratory 
however, working through the chromatin isolation procedure by chemical fixation and 
sonication with such small numbers of cells could prove to be detrimental to the 
quality of the resulting DNA. By using a carrier during chromatin preparation the 
target chromatin is less vulnerable to loss during the fixing and sheering steps. C-
ChIP using 1,000 and 10,000 target cells were set up and analysed for both native 
and crosslinked experiments. Figure 3.6 shows the percentage pull down relative to 
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the input for the UV and control samples using 1,000 and 10,000 target cells during 
X-ChIP. In addition to the previous results which showed a higher concentration of 
pull down of target cells after UV treatment compared to the control, similar results 
were observed here showing that this data was not accidental or a ‘one off’. The 
enrichment of target cells in the UV treated samples, as quantified by RT PCR, is 
hypothesised to be a result of damaged DNA. During UV treatment the radiation will 
damage the DNA therefore reducing the amount available for PCR amplification, 
thereby resulting in more reagents available to amplify the target DNA. Furthermore, 
figure 3.7, indicates that the pull down percentage from samples containing 1,000 
target cells was greater than that of the 10,000 cells. It should be noted that these 
results need be addressed with caution, although it is possible for the 1,000 sample 
to result in higher levels of pull down, it was concluded that amplification assessment 
of just 1,000 cells was edging close to the detection limits for the real-time PCR 
machine.  
4.1.8 Analysis of library prepared samples 
For this project to be termed a success the samples would be sequenced after 
library preparation. The produced DNA should correlate with the known genomic 
distribution of RNA PolII and H3K4me3 in LCLs, available form the ENCODE project. 
Before this however, gene-specific enrichment was checked using real-time PCR. It 
is important that the library prepared sample is amplified using both D.melanogaster 
and human primers. In the case of the Drosphila primers amplification would be 
expected to be considerably low in the UV treated sample in comparison to the 
control. Testing against the human primers however, it would be expected that the 
human genes would amplify more readily in comparison to the UV treated 
D.melanogaster amplicons. Furthermore, in the case of amplifying human DNA in 
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the UV treated carrier, lessons from previous results indicate that the LCL DNA 
would amplify better than in the non-UV treated carrier. In addition, given that the 
primer sets used corresponded to different locations on the gene, one of which being 
the TSS (methyl mark H3K4me3), it would be expected to find an abundance of DNA 
associated with this locus in comparison to the other sequences. The purpose of this 
experiment was to use human specific primers for real-time PCR amplification to 
confirm the presence of human DNA in the sample.  
Firstly, the results as shown in figure 3.11 confirm the presence of human DNA and 
therefore pull down of target LCL cells using 1,000 and 10,000 target cells. 
Secondly, when comparing the abundance of DNA in the control to the UV treated 
carrier sample, it is clear that the enrichment of the pull down DNA is greater in the 
treated sample when comparing to the input sample, correlating with the prediction. 
As mentioned above, it was predicted that this graph should show an abundance of 
material at the TSS. Figure 3.11 shows that human sequences are successfully 
amplified in both samples, proving the presence of human DNA in all experiments. 
To summarise, figure 3.11 shows human DNA is present within all samples and that 
the UV treated carriers provide a consistently higher enrichment of human DNA 
compared to the non-UV treated. To further investigate the success of a potential 
new carrier ChIP technique next generation sequencing is required. 
4.2 Troubleshooting 
Since the first paper on chromatin immunoprecipitation was published in 1978 
(Jackson 1978) a huge number of modifications have been applied to the ChIP 
protocol in order to establish optimal running conditions for many variables. It was by 
reading and combining information collected from these variations of ChIP that the 
advantages, limitation and applications of these techinques were collaborated to 
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provide a better, more versatile technique which is more applicable to real, clinical 
samples (see table 1.1). 
Most of the technical issues that occurred have been addressed for the purpose of 
optimising the protocol. However, there were various aspects of the protocol which 
were technically difficult and required adjustment between each experiment. Firstly, 
during native chromatin preparation the cell walls are broken down using a 
homogeniser (O’Neil et al. 2006). The number strokes required for each sample 
varied from 1-15, in order to assess the rate of cell breakdown during 
homogenisation the sample was viewed underneath a microscope between strokes. 
It was found that the UV treated samples were somewhat easier to breakdown than 
the control samples which proved to be problematic. Over homogenisation of a 
sample can cause the premature destruction of chromatin and in turn, sample is lost; 
under homogenisation leads to a lack of available chromatin kept as it is within the 
unbroken cell, neither outcome will provide good chromatin to pursue with further 
experimentation. The complex nature of the homogenisation step caused issues with 
a number of experiments that were attempted and even meant that some 
experiments had to be abandoned. The only way to overcome this was practicing 
being able to spot the difference between a free nucleus, cell debris and unbroken 
cells, this practice came from the volume of experiments that were attempted during 
this project. 
4.3 Further Work and Applications to the Field 
The successful development of cChIP-seq would allow the analysis of smaller 
populations of cells than is currently possible. All cell types contain different cell 
surface markers, a factor which can aid with therapeutic drug targeting, cancer 
diagnostics and cell sorting (Andrews et al. 2013). When tumour cells are recovered 
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from clinical samples a number of cell types are incorporated with in the sample. 
Flow cytometry is a cell sorting technique which has the ability to discriminate cells 
according to their cell surface markers, by doing so tumour cells and non-tumour 
cells can be separated. Further cell sorting can be achieved by separating cells 
according to their position in the cell cycle. Since clinical samples sent for research 
purposes are limited this project could provide a useful tool in analysis of primary 
cells lines. The use of these sample types can have major implications on 
pharmaceutical study, including drug discovery and target identification.  
DNA sequencing is an invaluable tool for the identification of genes, gene sequences 
and as identified here, for use as an analysis of ChIP data. Although the samples 
were prepared and libraries were analysed by real-time PCR, DNA sequencing was 
left incomplete due to time restraints. This project could be continued by the 
sequencing analysis of the library samples. From here, a definitive conclusion could 
be made as to whether or not UV treatment can be used as a valid regime to inhibit 
carrier DNA amplification during sequencing. If, as predicted, the damage inflicted 
upon the cells is enough to create reliable target DNA sequences, the improvement 
could provide a breakthrough in the way research on clinical samples is conducted, 
incorporating how post-translation modifications of histones and other proteins 
impact gene regulation.  
Although the results displayed reason to believe that the 1,000 cell sample contained 
pull down from the LCL cells, the results are unconvincing when addressing the 
relative amounts in the TSS and -500 ad -1,000 bp sequences. Additional time to 
continue with this research could mean the optimisation of the protocol with 1,000 
LCL cells. Since the real-time PCR analysis after immunoprecipitation showed 
enrichment of the target genes it can be concluded that DNA was lost during library 
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preparation. Further work could include the preparation of more ChIP samples, in 
turn more library DNA to take for analysis. Real-time PCR analysis of these libraries 
could provide evidence as to whether or not using 1,000 cells as a target for ChIP is 
beyond the detection limits for. Additionally, further experiments on the inhibition of 
the D.melanogaster DNA would provide a detailed insight into the rate of inhibition, 
especially if carried out with LCL analysis on the same plate where a comparision 
could be made between the enrichment of LCL cells and D.melanogaster.  
Ultimately, next generation sequencing is the next step for this project, since next 
generation sequencer can determine exactly what proportion of the read throughs 
are human, and what are Drosophilia final quantification cannot be made until after 
sequencing.  
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5. Conclusion 
Here, I have described the modification of a well-established technique which can be 
used to aid in the discovery of gene regulatory mechanisms for clinical samples e.g. 
cancers, tumours, diseases etc. Although other versions of ChIP for small cell 
numbers exist, their applications are limited. Despite efforts by researchers the 
analysis of post-translation modifications for clinical samples has proved technically 
difficult leading to gaps in the literature. Introduction of a valid and reliable technique 
which incorporates all of the advantages of using the original chromatin 
immunoprecipitation technique and discarding the disadvantage would have huge 
impacts and potentially revolutionise the way biopsies and clinical samples are 
researched, providing insight into epigenetics of tumour development which have not 
been possible before. The method described holds the benefits of C-ChIP for its 
application with a small cell number for both N-ChIP and X-ChIP experiments, while 
discarding the limitations of background interference of D.melanogaster by C-ChIP. 
The results and figures shown provide solid evidence that by UV treating the 
Drosohila melanogaster carrier cells prior to combination with target cells it is 
possible to inhibit PCR amplification to a substantial degree. It was not possible to 
complete DNA sequencing of the produced libraries within the timeframe of the 
project and this will clearly provide the definitive evidence of the success of the 
technique. Without the results of DNA sequencing, providing a solid conclusion to 
the aim of this project would be naïve and presumptuous. It is possible however, to 
reflect on the proposed objectives.  
Ultraviolet conditions were optimised by variation of the duration, volume and 
temperature of cells during treatment. Troubleshooting with the various conditions 
meant that, in keeping with objective one, it was possible to inhibit PCR amplification 
62 
 
without abolishing carrier qualities of the D.melanogaster cells. Unexpected issues 
arose during X-ChIP optimisation leading to an added step for use with a carrier after 
UV treatment. Objective two was achieved during this troubleshooting stage. Finally, 
immunoprecipitation was achieved for both native and crosslinked chromatin with 
further quantification and real-time analysis on the library prepared samples, 
demonstrating the success of objective three. In addition to these findings, ultraviolet 
treatment of the carrier cells proved to hold more benefits than initially expected. 
Firstly, with the use of real-time PCR, significant amplification inhibition was 
observed for both the native chromatin and formaldehyde crosslinked chromatin 
using carriers. Finally, the data consistently represented highly enriched pull down of 
target DNA when carried by UV treated cells compared to the LCL cells carried by 
non-UV treated D.melanogaster, as quantified by RT-PCR. To conclude, although 
solid conclusions cannot be made without results from DNA sequencing, the data 
represented here tells a story which leaves little doubt that UV treatment of carrier 
cells inflicts enough damage upon DNA to use C-ChIP as a viable and reproducible 
tool in conjunction with high throughput sequencing. 
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Appendices  
Appendix 1: Human CD74 gene primers for -1,000, -500 and TSS. 
gagtgcagtggcgtgatcttggctcactgcaagctccgcctcccgggttcacgccattctcctgcctcagcctccagagtatctgg
gactacaggcgcctaccaccacgcccggttaattttttgtatttttttagtagagatggggttttgccgtgttagccaggatggtct
cgatctcctgacctcgtgatccgcccgcctcggcctcccaaagtgctgggattacaggcgtgagccactgcccccagccataag
ctaggattttaaaggcaggggtaaatctgaggaaagcagaagttataggcaaaattctaaatcaatacatgaaggttatatatt
ggtttgacctaaaaaggtgggacatcttgaagtgggggtccacaggtcatgggtggatttaaagattttctcatttgtcattggtt
aaggacacgaacgtttgtctaaaaatctggggtcagaaaaaaggaatgttagctctggcctgtgggcatgacctcctccaggcc
cctcagaaagaaatttatttatttttaatgtttaaaatgtattatttattgagacaggggctcgctctgtcacccagactggagttta
gtgggacaatcagtgctcactgtagcctcaaactcctgggctcaagtgatccttctgcctcagcctcccatctagctgggactac
agatatgtgctgccacacctggctaattaaattttgttttgttttgttttgtttttgtagaaatgggggggtcttgctttgttgcccag
gctggtcttgaacttctggcctcaagcagtccttccaccttggcgtcccaaagtgctgagattacaggtgtgaaaggaagaaatt
tagagcaaagattggtggttagagtttagtcctctgctcccccttgtctgagatctatgagccagtggatctgtttggtgggggtct
gggtttatgaaaagcaatgcagggacataagttaagatgttatctttagtttttatagggagccaaataccccatgattctaactt
ttttggctattgtcttaagttattactatatttttgtttatcagcttgctcatttacttctcaaggctagctaggtgcctgaaatactttt
gaagaaacgtaagtttctttttcttttcttttcttttttctctttagagatggtcttactctgtcacccaagctgcagtacagtggcatc
atcacagctcactgcagcctggacactcaagcctccggggatcctcctgcctcagcctcctgagtagctgggactacaggcacg
tgccaccacgcctggctaattttagaaaaatttttgtggagacgggggtctcactgtgttgcccaggctggtctcgaactcctggc
ctcaagcgatcctcccaccttggacctgctaaagtgttggaattacaggtgtgagccaccatttctggcctagatttttctctctttt
tatgttggtggggtgctcagctggcccctaagaagggtccctgctctgtctcacagctatttgaaactgtatgttattgttaactat
agtcatcccacaggggtatagaaaatgagaacttagtcctatctaggtgcaattttgtatccttttgcatccccgtccctcccttcc
ccctacccttcccagcctctagtatcctctgttctacttttcacttctatgagttgaactttttttagcttccacatatgagttagaaca
ttctgtgtttaactttctgttcctggcttatttcacttacaaaatgtctccagttccatccagtttcatatcttcagcatcttctatggtg
cgaggctctggctaaatgcttatttagtctaacagctctgcaaggctagtattaccatccctgcattacaaagcagaaagcaaaa
tcagaaaggttgaggggccaggcgtggtggctcacgcctgtaatcccagcactttgggaggccaaggcaggcggatcacgag
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gtcaggagatcgagaccatcctggctaacacagtgaaacaccatctctactaaaaaaatacaaaaaattagctgggtgtggtg
gcgggcacctgtagtcccagctacttgggaggctgaggcaggagaatggcatgaacccgggaggcggagcttgcagtgagcc
gagatcgtgccactgcactccagcctgggcaacagagcaagactctgtctcaaaaaaaaaaaaaaaaagtaaagaaaggttg
agggactggttcagggactcacatgcctaggatgtttctgacttgggatttgaactcaggtctggccacatcaaaggccatgtct
gctcttcgctctcctcccaaaatacatgtactatctcatttgactcttgaaatccaaaactcattgaaccttcgaaccacaagtcta
aatttattaaaaaaaatttattaatgcaaattgtaaagcacacacaatacataaagattaataaaacaaatatggtatataaaa
ggaaacttgtttttttacactcacagcacttctgacaccaaatgtgtggattttttctacaccaacaacaaatgttctaactctctgg
acaccaactgggcatcctacaattcaattctgttcagacactatctacctggggttagcatctgaacccataggttgagggctca
gtcagacaagactcatccacttcagatgccaatcctaagtcccgggactccagtacttctgatgagttggctacaaattgggagt
tcccacgactccctcttcatacttgacaaatagctacaatggcccacagaactgagaagcactttacttactattaccagtttatta
taaaggatacagatgagcagctgatgaagaggtctatagcgtacggcatgtgggaggggtcctgaacacagcagcctctgtcc
ctgtccttgtggagttggggtgcaccaccctcctggcacatggatgtgttcgtctactcgaaagctctccaaacctagttgtttgg
gatttttatgcaagttccattatgtagacatggttggttaaatcactgattgaactcaacctccaacccctctctcctctctggaagt
cggggtggggcgggtgggggtgaggtctgaaagtcccgaccctctcctcacatggcacccagcctccatctgaagctctctagg
ggctttcagccaccagcatttcctgaatatataaaaaaagacattcttctcactctggagatacttttttttttgagatggagtctca
ctctgttgcccaggctgaagtgcagtggtgcgatctcgcacctccgcctccagggttcaagcgattttcctgcctcagcctctcga
gtagctgcgattacaggcacacgtcaacatgtccggctaatttttgtgtttttagtagcggggtttcactatgttggtcaggcttgt
ctcaaactcctgacctcatgatacacccacctcgacctcccaaagtgctgggattacaagcgtgagccaccgtgcctggtcttttt
ttcttttttttcttgtttttttttttttagacagagtcttgctctgtcacccaggctggagtgcagtggtgcgttcttggctcactgcagc
ctctgcctcctgggttcaagcaattcccctgcctcagactcccaagtagctgggattacaagtgtgtgccaccatgcctggctaat
ttttaaattttttgtagagacagggtttcaccatgttggccaggcaagtctcgaactcctgacctcaactgatcctcccgcctcagc
ctcccaaagtgctggaattacaggtctgagccaccacacccaggcttactctggagactctttggttcttagtggtccttgtgtca
ggaaccagggacagagaccagagacgtttttcactatgtcacagcacaggagccttgccaacacagtcccatcctcccaggca
ccctttcccaggctgtcctcttccctcccagcacaggcccccattctcctggatctgaaccacacaaggaggcagaggggtgga
gtggttaaaaatgcaggcgctactactttctggaggtgtgatcctggacaagagcccctgtgtccctatctgtaaatggagatga
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taaaacactcctcaaagggcctccgtaaagatcacaggaaacaaagcatggacaacgtgcctggcacgaaggagagcttggt
aagtggaggcaagtctgagtgccagagccttaaaaccatggactcttaggtttgaaggaaatcaaaatattcctctctaaaaac
ctgcggattttagttaaaggtaaaaggttaaaacccaggggcaccctctgccccttctctctgtcttgatcagctcagaagcaga
gctcagaggatcctggatcagacttgactgttcccatacattcaccttcccacatttccagccctttggaaccctgaagatatcctc
ttctctgtcctgtcactctatgggacttacggctctttgttaaaatactatttaagcaaggcccctaagccactgccttgagagaga
aatacttctcaactgaggcctctactgcataatgggtacagcatgtgttaatcaactttggctgatttttcttttgttaagttgacttt
tgtttccaggggagcgtgtcaactaagaacctaaacagggaaagaaaagaaatgttttcacccctgcacgtcgtccaaacttcc
tcctgcgtgtttgagacgacataacggaggccagagaagaggacttgtctgagctcaccaagggtgcacagcccctttctgcac
ccactcatctgtggatgagaaggggagacaaacaaaggtgtcttctgtttcaaagtgctttcctgtctagggagtggacatttgc
ctgtttcttgaaacattcaaagagccttatgaatccaaaggcctgcccagaaacaagtgatgagggccctgggcagccaatgg
gatcgtgctggcctttctacctgcctggggagcccccccgccccacatcctgccccgcaaaaggcagcttcaccaaagtggggt
atttccagcctttgtagctttcacttccacatctaccaagtgggcggagtggccttctgtggacgaatcagattcctctccagcacc
gactttaagaggcgagccggggggtcagggtcccagatgcacaggaggagaagcaggagctgtcgggaagatcagaagcc
agtcatggatgaccagcgcgaccttatctccaacaatgagcaactgcccatgctgggccggcgccctggggccccggagaggt
atgtgtgagcaccaggaaagggcacaccgatcctggactgcagagccgtgcgcatgtgctgggaagaagcaccggccagga
gtcacaggaaagagggattcaggctctgactctaacattgactttttgggtgattttgagcaagtctttggcctgctctgggctcc
ggctccctctcttgtcaaatgagggggttcctttaagagcaggagtttgtaactttccttgcatcacaccgcctccttctgaaaagc
agaagagagcatgggttctctccctagagtttcacatgctatgcaggggctttgagatcccactaaagctgggctgtgaatgcta
ggttaaaggccttggaacaggctgtgcctggtggctcccgcctgtaatcccagcactttgggaggctgaggcgggcagatcagc
tgaggccaggagttcgagaccagcctggccaacatgttgaaaccccatctctactaaaaatacaaaaattagccagatgtggt
ggtgtacacctgtaatcccacctacttgggaggttgagacatgagaatcacttcaacctgggaggcagaggttgcagtgagcca
agattgtgcaactgtaccccaccctgggtgacacagtgacactctgtctcaaaaaaaataaataaataaataaagaccttgcac
cagattttgaaaatgttcaagatcccagtggagaaagagtttctaaaagaggatggtagaagcagttcttcacagaggagttcc
ctcctaattaccacggatcaagggaatgatagttgcaggtgtctgtagagtagatggagacatctgccatcacaggagggattg
tgagatgttgggggcaggcaagaaaggagggacaggctctggttaaatttctggagggggctcagggttgacgggggtcatgt
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ccttgcctgtgcccctctcccttgcagccagaggccagcacagccatccaggggacaccaggcccccacttcccagccccaaa
atagcctcacccatgtgtttccctcaaaaagggctagaaggctattaccccaatgcccctgctacccccagtctccaaaaagtaa
tttgcgatctacagggacttacagctaggtgtgatgtcagctgttgccaggcagaaaggggtttgggagaaccctgcagagatg
ttatgacaagctatgttctggggaacaaggtaacctgctgcagaccattagagctgtggcctgtgaaaaccccagggaatccca
tggcaaggagggagactgttttgtgaggaatggattcaggtctaggccacgcgtgaccttggataaatcactgcctctccctga
gtctcagtaataatataatagccataatagttctcatccactgtgtacctgtcaccaggcctcagccactgttagttagtactgtga
ttatttacatacgtaaaggctaaactcaattttaattcttacagtcaccctatgaatcaggtacttttgttgtccctttttacagaag
aggaaattgaggtcatattggtaagtgacttacccaagtaatcatagctagtgagtggttggaggcagaatttgaaccaggact
agtctgacatcaaagtgttagctcactccaccatttggccccctttcagaggtgcattttgtgggaaggggaggtgagacccctc
tgagctcagaccactcagtgatttacagacccaggtgggctcagtgttcagagtgcatgtccccttgtctaatccttgtctagtttt
ccctttattcagttactgcttctaaagctggctatgtgtgcttaggccattccagactggagcctgttttggaggcttttgtgaatgc
ttctgcctggcaacatctgtgtcacgattcctgctagctctggttggctcctgactttggcttttttttttttttttttaattgcagaaga
aggtagtgtaaatgaggaaataaagaggggggtgacaagagttggcactctaccagaaccaggggacaggcgttcaagatg
cataaagaggaagaaaagcagatgctaaacttaactacgaactcccctgagaattgcactgagtgtaatttatttatagagtgc
taacaatgtgctaggtgtggagccaagagctttaccctcatcatcttatttaatgtaacagcccttggagcagatgttttacccga
ttttactcacacagagggttaatcaacttagatggtcccagaactaaccgactccagagccaggattccaatccaggttatgtgg
tctcgtcttcagggtgaatctctaggttcttaggcctcctgaggaactgtggtgcagagaggggaaggtactgtcccatgtcgtgt
gtgggaggtagagctggggctagaattgggtgtggggttgcagaagcactgaacaggtggaggatgaggctggagagcctga
acacaggctaggccacccgtgttccttgagaaggccaagaagtagaatttgttttcccttcctgtctggtctccccacttcccccc
cgccccccgcccaccgtcgggtttttgctgtttccttcccgaataactctcccttgggctgggccttatcccagaaagcacagact
ggcacgcagcaagccaatgagaatgagccagtctgtgatgtcatgagttaccaggcacaagggactcctggagcgtcctaaac
catccttgctggttgctggagtaggcagggtgcagcctcatccttgcagttcccaatgggtctgttttagtccgttttgtgccgcttt
aacagaataccacagactgcgtaatatacaaacaaacaaacaaacaaacaaaaaacacccagaaatttatttctcacagttct
ggaggggctttcttgttttttttttttttttttgttatgttttttgagacagagtctcactctatcccccaggatggaatgcagtggtgt
gatcttggctcacagcaacctctgcctcccaggttcaagtgattctcctgcctcagcctcctgagtagctgggactacaggtgccc
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accactacgcccggctaattttttcttttttttttgagatggagcctcactctgttgcccaggctggagtgcaatggcatgatctcag
ctcactgcaacctccaccttccaggttcaagggattctcctgcctcagcctcccgagtagctgggattacaggtgctcgccacca
cgtccggctaatttttgcatttttagtagagacagggtttcaccacgttggccaggctggtctcgaactcctgacctcaggtgatct
acctgtcttggcttcctaaagtgctgggattacaggtgtgagccaccgcgcccggcctagcttgctttcttttttttttctgagacag
tctccttctgtcacccaggctggagtgcagtgacgtgatctcggctcactgcaacctccgcctcccgggttcaagtgattctccca
cctcagcctcccaagtagctgggactagaggtgcacgccaccatgcctggctaagttttttgtatttttttgtagagacggggtttc
gccatgttggccagactggtctcgaactcctggcctcaagtgatccacctgccttggcctcccaaagtgctgggattacaggcgt
gagtcaccacacccagcctggtgaggggcttccttgatgtgtcctcatatggtggaaggcagaagggcaagagagaaccaact
ccttccatcaagccgtcttacagggcacctaatcccattcgtgagggagaaggccttgtggcccgatcacctcccaacaccttca
cattggcaacacctggactagggtcttagtagtcccacccctggggtcgtcaaagaacagatcagaaactcctggggtgtagg
ggcaggatccttacatcccctgtactgtaacatatgcatgcaccccccagtcgcatccaagtcccacagatacaagggcttgctg
aggtccgagggtctggatggtgagtccagggagcatgagaaattcatccaggccacacaggctcaggcacctatactcctgcc
caccccctgcaggatggatattaccatttgaaatactttggcgcttgcagtgagatcttgcttaaaagaagaaacccaccaaatt
ctagaatcgcagaggtgggggcacctatgtgacaaatgagggaacagaggcacagagattggcagggacatgctcaaagac
atggagagcctgggcagaggatggccccagagtgggtggtgcctggccctgcttcagcctgacattgtccaagcctcccccag
cccactcctaaaatggccaggccccacttcttcccaggtgggctacattttctgctgtcccggtcccacttccttaccttttctcctt
aaatctgatttcactgtgagggtgggaggttgggcagaggggtgaaaaccctcttccccttacttggtaagcacatacaatttttt
ttggttttgtcaattaaaaaaaataacatacctggttgatcctgccagcagaaaaaaaaaacaaaacaaaaggctgggcgcgg
tgactcacgcttgtaatcccagcactttgggaggctgaggtgggtggatcacgagatcaggagatcgagaccacggtgaaacc
ccgtctctatcaaaaatacaaaataattagccaggcgtggtggcgggtgcctgtagtcccagctactcggagaggctgaggaa
ggagaatggcataaacccaggaggtggaggttgcagtgagccgagatcgcgccactgcactccagcctgggcgacagagca
agactccgtctcaaaaaacaaaacaaaacaaaacaaaacaaaaaccaaacctgttccccttgagggcagccctgatcatcag
gagatccgcacggcaaagggagcctgggaagacccccccacctcaacccctcatcgcacaggcaggaccctaaggtccaga
gaggacaaagagcatgcctctttgctcttctctgttcaactcaggcccgtggcagctgcagggtctctgccagggaagacttcag
gcacatcgatggttggaaggaggggtggggtgaggtcttcaagctgtgtttccatagccagcttactgtttgtgcttcaaatgcat
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tgtttattaggggtggcttaggggtctaatggagatgggggtatacatttccccattcctagccagcccttggggcagccaccact
gtggatcctcctctgacctatcctccccacctcccacagcaagtgcagccgcggagccctgtacacaggcttttccatcctggtg
actctgctcctcgctggccaggccaccaccgcctacttcctgtaccagcagcagggccggctggacaaactgacagtcacctcc
cagaacctgcagctggagaacctgcgcatgaagcttcccaagcgtgcgtgcacccctacatcctgataccccccacctcccacc
atccctcaactcagagacccgcatccctgcacccagctgggcccactgtcctctccctccggtttggaattccagcccttcctcat
ctgggtctgataccctcctccctgggcaccggggccacacttaccctcgttcctgtccccacagctcccaagcctgtgagcaaga
tgcgcatggccaccccgctgctgatgcaggcgctgcccatgggagccctgccccagggggtaaggacagccccagggtggtg
ggaggggcaaggttatcccgcctggatggaggacagtgccaaggggaggggcagggaagagagcccacctggggaggggt
cctgactgctgcgggagggacagtgcctgcctcaggaagaatcgggctccccaggtgtggagggcacaggtgaagagtctctt
ggtgccatccctgggaggaaggctcagccctctacagtttacaaagtgcttctcatttcctatagcatctcactgtcctctcccatt
ctcaaagaccttgctatcatgcattgacaatatttatattcacaatactgtgctgtggacaaaaccctgggcaggaaagcttatgc
cagtttgaccaatgaggacattgaggcaggaagctaaagtgacttgctcgagctctcatgtttggaggtggcagagatggaac
cattgaccaagtgcctgcgattccagtctcttacctagatcccagcaaccggctcctgctccataccccctgctccagggaccag
ctctggtaaccttctgttacttcctcccacagcccatgcagaatgccaccaagtatggcaacatgacagaggaccatgtgatgca
cctgctccaggtgagtgcagggagctagctgggtggtcctgcctgcccacccaggaccctggccgggccaagctccaaggcct
gtatacctggctcatggcagactttcaacatgtgctctctggattactgaatacaagggtgacccttaaatgttatatgtagtctgg
cctctgcatttttgagataaacaggctcggctgggtgcagtggctcatgcctgtaatctcagcactttgggaggcctaggcaggc
agatcacctgaggccaggagttcgagaccagcctggccaacatagtgaaagtctctactaaaaatacaaaaattagccggatg
tggtggcagtcacctgtaatcccagctactcatgaggttgaggcaggagaatcgctttaacccgggaagtggaggttgcagtga
gccgagatcatcacgccactgcactccagcctgggtgacagagtgagactccatttcaaaaaataaaataaaataaaaataaa
aaaagaaactgaggctcaaagtttggaagtgacttgctcaagacaccctttttttctccccaaatttgtactgcgtgtctgtcctat
gccagcactgtgcaaggctctgggcccacaatggggagcaattggacccagctcctgaagccatggggatcccaggctagtgt
gggagacagacaagtgaccaggtgatgacagaagtgcagggggctttgtgaagaaagaggcagaggactcaacctagctgg
gggcagtcaaggttgggtcctcacctgctggagcaggtaagacctgaaagctgagcagccatccacagggaggacactgggg
cttgttggtagagctggcctggaatctggaactcgactcgcaacgctgcagtctcgtagctgaacagctggactacccttacccg
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taccctcccctcccctcccatcatggctgaagtccagggtttaggcttggtgtagctctggtccattcctcagaatggaagaccaa
gggaacgtgggctacacatttcacactgcctgccagggagctcttcttgaaccatccttcctgccctgctaccctgtagaatgctg
accccctgaaggtgtacccgccactgaaggggagcttcccggagaacctgagacaccttaagaacaccatggagaccataga
ctggaaggtcagcaggtttccctgcatgggaactctctctttcctctggtgtctagggcagggctaggagaggtggggtgagggt
gggctggggaagccattctcaggaagctgaaggggtttaccagcacttccaaaacctggatgctgcagagtatgtggggttca
gccccaggggtctttaagagggaaccaggctgcagctggacccgggtgttggggccctatttggccctgcatgtttctgtcccca
ggggcaaagccaggcagtgtaggggcttggtggtggccatcgaacctgacctccacctctatccgtattaggtctttgagagct
ggatgcaccattggctcctgtttgaaatgagcaggcactccttggagcaaaagcccactgacgctccaccgaaaggtacaggg
agtgggagctttagcgtgccagggcttctggaccctcggggctctcctgaagctgctgaggccggggcctccagcactccctgg
tcccagcaccgcggaatctcccatcctctcagctctcacttctttctcacttctctctctctcctgtctgttccttcttggtttggctgtc
cccctcccctgacccacccccatcttgtctaagggttcctaagggcccacagaggcctgtcaccacagggtacaggtgacctctc
tcatagaggatggtacagcacagggtgcctggggtagaacctgcccgaaacactgcagaaaggaatccttgtaatgaccttgc
cccagtgctgcccgcaatccagtgagggcgccaaggtcacagctgctgccaagagagccttgggcgtttcccacctcatggac
aatgcagactaggatgtttttagacccaaagacagagtgctgtttctatcccggtgctgtctctaatttgctatgtaactttggaca
agtccccttccctctaggattcagggtcctgaagtagaaggtcaaagggccaccctgcctggggcctcagtttctgcatcagatt
catagaaggcaccttacatgctatctccaactcctagctgatgcttaaacccctctaagacatctccaacaaacggtaaacccca
tttctacttgagaactcccagtaacaggaagcttagacttaccaaggtgcccattgcttttctctagaatcagaatcgcaagtgca
attccaaactgtaatggtgtttttttgtttgattgtttgtttttgagatagagtctggctctgtcgcccaggctggagtgcagtggtgc
gatctcagctcactgcaacctcagcctcccgggttcaagcaattctcctgcctcggcctcccgagtagctgggattataggcatgt
gccaccacgcccagctaatttttgtatttttagtagagacagggtttcaccatgttggccaggctggtcttgaactcctgacctcaa
gtgatccgcccacctcggcctcccaaagtgctaagattacaggcatgagccactgtgcctggcccaaaactgtaatgggctttg
agtgtcagaagaaaccatcaacttctgaggtgaattggacacatggccattcacttcctttttgatctcagaccttgttggtctag
gcctcagttttcccatccgtgtgatggctggagtgagtaaagccacttgggaagaaggcattaagcccacagcagtggtgtgtg
ggtctttagctctgctcagaccctggttcagagctcactcactcactgtgtcctcatcatgcctgtcgcttcagtactgaccaagtg
ccaggaagaggtcagccacatccctgctgtccacccgggttcattcaggcccaagtgcgacgagaacggcaactatctgccac
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tccagtgctatgggagcatcggctactgctggtgtgtcttccccaacggcacggaggtccccaacaccagaagccgcgggcac
cataactgcagtggtaagcagtggcactgtgccagtgtcagaggaccaggaaggactaggaaggttgaggggcaagaggtcc
cctctgaagcacatgggaccaggacacccaggatggcagctcctgggggcagtgacgtagtcatgcgtccagccctttatccat
ccacccacctgtgcattcctatttgtccatttatcatctctcctcttacatgcactcatatttgttcacttatccgtcagtcctttcatct
gtgaatttcatccatccacgcgccatcctctagcatccaggagtcctacagacccacccatctcatttcatcacccccttctcactc
gagcccccattacacctctttgttgctgcttgcagctgtccttccctgggtacctgctttcccaggcactaagcctgtggctaggtg
ggaagcactgccctcaggcatcttgggtcaggtaggctgcacttcaagtgacaaacggacttgctgctcctttgcagagtcactg
gaactggaggacccgtcttctgggctgggtgtgaccaagcaggatctgggcccaggtaagggccttgcagaggggcatctggt
caccagcagctcatccccagcagggccagctcctttgtgggcaggtgaaggagtgtgacgctgggccactctccaacattcctg
ggatgtccatttcacagacgaaggaacagggttggggggctgtggggagttacacaaatccatgatggtcattattggacctga
gcagggggcaggggagggtggacagtccttaactgctctgcaggtccaggatgttagaaaggggcagggacaacaaatggg
tgaccccaacctcaacctgctgcttctctctccagtccccatgtgagagcagcagaggcggtcttcaacatcctgccagccccac
acagctacagctttcttgctcccttcagcccccagcccctcccccatctcccaccctgtacctcatcccatgagaccctggtgcctg
gctctttcgtcacccttggacaagacaaaccaagtcggaacagcagataacaatgcagcaaggccctgctgcccaatctccatc
tgtcaacaggggcgtgaggtcccaggaagtggccaaaagctagacagatccccgttcctgacatcacagcagcctccaacac
aaggctccaagacctaggctcatggacgagatgggaaggcacagggagaagggataaccctacacccagaccccaggctgg
acatgctgactgtcctctcccctccagcctttggccttggcttttctagcctatttacctgcaggctgagccactctcttccctttccc
cagcatcactccccaaggaagagccaatgttttccacccataatcctttctgccgacccctagttccctctgctcagccaagcttg
ttatcagctttcagggccatggttcacattagaataaaaggtagtaattagaacactctggctcctggctcttctgttgagatcca
gttcatttatcctaaagaggtaactaaagacgctaaatccagtcactgaggtgggagaacgcagcccaagtaacccacagaga
tgcctgcggggccaggcaggcctgggggggggcttgtagtctttggacacagacatacttgattacatgtttaacacacacgaa
cactctacttccaaaaagaaataggctcttgcctagtttaagcacaagctcttcttggtacagctttcattttcctatgtccccaatt
tcatttctatactaagaacagtgtgaatgtgatgacagatggcaaccgacatagggcctccgtgtcaggatggacaggaagtag
gggactgtggagaactgggtgcccatgccttacctaaggggctgactgctactcagctctatctggttgctgccaggaggaagc
acagcccccgttgccagatgttatctttttaagaggagccagaaatcaagaactgcagtgaaatcaccccatttttaagtttaaa
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gtcttgctgtgggtcaacaaggcccaatgaggacactactctgtagttctgttctagagcaacatgcttgagaggagagaggcc
agatggtggagggtctggccccgggccccgagtcaagggtgcagctggatgccaacctgggtctccgacacctccagccatgc
attccttttctgcactgcctctggctgtttccagcatgaggctaaaagctctggagaccatctccaggacccctggtgttccacatg
gctctgggcccagggaagtgggcttctgcatttccaggctggagcagcagaccacctcctttgctatccctcccctccctcagtcc
acacccaagacatcatcctgtctttcatgttcatccacttcttgccctcaccaccacagaaccatggtgagctcgatttgaggggc
aactcacttccgattttcctagacctgctgtgcctgccacagctgttcaccaggcacctccagggagcctgcccctagctcgagg
cctaactcgaggattctcagccccttccatttcttgtctttgggtatttacatgacttactctggcaacaggaaatcaaccatgacc
atcctttagttccatcctttagtttagatgccacctcatccaggaagccttccccaccaattcggcactcaggcacttcactgctca
ctgcctgtcccactaaccacggtcacccatagcctcaacatgcaggcaagagggaatcccgagtgtcggcgagacagtccctt
ccaagaaacatgtgccccagatgcactgggagcttgcacccttcctccaagtcttttattttttttttgagttattaaaaaaaaaac
aaaaaacacaaccaaaagaactgacgagaggaagacaaagcctcgggatcagccagagaccgagcggcacgggatgagg
cacaggtcaggcctagctggatctgtggagcaaggtggtgggaagtcccgaggcctttgggcatgtggggtctgtggaaggag
aggaggtcacttaaaaaaatacatatactgtacacatctatatgaagcgtcctgtgttgggggagtggggtgaggtcatgggag
ctggtccactttctccttggaccagcctccccgcaggctcactggcttggccagcacagggacccctgaagctggctgtcttcttc
tgtggagcgagggaaggtaacagtttagttccaacccatggtgggcagaggtcggtggaggtcagaggcatggggatggcca
ctgctcggctaggaaatccctaggggaaggaaacacatgcagatgtcaaatttcctgacccttttcccctgcaaggaaaatgaa
atctggcatctccaatgcaggggggaggcattaaccacagtggacattttttagcacttggaatgttctgagaactgggctgagt
cctttagtgtttagtttagcttc 
 
-1000 Primers  F – C T T G C C A A C A C A G T C C C A T C  
   R –G T G A T G T T T A C G G A G G C C C T 
 
Transcription Start Site  F - A T G C A C A G G A G G A G A 
    R – A C C C A A A A A G T C A A T G T 
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Appendix 2: Drosophila melanogaster GapDH gene primers for 132 bp 
amplicon. 
tctagaacttaaagaactaacttggcaacaatgtaaagaaaaactttagtgcaagatgaaggaattttatacttgacaatgcta
atttttgtataaacttcattacgtaaagggtcctacaacccatatatatcattagttgttagaggctctttttaaggcgcttatataa
tcaaaccctttgtaaaaattaaagttttaaatggaattctaatcgatttatttcacattagctttatttaagtgtgacctacgcagaa
agctagcgaaatactcatcaaccctcccccgccatcgccagcgccattctcctaatttgcgaaaaaagctccgggaaaaggaa
aaagcggcagtcgtaatagcgaactgaaactgaacgagagtaaaagttaaaagacagcaggaactcagccatgtcgaagat
cggaatcaacggatttggccgcatcggccgcttggtgctccgcgccgccatcgataagggcgcctccgtggtggccgtcaacga
tcccttcatcgatgtcaactacatggtttacctgtttaaattcgactcgactcacggtcgtttcaagggcaccgttgcggctgagg
gcggattcctggtggtgaacggccagaagatcaccgtgttcagcgagcgcgacccggccaacatcaactgggccagtgctgga
gccgagtatgtggtggagtccaccggagtgttcaccaccatcgacaaggcgtccacccacttgaagggcggtgccaagaaggt
catcatctcggccccatccgccgatgcgcccatgttcgtgtgcggcgttaacctggacgcctacagccccgacatgaaggtggt
ctccaacgcctcgtgcaccaccaactgcctggctcccctggccaaggtcatcaatgacaacttcgagatcgtcgagggtctgat
gaccaccgtgcacgccaccactgccacccagaagaccgtcgacggtccctctggcaaactgtggcgcgatggacgtggcgcc
gcccagaacatcatcccggccgccaccggagccgccaaggctgtgggcaaggtcatccccgccctgaacggcaagctgaccg
gcatggctttccgcgtgcccacgcccaatgtctccgttgtggatcttaccgtccgcctgggcaagggagccacctatgacgaaat
caaggctaaggtcgaggaggcctccaagggacccctgaagggaatcctgggctacaccgacgaggaggtggtctccaccgac
ttcctcagcgacacccattcgtctgtgttcgacgccaaggctggcatttcgctgaacgataagttcgtcaagctaatctcgtggta
cgacaacgagttcggttactccaaccgcgtcatcgacctgatcaagtatatgcagagcaaggactaaactagccacaactatcg
tacaaacccggccagcagctggtcgggaatcactgttgcataatccgcaaggggcgcaattgaggatgctttttttttcaaatgc
acaaaatagccataattacgcaaagtacatatttattgttgttgaataaagtatcgccctgttactgtatttaaatgccagctattt
gaaaaataaaacttgtgcatcgaatgaagaacgttgcttgtgtaagcccaaggcgtgtgaaggttatatcgggcggacttgctg
agatatgcagtgaatacacaaataagtatctgtgcttcgcctgggggagtcatcccaatcccaaaggaacgatgtttctatttat
gtcatcatatgtatgtatgtacgtttgttgttgccaactctggcagtctcgaaattcgaagataacgaacaaatatattctcttacc
gctgcactttcaaacctgtgcggatgctgtttgtttgtctcggattttgattccttcggcaaaacaacataaatacacataacgacc
aattgaactcagaccatataaacatatatgcttatatatactttatactttttggtggataaagggtttgttttcatatatcgacctg
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cgttcctatacaaagaggctttcttatgagcataaccaaggtcacgaaaggtcatacatatacttgctgcttggtacataacttat
cggcattacagaattgaatcgat 
 
Forward primer:     AGCGAACTGAAACTGAACGA 
 
Reverse primer:    TATTCCCGCGGAGGCA 
 
Total amplified sequence:    133bp 
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Appendix 3: Drosophila melanogaster GapDH gene primers for 211 bp 
amplicon. 
tctagaacttaaagaactaacttggcaacaatgtaaagaaaaactttagtgcaagatgaaggaattttatacttgacaatgcta
atttttgtataaacttcattacgtaaagggtcctacaacccatatatatcattagttgttagaggctctttttaaggcgcttatataa
tcaaaccctttgtaaaaattaaagttttaaatggaattctaatcgatttatttcacattagctttatttaagtgtgacctacgcagaa
agctagcgaaatactcatcaaccctcccccgccatcgccagcgccattctcctaatttgcgaaaaaagctccgggaaaaggaa
aaagcggcagtcgtaatagcgaactgaaactgaacgagagtaaaagttaaaagacagcaggaactcagccatgtcgaagat
cggaatcaacggatttggccgcatcggccgcttggtgctccgcgccgccatcgataagggcgcctccgtggtggccgtcaacga
tcccttcatcgatgtcaactacatggtttacctgtttaaattcgactcgactcacggtcgtttcaagggcaccgttgcggctgagg
gcggattcctggtggtgaacggccagaagatcaccgtgttcagcgagcgcgacccggccaacatcaactgggccagtgctgga
gccgagtatgtggtggagtccaccggagtgttcaccaccatcgacaaggcgtccacccacttgaagggcggtgccaagaaggt
catcatctcggccccatccgccgatgcgcccatgttcgtgtgcggcgttaacctggacgcctacagccccgacatgaaggtggt
ctccaacgcctcgtgcaccaccaactgcctggctcccctggccaaggtcatcaatgacaacttcgagatcgtcgagggtctgat
gaccaccgtgcacgccaccactgccacccagaagaccgtcgacggtccctctggcaaactgtggcgcgatggacgtggcgcc
gcccagaacatcatcccggccgccaccggagccgccaaggctgtgggcaaggtcatccccgccctgaacggcaagctgaccg
gcatggctttccgcgtgcccacgcccaatgtctccgttgtggatcttaccgtccgcctgggcaagggagccacctatgacgaaat
caaggctaaggtcgaggaggcctccaagggacccctgaagggaatcctgggctacaccgacgaggaggtggtctccaccgac
ttcctcagcgacacccattcgtctgtgttcgacgccaaggctggcatttcgctgaacgataagttcgtcaagctaatctcgtggta
cgacaacgagttcggttactccaaccgcgtcatcgacctgatcaagtatatgcagagcaaggactaaactagccacaactatcg
tacaaacccggccagcagctggtcgggaatcactgttgcataatccgcaaggggcgcaattgaggatgctttttttttcaaatgc
acaaaatagccataattacgcaaagtacatatttattgttgttgaataaagtatcgccctgttactgtatttaaatgccagctattt
gaaaaataaaacttgtgcatcgaatgaagaacgttgcttgtgtaagcccaaggcgtgtgaaggttatatcgggcggacttgctg
agatatgcagtgaatacacaaataagtatctgtgcttcgcctgggggagtcatcccaatcccaaaggaacgatgtttctatttat
gtcatcatatgtatgtatgtacgtttgttgttgccaactctggcagtctcgaaattcgaagataacgaacaaatatattctcttacc
gctgcactttcaaacctgtgcggatgctgtttgtttgtctcggattttgattccttcggcaaaacaacataaatacacataacgacc
aattgaactcagaccatataaacatatatgcttatatatactttatactttttggtggataaagggtttgttttcatatatcgacctg
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cgttcctatacaaagaggctttcttatgagcataaccaaggtcacgaaaggtcatacatatacttgctgcttggtacataacttat
cggcattacagaattgaatcgat 
 
Forward primer:    AGCGAACTGAAACTGAACGA 
 
Reverse primer:     GAAACGACCGTGAGTCGAG 
 
Total amplified sequence:    212bp 
  
84 
 
Appendix 4: Drosophila melanogaster GapDH gene primers for 310 bp 
amplicon. 
tctagaacttaaagaactaacttggcaacaatgtaaagaaaaactttagtgcaagatgaaggaattttatacttgacaatgcta
atttttgtataaacttcattacgtaaagggtcctacaacccatatatatcattagttgttagaggctctttttaaggcgcttatataa
tcaaaccctttgtaaaaattaaagttttaaatggaattctaatcgatttatttcacattagctttatttaagtgtgacctacgcagaa
agctagcgaaatactcatcaaccctcccccgccatcgccagcgccattctcctaatttgcgaaaaaagctccgggaaaaggaa
aaagcggcagtcgtaatagcgaactgaaactgaacgagagtaaaagttaaaagacagcaggaactcagccatgtcgaagat
cggaatcaacggatttggccgcatcggccgcttggtgctccgcgccgccatcgataagggcgcctccgtggtggccgtcaacga
tcccttcatcgatgtcaactacatggtttacctgtttaaattcgactcgactcacggtcgtttcaagggcaccgttgcggctgagg
gcggattcctggtggtgaacggccagaagatcaccgtgttcagcgagcgcgacccggccaacatcaactgggccagtgctgga
gccgagtatgtggtggagtccaccggagtgttcaccaccatcgacaaggcgtccacccacttgaagggcggtgccaagaaggt
catcatctcggccccatccgccgatgcgcccatgttcgtgtgcggcgttaacctggacgcctacagccccgacatgaaggtggt
ctccaacgcctcgtgcaccaccaactgcctggctcccctggccaaggtcatcaatgacaacttcgagatcgtcgagggtctgat
gaccaccgtgcacgccaccactgccacccagaagaccgtcgacggtccctctggcaaactgtggcgcgatggacgtggcgcc
gcccagaacatcatcccggccgccaccggagccgccaaggctgtgggcaaggtcatccccgccctgaacggcaagctgaccg
gcatggctttccgcgtgcccacgcccaatgtctccgttgtggatcttaccgtccgcctgggcaagggagccacctatgacgaaat
caaggctaaggtcgaggaggcctccaagggacccctgaagggaatcctgggctacaccgacgaggaggtggtctccaccgac
ttcctcagcgacacccattcgtctgtgttcgacgccaaggctggcatttcgctgaacgataagttcgtcaagctaatctcgtggta
cgacaacgagttcggttactccaaccgcgtcatcgacctgatcaagtatatgcagagcaaggactaaactagccacaactatcg
tacaaacccggccagcagctggtcgggaatcactgttgcataatccgcaaggggcgcaattgaggatgctttttttttcaaatgc
acaaaatagccataattacgcaaagtacatatttattgttgttgaataaagtatcgccctgttactgtatttaaatgccagctattt
gaaaaataaaacttgtgcatcgaatgaagaacgttgcttgtgtaagcccaaggcgtgtgaaggttatatcgggcggacttgctg
agatatgcagtgaatacacaaataagtatctgtgcttcgcctgggggagtcatcccaatcccaaaggaacgatgtttctatttat
gtcatcatatgtatgtatgtacgtttgttgttgccaactctggcagtctcgaaattcgaagataacgaacaaatatattctcttacc
gctgcactttcaaacctgtgcggatgctgtttgtttgtctcggattttgattccttcggcaaaacaacataaatacacataacgacc
aattgaactcagaccatataaacatatatgcttatatatactttatactttttggtggataaagggtttgttttcatatatcgacctg
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cgttcctatacaaagaggctttcttatgagcataaccaaggtcacgaaaggtcatacatatacttgctgcttggtacataacttat
cggcattacagaattgaatcgat 
 
Forward primer:     AGCGAACTGAAACTGAACGA 
 
Reverse primer:    CTGGCCCAGTTGATGTTG 
 
Total amplified sequence:   310bp 
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Appendix 5: Drosophila melanogaster GapDH gene primers for 410 bp 
amplicon. 
tctagaacttaaagaactaacttggcaacaatgtaaagaaaaactttagtgcaagatgaaggaattttatacttgacaatgcta
atttttgtataaacttcattacgtaaagggtcctacaacccatatatatcattagttgttagaggctctttttaaggcgcttatataa
tcaaaccctttgtaaaaattaaagttttaaatggaattctaatcgatttatttcacattagctttatttaagtgtgacctacgcagaa
agctagcgaaatactcatcaaccctcccccgccatcgccagcgccattctcctaatttgcgaaaaaagctccgggaaaaggaa
aaagcggcagtcgtaatagcgaactgaaactgaacgagagtaaaagttaaaagacagcaggaactcagccatgtcgaagat
cggaatcaacggatttggccgcatcggccgcttggtgctccgcgccgccatcgataagggcgcctccgtggtggccgtcaacga
tcccttcatcgatgtcaactacatggtttacctgtttaaattcgactcgactcacggtcgtttcaagggcaccgttgcggctgagg
gcggattcctggtggtgaacggccagaagatcaccgtgttcagcgagcgcgacccggccaacatcaactgggccagtgctgga
gccgagtatgtggtggagtccaccggagtgttcaccaccatcgacaaggcgtccacccacttgaagggcggtgccaagaaggt
catcatctcggccccatccgccgatgcgcccatgttcgtgtgcggcgttaacctggacgcctacagccccgacatgaaggtggt
ctccaacgcctcgtgcaccaccaactgcctggctcccctggccaaggtcatcaatgacaacttcgagatcgtcgagggtctgat
gaccaccgtgcacgccaccactgccacccagaagaccgtcgacggtccctctggcaaactgtggcgcgatggacgtggcgcc
gcccagaacatcatcccggccgccaccggagccgccaaggctgtgggcaaggtcatccccgccctgaacggcaagctgaccg
gcatggctttccgcgtgcccacgcccaatgtctccgttgtggatcttaccgtccgcctgggcaagggagccacctatgacgaaat
caaggctaaggtcgaggaggcctccaagggacccctgaagggaatcctgggctacaccgacgaggaggtggtctccaccgac
ttcctcagcgacacccattcgtctgtgttcgacgccaaggctggcatttcgctgaacgataagttcgtcaagctaatctcgtggta
cgacaacgagttcggttactccaaccgcgtcatcgacctgatcaagtatatgcagagcaaggactaaactagccacaactatcg
tacaaacccggccagcagctggtcgggaatcactgttgcataatccgcaaggggcgcaattgaggatgctttttttttcaaatgc
acaaaatagccataattacgcaaagtacatatttattgttgttgaataaagtatcgccctgttactgtatttaaatgccagctattt
gaaaaataaaacttgtgcatcgaatgaagaacgttgcttgtgtaagcccaaggcgtgtgaaggttatatcgggcggacttgctg
agatatgcagtgaatacacaaataagtatctgtgcttcgcctgggggagtcatcccaatcccaaaggaacgatgtttctatttat
gtcatcatatgtatgtatgtacgtttgttgttgccaactctggcagtctcgaaattcgaagataacgaacaaatatattctcttacc
gctgcactttcaaacctgtgcggatgctgtttgtttgtctcggattttgattccttcggcaaaacaacataaatacacataacgacc
aattgaactcagaccatataaacatatatgcttatatatactttatactttttggtggataaagggtttgttttcatatatcgacctg
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cgttcctatacaaagaggctttcttatgagcataaccaaggtcacgaaaggtcatacatatacttgctgcttggtacataacttat
cggcattacagaattgaatcgat 
 
Forward primer:    AGCGAACTGAAACTGAACGA 
 
Reverse primer:    CGAGATGATGACCTTCTTGG 
 
Total amplified sequence:   410bp 
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Abstract  
Fanconi anaemia (FA) is a rare, recessive, inherited disease characterised by the 
biallelic instability of one of 16 proteins associated with the DNA double-stranded 
break (DSB) repair pathway – FANCA, FANCB, FANCC, FANCD1, FANCD2, 
FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN, FANCO, 
FANCP and FANCQ. Affected individuals with gene deficiency affecting the FA core 
complex have a similar clinical appearance, while patients whose defect (eg in 
FANCD1, FANCN) is in the pathway downstream of this show a more severe 
presentation including the occurrence of embryonal tumours and may not survive 
infancy. The FANCN gene otherwise known as PALB2 (Partner and Localiser of 
BRCA2), was originally described as a FA associated gene in 2006 and most of the 
laboratory work reported to date has been carried out on cells from a patient, 
EUFA1341. I describe here work towards an investigation of the role of two mutant 
PALB2 proteins identified in an unusual FANCN family, with a milder presentation of 
Fanconi anaemia. I was able to confirm the presence of the correct PALB2 mutant 
DNA sequence following transfection of separate constructs into U2OS cells. I was 
also able to show PALB2 protein expression from each PALB2 mutant construct in 
these cells as the first step to examining the functions of these separate mutant 
PALB2 proteins. 
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1. Introduction 
1.1 Fanconi Anaemia 
Fanconi anaemia (FA) was originally identified as a familial panmyelopathy by Dr 
Fanconi (Lobitz 2006) and later confirmed as inherited in an autosomal recessive 
manner. The typical clinical presentations in FA patients include marked growth 
retardation, congenital malformations (most famously absent thumbs and radial 
aplasia), progressive bone marrow failure (the origin of the name), and tumour 
predisposition, particularly, myeloid leukaemia and also some epithelial tumours.  
It was not until 1964 however, that spontaneous chromosome instability was 
identified as being associated with FA (Schroeder et al. 1964, Lobitz 2006). At about 
the same time it was discovered that FA patient’s cells were chromosomally 
unusually sensitive to DNA crosslinking agents like Mitomycin C and subsequently, 
diepoxybutane (DEB). It was not until 1991, however, that the first Fanconi anaemia 
defective gene was identified, FA-A, on chromosome 20q (Mann et al. 1991). Since 
then, 15 additional genes have been identified which, when mutated, cause FA. 
These are now named FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, 
FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN, FANCO, FANCP and FANCQ 
(Strathdee et al. 1992, Joenje et al. 1995, Levitus et al. 2004, Reid et al. 2007, Xia et 
al. 2006a, Vaz et al. 2010, Cybulski and Howlett 2011, Osorio et al. 2013). Fanconi 
anaemia occurs when the offspring of two carrier parents inherit both FANC 
mutations (biallelic mutation). Heterozygous carriers of some FANC genes are also 
known to have a predisposition to some cancers (Reid et al. 2007, Tischkowitz and 
Xia 2010).  
1.2 The Fanconi anaemia signalling pathway 
Over the past 20 years the proteins associated with the many FANC genes have 
been studied in detail and it is now clear that there are many protein complexes 
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which form during the repair pathway. The first to be defined was the FA core 
complex. The core complex was initially identified when Kupfer et al. (1997) 
identified an interaction between FANCA and FANCC, enabling their localisation to 
the nucleus which could not be achieved as a single protein. Further work identified 
FANCG as being part of the same complex (Garcia-Higuera et al. 1999). Eight 
proteins, FANCA, FANCB (FAAP95), FANCC, FANCE, FANCF, FANCG, FANCL 
(PHF9/ FAAP43) and FAAP100 (Kupfer et al. 1997, Garcia-Higuera et al. 1999, 
Garcia-Higuera et al. 2001, de Winter et al. 2000, Meetei et al. 2003a, Meetei et al. 
2003b, Ling et al. 2007) have been identified as the proteins which function as the 
Fanconi anaemia core complex. Following exposure of cells to a DNA damaging 
agent, the FANC core complex facilitates ubiquitination of FANCD2 via FANCL 
which allows an association with FANCI (the ID2 complex). The ID2 protein complex 
is targeted to chromatin where it interacts with BRCA1/BRCA2 and other proteins to 
allow repair of the cross link. 
A chromatin bound DNA translocase protein, FANCM (FAAP250) in association with 
FAAP24 (Fanconi anaemia-associated protein 24), recognises DNA damage; in 
response FANCM is phosphorylated at Ser1045 in an ATR-dependant reaction (Kim 
et al. 2008, Singh et al. 2013). FANCM is able to recognise a stalled replication fork 
and stabilise it until downstream proteins are localised to damaged foci. 
Phosphorylation of FANCM activates the DNA damage response by assembling of 
the FA core complex. In turn FANCM is recruited to the site of DNA damage where 
the FANCM-FAAP24 complex acts as an anchor, stably binding the core complex in 
position. Meanwhile, FANCD2 and FANCI are phosphorylated in another ATR-
dependent reaction following DNA-damage response activation (Ishiai et al. 2008). 
Monoubiquitination of FANCD2 (FANCD2ub) via the E3 ubiquitin ligase, FANCL of 
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the core complex, at K561 sequentially follows the assembly of the core complex; an 
action essential for the targeting and co-localisation of FANCD2 within the nuclear 
foci (Kim et al. 2008, Garcia-Higuera et al. 2001, Ling et al. 2007, Meetei et al. 
2003b). FANCD2ub is consequently transported to chromatin at the site of DNA 
damage where it signals for the pre-formed complex between FANCN-FANCD1 
(PALB2-BRCA2) to form FANC(CD1-N-CD2) (Zhang et al 2009a, Zhang et al. 
2009b, Sy et al. 2009a), thereby initiating DNA repair via homologous recombination 
through interactions between proteins such as RAD51 (Xia et al. 2006a).The 
Fanconi anaemia pathway is complex, it is involved in repair of DNA crosslinks, 
recognition of stalled replication forks and in the repair of DNA double strand breaks. 
Phenotypically, Fanconi anaemia patients diagnosed with mutatons within proteins of 
the core complex (FANC-A, -B, -C, -E, -F, -G, -L, -M) display a less severe version of 
the disease compared to patients with mutated proteins downstream of the core 
complex, i.e. FANCN, FANCD1 and FANCJ. FA core complex patients on average, 
show onset of squamous cell carcinoma (SCC) at around 31 years (Kutler et al. 
2003), in contrast Reid et al. (2007) published a collection of several FA-N patients 
and their phenotypes (extended version in table 1.1), the median onset of tumour 
growth started at 2 years, these patients also suffered with more severe and often 
multiple tumours. This difference in severity and age of growth suggests a more 
aggressive disease which can be easily differentiated from core complex related FA 
(Howlett 2007).  
1.3 PALB2 
Located on chromosome 16q12.2, PALB2 is a 131 kDa, 1,186 residue nucleoprotein 
involved in the DSB repair pathway (Xia et al. 2006a). The structure of PALB2 is 
complex and it is composed of several domains and motifs which are essential for 
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various protein-protein interactions required within the DSB pathway. Figure 1.1 
shows the structure of PALB2. PALB2 N-terminal sequence from a.a 6-90 reveals a 
conserved coiled coil domain (see figure 1.3) (Sy et al. 2009a, Zhang et al. 2009a, 
Zhang et al. 2009b). Similar to that of the DNA double helix, a coiled coil domain is a 
protein domain in which a collection of heptad repeats crystallise to form an α-helix. 
When 2-4 α-helices are present they form a super-helix. The amino side chains 
perform in a ‘knobs into hole’ mechanism whereby one amino acid (the knob) will 
lodge into the surrounding area of four residues on an equivalent helix (see figure 
1.2). The ‘knob’ residue is located at either the ‘a’ or ‘d’ position in an a-g heptad 
repeat structure where each repeat includes two coils (Lupas 1996, Liu et al. 2006). 
Residues 395-446 encompass a structural motif broadly conserved among 
vertebrates known as the Chomatin Association Motif, ChAM (figure 1.4). The 52 
amino acid sequence mediates PALB2-chromatin interaction via nucleosome binding 
and deletion of this motif has been shown to cause disruption to chromatin 
localisation of PALB2 in damaged and normal cells (Bleuyard et al. 2012). The 
PALB2 C-terminus is comprised of 7 chain WD40 repeat sequence, whereby each 
repeat constitutes a symmetrical, 4 tier anti-parallel β-sheet; together it combines in 
a velcro-like locking mechanism where the N-terminal repeat links via hydrogen 
bonding to the C-terminus on the 7th sheet creating a 7 spear β-propeller (Fulop and 
Jones 1999, Oliver et al. 2009). This domain is essential for stability of the protein 
and has been implicated in many protein-protein interactions required for DSB repair 
such as BRCA2, RAD51, RAD51C (figure 1.5) (Park et al. 2013) and Polyermase η 
during DNA synthesis at blocked replication forks (Buisson et al. 2014). 
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Figure 1.2 [Reproduced from Liu et al. 
2006, figure 3F] A Standard Coiled Coil 
Motif. The diagram shows 7 heptad 
repeats where positions ‘a’ and ‘d’ form 
the side chains needed for the ‘lock in 
hole’ mechanism.  
PALB2:  
Chromosome 16q12.2;  
131 kDa; 1,186 a.a 
6 90 
Coiled 
coil 
395 446 
ChAM 
853 118
6 
WD40 heptad 
repeats 
611 764 
MRG15 
binding 
site 
BRCA
1 
Chromatin MRG1
5 
BRCA2 
RAD51C 
RAD51 
Figure 1.1 PALB2 basic structure identifying the locations of the coiled coil domain, 
ChAM motif and WD40 repeats. The figure also shows where BRCA1, chromatin, 
MRG15, BRCA2, RAD51 and RAD51C bind. 
Figure 1.3. [Modified from Sy et 
al. 2009a, figure 2A] PALB2 
coiled-coil domain. Located at the 
N-terminus of PALB2, the heptad 
repeat structure interacts with 
BRCA1 at the isolated LYL ‘a’ 
position.  
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Figure 1.4 [modified from Bleuyard et 
al. 2012, figure 5] ChAM in association 
with PALB2 and chromatin. The 
diagram shows the location of ChAM 
on PALB2 with respect to chromatin, 
BRCA2, MRG15 and RAD51 
Figure 1.5 [Reproduced from Oliver 
et al. 2009, figure 1b] PALB2 WD40 
domain. Each β-propeller (1 - 7) is 
made up of 4 tiers (A – D), the 
arrows indicate the direction N-
terminal to C-terminal. The blue tier 
(7D) represents the ‘velcro-like’ 
locking mechanism.  
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1.4 BRCA1/BRCA2 Complex 
A major breakthrough came when BRCA2 was identified as FANCD1, a discovery 
which confirmed a long debate about the association between the BRCA and FA 
proteins. Howlett et al. (2002) sequenced both BRCA1 and BRCA2 in cells of FA-B 
and FA-D1 patients. Normal sequences were found in the BRCA1 gene but biallelic 
mutations were discovered in the BRCA2 gene leading to the finding that FA-D1 is 
characterised by defects in BRCA2.  
PALB2 functions in homologous recombination as one part of a multi-subunit 
complex with BRCA1 and BRCA2 (FANCD1). Shortly after the discovery of PALB2, 
Reid et al. (2007) and Xia et al. (2006b) identified PALB2 as the gene for Fanconi 
anaemia subtype-N. This discovery allowed for diagnosis of FA-N in many patients 
who were of a previously unclassified FA subtype.  
Previous studies have shown that interaction between PALB2, BRCA1 and BRCA2 
proteins is an essential component of the DSB pathway. Using co-IP these studies 
have shown that BRCA1 binds to N terminus of PALB2 (Xia et al. 2006b, Reid et al. 
2007, Sy et al. 2009a, Zhang et al. 2009a, Zhang et al. 2009b) in the coiled coil 
motif. BRCA1 also contains a C-terminal, double helical, coiled coil domain between 
exons 11 and 13 at residues 1364-1437 (Clark et al. 2012). Coiled coil domains are 
known for their role in protein-protein interactions and the BRCA1-PALB2 interaction 
is no exception, refinement experiments showed that the second α-helix in BRCA1 
(a.a. 1397-1424) is responsible for formation of a BRCA1-PALB2 heterodimer 
complex (Sy et al. 2009a).  
BRCA2 binds to the PALB2 C-terminus. Zhang et al. (2009b) originally specified the 
point of interaction to the 3rd and 4th WD40 repeat, however more recent evidence 
located this interaction to the 4th and 5th β-sheet (Oliver et al. 2009). These residues 
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have since been identified as a hydrophobic ‘pocket’ found between the 4th and 5th 
spear in the β-propeller. Residues Val 1019, Met 1022, Ala 1025, Ile 1037, Leu 1046, 
Lys 1047, Leu 1070, Pro 1097 and Lys 1098 have so far been implicated in the 
functional formation of this pocket. Immunoprecipitation using mutant PALB2 
proteins, A1025R, M1022A and M1022R indicated that the alanine at amino acid 
position 1025, located at the bottom of the hydrophobic pocket on PALB2 has a 
more pivotal role in the bond between BRCA2 and PALB2, abolishing the BRCA2 
binding affinity in mutant cells (Oliver et al. 2009). Xia et al. (2006a) were first to 
locate the site of PALB2 binding within the first 40 residues of the amino tail on 
BRCA2, further evidence identified that a tryptophan at residue 31 located at the N-
terminus of BRCA2 is responsible for binding to PALB2 alanine 1025, therefore 
indicating that this residue also holds a crucial role in the BRCA2-PALB2 interaction. 
1.5 Other PALB2 interacting proteins 
RAD51, a 339 amino acid recombinase protein, is the central protein involved in 
homologous recombination. It forms helical nucleoprotein filaments at the site of 
DNA damage in an ATP-dependent reaction (Ogawa et al. 1993, Galkin et al. 2006). 
BRCA2 plays a critical role in the localisation of RAD51 to sites of DSB; however 
PALB2 is required for enhanced RAD51 function (Buisson et al. 2010). PALB2 
utilises the role of its N-terminal WD40 repeat domain to mediate the direct 
interaction with RAD51 and the location has been refined to residues 853-1186 on 
PALB2 (Park et al. 2013). Additionally, a RAD51 binding site has been observed at 
the C-terminal coiled coil located at residues 1-200. RAD51 was reported to bind to 
PALB2 at amino acids 184-257.  
RAD51C, another FANC protein categorised as complementation group FA-O, is 
one of five paralogues of RAD51 which also include, RAD51B, RAD51D, XRCC2 
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and XRCC3 and all play a role in HR. It has been proposed that RAD51C, PALB2 
and BRCA2 work in a complex as the central component controlling homologous 
recombination and in turn, genomic stability. The 376 aa polypeptide, RAD51C, has 
been identified as a direct binding partner of PALB2. Mutant PALB2 lacking blades 
5-7 from the WD40 repeat domain was unable to co-immunoprecipitate Rad51C, 
therefore, indicating these residues (1098-1186) on PALB2 as essential for RAD51C 
binding affinity (Dosanjh et al. 1998, Park et al. 2013). 
MRG15 has been indicated as another direct binding partner of PALB2 within the 
BRCA complex where residues 611-764 of PALB2 are required for MRG15 
interaction (Sy et al. 2009b). Conflicting reports on the effects of MRG15 and its 
function have been published. In one study Sy et al. (2009b) reported that PALB2 
mutant cells deficient in the MRG15 binding domain demonstrated no difference in 
BRCA2 localisation to the site of DNA damage after MMC treatment compared to 
unperturbed cells, and that these mutant cell lines conferred resistance to MMC. 
Conversely, Hayakawa et al. (2010) later suggested that MRG15 acted 
independently of BRCA1 in localising PALB2, BRCA2 and RAD51 to DNA damage 
foci and that depletion of MRG15 also lead to the decrease of BRCA2 to DNA 
damage site therefore inducing hypersensitivity to MMC. 
1.6 Fanconi anaemia, caused by mutation of FANCN. 
In 2006, Xia et al. (2006b) published the first case of Fanconi anaemia caused by 
mutation of PALB2 which they designated FANCN. Having ruled out all other FANC 
genes known at that time, they tested for mutation of PALB2 as a plausible 
candidate gene, and showed that their patient, indeed had biallelic PALB2 mutations. 
Since then, more studies have revealed more cases of the FA-N subtype with 
PALB2 mutations (see table 1.1), including an interesting mutation giving a truncated 
99 
 
protein just 3 residues before the original stop codon. This mutant is noteworthy as it 
represents the importance of the WD40 domain located at the C-terminus of PALB2. 
The locking mechanism found within the WD40 domain, where the N-terminus joins 
the C-terminus as the 4th tier on the 7th blade, is removed.  In turn, the loss of this 
mechanism renders the protein unstable and PALB2 can no longer localise to the 
site of DSB on chromatin, leading to ineffective DSB repair and therefore, chromatin 
instability (Xia et al. 2006b, Reid et al. 2007, Oliver et al. 2009).  
Analysis of one FA-N patient, EUFA1341, identified two novel mutations, the 
paternally inherited deletion of exons1-10 and the maternal mutation, a nonsense 
nucleotide mutation resulting in a truncated protein at residue Y551X (Xia et al. 
2006b). In their study Xia et al., identified a revertant cell line in which the maternal 
mutation had undergone a further change (as a result of growth of the cultured cells 
in the presence of a cross linking agent) and had become resistant to the killing 
effect of this agent.  The revertant protein occurred as a result of loss of exon 4 and 
retained both N- and C-terminal sequences of PALB2 and therefore potential 
function. These mutants (the germline Y551X and the revertant due to loss of exon 4 
mutation) are significant here since they may have similar end products to the likely 
proteins expressed from the mutations in the family that I studied. Xia et al. 
concluded that, the PALB2 revertant with the large exon 4 deletion was functional. 
However, the N-terminal Y551X PALB2 mutant was unable to function. Moreover, in 
another publication by Reid et al. (2007) a truncated protein, Y1183X, depleted 
PALB2 activity due to the loss of just the final 3 residues in the C-terminal WD40 
repeat locking mechanism destabilising the protein, and in turn PALB2 activity is lost.   
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1.7 Lymphoma 
Lymphoma is a cancer affecting lymphoid cells of the immune system and can occur 
through a variety of mechanisms most notably through the inhibition of tumour 
suppressor genes or the activation of oncogenes. All lymphomas arise as a 
consequence of a chromosome translocation involving an immune system gene and 
an oncogene. Prior loss of a particular tumour suppressor gene may increase the 
frequency of such translocations. When the body is invaded by an infectious agent 
the immune response is activated, this initiates lymphocytes to recognise the 
infection and increase production of antibodies as a line of defence. T cells control 
the pathway by recognising the antigen and in turn, secreting other proteins which 
initiate the full immune response. B cells produce two types of immunoglobulins with 
antigen binding capacity, the B-cell receptor and antibodies, the first is an integral 
membrane protein which sits on the membrane and lies dormant until acted upon, 
the antibody is a secreted protein with duplicated antigen binding specificity. The 
production of both functional immunoglobulin and T cell receptor requires the 
rearrangement of both immunoglobulin and T cell receptor genes, which involves 
breakage and re-joining of the DNA in these regions. The same is true for class 
switching. DNA DSB repair pathways are required for this process. The cell may be 
vulnerable to chromosome translocation at these times and indeed many lymphoid 
tumours carry translocations where the breakpoint is within an immune system gene, 
indicating a role for this process in tumourigenesis (Bastard et al. 1992; Kerckaert et 
al. 1993; Miki et al. 1994). These translocations can either be the switch needed to 
activate oncogenes, or deactivate tumour suppressor genes (Ekstrom-Smedby 
2006). In light of this, the importance of the DSB repair pathway becomes 
increasingly highlighted by stabilising genomic aberrations.  
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Dr Thomas Hodgkin first described 7 patients with what is now known as Hodgkin 
lymphoma in 1832 (Hodgkin 1832). The most recent universally accepted 
classification, as outlined by the World Health Organisation (WHO), organised 
lymphoma cases into a number of sub-types. The document denoted an adaptation 
of the original, REAL classification (Revised American-European Lymphoma 
Classification) (Campo et al. 2011). Lymphoma neoplasms are either derived from B 
or T cells, with B cell neoplasms being the most prominent in 2010 (94%) (Cancer 
Research UK 2013). Inevitably, since there are significantly more cases, B cell 
lymphoma is considerably better understood with the 5 most common subtypes 
including Diffuse Large B-cell Lymphoma (DLCL), Follicular lymphoma, Marginal 
Zone lymphoma, Mantle Cell lymphoma and Burkitt lymphoma. According to the 
American Cancer Society more than 350,000 new cases of NHL were diagnosed in 
2008, globally (American Cancer Society 2008). In the UK, more recent data 
identified NHL as being the 6th most common cancer in 2010 with 12,180 new 
patients diagnosed (Cancer Research UK 2013).  
1.8 Fanconi Anaemia and Lymphoma 
Fanconi anaemia is associated with myeloid tumours. However, since the FANC 
pathway is involved in DNA DSB repair, lymphoid tumours (which arise as result of a 
defective repair in DNA DSB) might be expected to occur in at least a proportion of 
FA patients; those who have defects in DNA DSB repair. Indeed there are 
occasional reports of such tumours in FA patients but, they are unusual (Shen et al. 
2006, Smedby et al. 2006, Hill et al. 2006, Xiao et al. 2008). Shen et al. sequenced a 
catalogue of 29 NHL cell lines and four genes associated with the FANC/DSB repair 
pathway were identified, WRN, XRCC3, BRCA1 and BRCA2/FANCD1. The endpoint 
examined was loss of protein by Western blotting. However, according to their 
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results only single nucleotide polymorphisms (SNPs) found in BRCA1 and WRN 
could be correlated to NHL with statistical confidence. More interestingly, light has 
been cast on to the expression of FANCN/PALB2 and its correlation with lymphoma 
(Xiao et al. 2008). Xiao et al. speculated a negative correlation between the level of 
FANCN/PALB2 expression and susceptibility to lymphoma from a SNP in exon 5 
found in 2 patients. Since FANCN/PALB2 plays a major role in homologous 
recombination during DNA double strand break repair it would be valuable to look 
deeper into the epidemiology of lymphoma caused by genetic variation in 
PALB2/FANCN.  
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Table 1.1. Summary of published FA-N patients. Table extended from Reid et al. 2007, Table 1. 
Patient Location Modification Resulting in Associated 
phenotype 
Reference 
 Nucleotid
e position 
Amino 
acid 
position 
Nucleotide 
change 
Amino acid 
change 
   
1 
 
1,653 551 T > A Y > X Truncated protein 
at residue 551X 
Skin, thumb, heart 
and kidney 
abnormalities; 
growth retardation; 
endothelial cancer. 
Xia et al. 2006b 
Exon 1 - 10 Deletion Shortened protein 
2 
 
3113 1105 2835_3113del
279/A946 
 Protein truncates 
at frame shifted 
residue 1,093X 
Growth retardation, 
loss of right kidney, 
medullablastoma 
Reid et al. 2007 
395 132 Del T Frame shift Protein truncates 
at frame shifted 
residue 527X 
3 
 
757_758 253 Del CT Frame shift Protein truncates 
at frame shifted 
residue 254X 
Growth retardation, 
left pelvic kidney, 
hypoplastic 
thumbs, Wilms 
tumor, AML, 
medulloblastoma 
Reid et al. 2007 
3294_3298 1,098 Del GACGA Frame shift Protein truncates 
at frame shifted 
residue 1,119X 
4 2257 753 C > T R > X Truncated protein Growth retardation, 
microphthalmis, 
microcephaly, 
bifurcated anus, 
Wilms Tumor 
Reid et al. 2007 
3549 1183 C > A Y > X Truncated protein 
5 2393_2394 799 Ins CT Frame shift Protein truncates 
at frame shifted 
residue 850X 
Growth retardation, 
microphthalmia, 
microcephaly, 
Reid et al. 2007 
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3350 1118 Ins GCAG Frame shift Protein truncates 
at frame shifted 
residue 1,122X 
bifurcated anus 
6 2521 841 Del A Frame shift Protein truncates 
at frame shifted 
residue 849X 
Growth retardation, 
microcephaly, 
horseshoe kidney, 
gonadal 
dysgenesis, Wilms 
tumor, 
medullablastoma 
Reid et al. 2007 
3323 1108 Del A Frame shift Protein truncates 
at frame shifted 
residue 1,122X 
 
7 2962 988 C > T Q > X Truncated protein Growth retardation, 
hypoplastic thumb, 
microcephaly, 
medullablastoma 
Reid et al. 2007 
3549 1183 C > G Y > X Truncated protein 
8 3116 1039 Del A Frame shift Protein truncates 
at frame shifted 
residue 1,039X 
Growth retardation, 
microcephaly, hand 
abnormalities, skin 
hyperpigmentation, 
Neuroblastoma 
Reid et al. 2007 
3549 1183 C > G Y > X Truncated protein 
9 1676_1677 
Homozygous 
526 Del AA, Ins G Frame shift Protein truncates 
at frame shifted 
residue 559X 
Abnormal thumbs, 
Horseshoe kidney, 
Neuroblastoma, 
Wilms tumor. 
Serra et al. 2012 
11 1176_1677 526 Dell AA, Ins G Frame shift Protein truncates 
at frame shifted 
residue 559X 
Non-Hodgkin 
lymphoma 
This thesis 
Exon 6 In frame deletion Shortened protein 
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1.9 Aims and Objectives 
1.9.1 Objective 
Using experimental procedures my aim was to clone the two PALB2 mutations, in a 
particular PALB2 family, into different cell lines so that the consequences of each 
mutation could be examined independently at the cellular level.  This involved 
isolating many clones, testing each one for PALB2 expression and potentially the 
activity of the two different proteins. This was to be done by determining whether 
these mutant proteins were able to directly interact with BRCA1 and BRCA2, and 
whether they localised BRCA2 to the site of DSBs. EUFA1341 mutant cells, Y551X, 
and the exon 4 revertant were used as controls. 
1.9.2 Aims 
1. Using Western blotting to confirm the size and quantity of PALB2 protein in cells 
from family members 
2. Using site directed mutagenesis to create separate cell lines for each mutation 
from this new family and using DNA sequencing to confirm that the target mutations 
were present and also check protein expression in these lines.  
Site directed mutagenesis cell lines to include: 
 Y551X- EUFA1341 
 Q559R fsX2 (Del/ins) – my patient 
 Exon 4 deletion (revertant of Y551X) – EUFA1341 
 Exon 6 deletion- my patient 
 Wild type 
3. Perform siRNA knockdown of the endogenous protein in order to remove 
endogenous PALB2 activity to allow visualisation of induced PALB2.  
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4. Immunoprecipitate the knockdown cells with antibodies for BRCA1, BRCA2 and 
FLAG to determine whether mutant PALB2 interacted with these proteins. 
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2. Materials and Method 
 
2.1 Creating U2OS/FRT/T-REX cell lines that express wild type or the mutant 
PALB2 
PALB2 mutant cell lines were created for wild type (WT), revertant exon 4 deletion 
(X4), patient exon 6 deletion (X6), Y551X and Q559RfsX2 (1676_1677delAAinsG 
deletion_insertion (del/ins) for experimental purposes. To facilitate the integration of 
the PALB2 gene into the FRT site in the  U2OS Flp-In T-REX cells, wild type and 
mutant cDNA copies of PALB2 had been cloned previously into the expression vector 
pcDNA5/FRT/TO that had been modified to include the FLAG peptide sequence N- 
Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C (DYKDDDDK). Induction of expression of the 
PALB2 cDNAs in the U2OS cells would produce PALB2 protein with the FLAG 
peptide fused in frame to the N-terminus of the PALB2 protein. Inclusion of the FLAG 
peptide would allow the PALB2 protein expressed from the integrated cDNA copies 
of PALB2 to be identified against the background of the PALB2 protein normally 
expressed by the U2OS cells. The FLAG sequence, DYKDDDDK, had been inserted 
into pcDNA5/FRT/TO plasmid from pcDNA3-NTAP (Gingras et al. 2005, Tasto et al. 
2001) using the restriction endonucleases KpnI and PmeI (Chen et al. 2008).  
Parental U2OS/FRT/T-REX cells were maintained in DMEM medium containing 10% 
foetal bovine serum (FBS), 50g/ml Zeocin and 5g/ml blasticidin. Covalently closed 
circular plasmid (bulk prep) DNA was transfected into the U2OS/FRT/T-REX cells 
using lipofectamine® 3000 (Invitrogen). Adherent U2OS/FRT/T-REX cells were 
plated at 3x106 cells per 10cm dish in DMEM and serum, but without antibiotics, prior 
to transfection the following day. Plasmid DNA was diluted to 160ng/l in Opti-MEM 
medium without serum. Diluted plasmid DNA (1.6g in 10l) was mixed with 14.4g 
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of plasmid pOG44 and 32l P3000 Reagent in Opti-MEM without serum, made up to 
1ml with the medium.  Lipofectamine 3000 Reagent (40l) was diluted to 1ml in Opti-
MEM medium without serum. The 1ml aliquot of diluted DNA (PALB2 plasmid and 
pOG44) with P3000 Reagent was mixed with the 1ml Opti-MEM/Lipofectamine 300 
Reagent and incubated at room temperature for 5 minutes. During the incubation 
period the U2OS cells, still adhering to the tissue culture plate, were washed in 
phosphate buffered saline (PBS) which was subsequently replaced with 8ml of Opti-
MEM medium without serum. The 2ml of DNA/Lipofectamine, now containing DNA-
lipid complexes that were formed during the incubation period, was added to the cells 
and incubated at 37oC in a humidified atmosphere of 5% CO2 in air. After 4.5 hours 
the Opti-MEM containing the DNA and Lipofectamine was removed and replaced 
with DMEM containing 10% FBS but omitting antibiotics. The following day each dish 
of transfected cells was split to four 75cm2 tissue culture flasks and each culture 
incubated in 12ml DMEM with FBS but without antibiotics. The following day the 
medium was removed and replaced with DMEM 10% Tetracycline-free FBS 
containing 200g/ml hygromycin and 5g/ml blasticidin. The medium was removed 
and replaced with the same medium every five days. After approximately 14 days 
colonies of selected cells became apparent. The four flasks of selected colonies for 
each PALB2 plasmid construct were pooled together and aliquots taken for further 
growth and freezing down. Cells were frozen down in 1.0ml vials in freezing medium 
that contained 50% Tetracycline-free FBS, 40% DMEM and 10% dimethylsulfoxide 
(DMSO). U2OS/FRT/T-REX cells that had been selected for retention of PALB2 
constructs were grown routinely in DMEM 10% Tetracycline-free FBS containing 
200g/ml hygromycin and 5g/ml blasticidin. Confluent cultures of cells were 
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washed in PBS, detached from the plastic surface of the tissue culture plate/flask 
using small volumes of TrypLE Express (1x) stable trypsin replacement enzyme and 
diluted into fresh DMEM 10% FBS containing antibiotics. 
An aliquot of the pooled selected colonies for each PALB2 construct was taken for 
DNA extraction to check that the U2OS/FRT/T-REX cells had been transfected with 
the correct plasmid. DNA was extracted using the Qiagen DNeasy Blood and Tissue 
Kit for Purification of Total DNA from Animal Blood and Cells (Spin-Column Protocol) 
(Qiagen 2006). An initial PCR reaction was used as an indicator of whether or not the 
transfections had been successful. The PCR products were analysed on a 1 % 
agarose gel (containing Midori Green to aid visualization of the DNA) against a 1 kb 
ladder, actual amplicon sizes were compared with expected values. 
 
 
2.2 DNA sequencing 
Following PCR amplification the sample was cleaned using the ExoSAP-IT® protocol 
from Affymetrix removing excess primers and dNTPs. The Applied Biosystems 
BigDye® Terminator v3.1 Cycle Sequencing Kit provides fluorescently tagged dNTPs 
for use during sequencing using PCR amplification of single stranded amplicons. 
Following the manufacturers guidelines a BigDye® reaction was set up. 
Table 2.1 Primer sequences used during sequencing and futher PCR reactions 
Primers 
77143F  G T T G T T G A A T T C G G C G C G C C A A T G G A C G A 
G C C T C C C G G G A A G C 
1975R G A C T C A G G A T T T G C G T A C C T A T G T 
1513F C T T G T C T A G G A A G G C A G T T G 
1803R T T T A A A C T C A G C A T T C C A T C 
2143F C T T T A A A T A C G G T T G C G C C T G A T G 
2463R C T A T C A A G G T C A C G G A C T A C A 
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After BigDye® PCR, precipitation of 50 ng of PCR product was achieved by 
incubation in a solution of ethanol and sodium acetate for 20 minutes. DNA and other 
moieties were separated by centrifuging for 22 minutes, 16,000 x g. The supernatant 
was removed and the pelleted DNA was washed with 70 % ethanol. DNA was air 
dried at room temperature for 10 minutes and resuspended in 12 µl of HiDi (highly 
deionised) formamide. DNA was denatured at 100 ºC for 5 minutes and quenched on 
ice to inhibit any re-annealing during sample loading. Samples were loaded on to a 
96 well plate and sequenced using an Applied Biosystems 3500XL Genetic Analyser. 
2.3 Bradford Assay 
 
Protein was quantified using the Bradford assay by calculating the light absorbance 
of the protein in a coloured dye at various wavelengths. In high protein conditions the 
dye turns blue, in low protein conditions the dye is red. A controlled protein gradient 
using diluted BSA at concentrations of 100, 200, 300, 400 and 500 µg /µl was used to 
y = 0.0014x + 0.3058 
R² = 0.9985 
0
0.2
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(Series1)
Figure 2.1 Example graph used for R2 values to assess pipetting accuracy 
during the BioRad Bradford protein quantification assay. 
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monitor accuracy of pipetting and potted on a graph for R2 values, an example is 
shown in figure 2.1.  
2.4 Western Blot  
A Western blot is used to measure protein length and expression by blotting the 
protein against an antibody specific to the protein of interest. Firstly, the cell lysate 
was created by purification from other cellular debris and quantified using the BioRad 
Bradford protein quantification assay. A 6 % SDS polyacrylamide gel (0.1 M Tris, 0.1 
M Bicine, 6 % Acrylamide, 0.1 % SDS, Temed, APS) was set, loaded and run for 4 
hours 30 minutes to ensure clear separation of the larger proteins. Proteins were 
transferred onto nitrocellulose paper overnight by electrophoresis in transfer buffer 
(400 mM glycine, 50 mM tris, 20 % v/v methanol) and then cut to size ready for 
immunoblotting. To block the unspecific binding of antibodies the protein bound 
nitrocellulose paper was shaken in a 5 % milk in TBST solution (20 mM tris, 200 mM 
NaCl, 0.1 % tween 80) for 1-4 hours. Following unspecific blocking, the nitrocellulose 
paper was washed in TBST buffer and the primary antibody was added (See table 
2.2). The primary antibody was blotted in a 5 % milk/ TBST solution, shaking 
overnight. The primary antibody is specific to the protein of interest and will therefore 
only bind where the designated protein is located. After washing, the secondary 
protein was blotted by shaking the nitrocellulose paper in diluted 5 % milk in TBST 
buffer. The secondary antibody contains a tag which binds to the primary antibody 
and reacts with luminescent reagents during the development of the autoradiography 
film. The nitrocellulose was washed a final time and treated with the imaging agents, 
ECL or illuminol. 
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2.5 Colony selection 
Colonies of growing mutants with variable morphologies were selected by pipetting 
the target colony under a microscope and transferring to 1 ml of media in a 3 x 4 well 
plate. 48-96 colonies were chosen for each cell line.  
2.6 Doxycycline induction 
The plasmid vector, pcDNA5-FLAG contains a tetracycline inducible promoter region, 
in order to test the activity of the cloned PALB2 peptides the cells were induced using 
the tetracycline derivative, doxycycline. After 24 and 48 hours the adherent cells 
were treated with trypsin and harvested ready for protein quantification before 
Western blot analysis. 
2.7 Knockdown of endogenous PALB2 using siRNA. 
The siRNA used here was specific to the 3’ UTR region of PALB2 mRNA (see table 
2.3), since pcDNA5-PALB2 constructs did not include this site only endogenous 
PALB2 would be knocked down. Cell were split, counted and divided up into 
approximately 0.25 x 106 cells per 10 cm tissue culture dish and left to multiply 
overnight. The following day a fresh transfection buffer including warm optimem, 
oligofectamine and siRNA to 180, 90, 45 and 22.5 nM final concentration was made 
in an RNAase free tube and incubated at room temperature for 30 minutes. Cells 
were washed and resuspended in optimem before adding the transfection buffer 
(dropwise), mixing by agitation the cells were then left for several hours. Cells were 
incubated overnight in 2 ml of McCoys medium + 20 % Fetal Calf Serum (FCS) (no 
Table 2.2 Antibodies used during experimental procedures 
Antibody Epitope binding site Purchased from 
PALB2 246A (Rabbit) Residues 200-250 Bethyl Laboratories Inc. 
PALB2 247A (Rabbit) Residues 675-725 Bethyl Laboratories Inc. 
Anti-FLAG M2 (Mouse) FLAG sequence 
(DYKDDDDK) 
Sigma Aldrich 
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penicillin/streptomycin). Knockdown efficiency was analysed using a Western blot, 
using antibody PALB2 246A. 
 
 
2.8 Immunoprecipitation 
Cell lysates were created using 8 x 106 cells per IP. The cells were treated with IP 
lysis buffer and incubated on ice for 30 minutes. After incubation the solution was 
centrifuged for 5 minutes at 10,000 x g and the supernatant was kept. Using antibody 
concentrations 2, 4, 6, 8 or 10 µg, FLAG antibody was added to the cell lysate and 
left to rotate overnight at 4 ᵒC. Finally, 25 µl of protein G beads were added (50 µl of 
50 % beads + NETN solution) to each lysate and left to rotate at room temperature 
for another 4 hours.  
To remove additional cell debris from the sample the beads were centrifuged and 
washed with 1 % NETN solution (20 mM Tris-Cl, 100 mM NaCl, 0.5 mM EDTA, 0.5 % 
v/v NP40) twice. Before Western blot analysis the control samples were quantified 
using the BioRad Bradford assay, control and immunoprecipitated cell lysates were 
then mixed with 4 x loading dye ready for Western blot analysis. 
 
 
 
 
Table 2.3  SiRNA sequence used during knockdown of endogenous PALB2 
Forward G G A G A A U A U C U G A A U G A C A d T d T  
Reverse U G U C A U U C A G A U A U U C U C C d T d T 
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3. Results 
3.1 Assessing PALB2 size and level of expression in lymphoblastoid cell lines 
derived from six family members 
 
PALB2 mutations were located by DNA sequencing before the start of this project. 
The project began by analysing protein levels from the patient cell lines using 
Western blotting. Cells from each family member were assayed, in addition to a 
control ‘normal’ sample. In order to do this, cells were lysed to enable a full protein 
profile screen and a Western blot was performed. The nitrocellulose was probed with 
antibodies PALB2 246A (figure 3.1a) and PALB2 247A (figure 3.2a) for PALB2 
analysis and aprataxin was used as a 50 µg loading control (figures 3.1b and 3.2b). 
Figure 3.1b suggest that the loading of protein in Figure 3.1a was not consistently the 
same across all lanes, particularly lanes 1 and 2. This is probably a consequence of 
unequal loading rather than being a fault of the loading control used, aprataxin, as 
this was regularly and frequently used in the laboratory, was reliable and was 
unrelated to the samples being analysed. β-actin, however, a highly conserved 
protein present in all eukaryotic cell lines (Hanukoglu et al. 1983), could have been 
used and in future work perhaps should be used as it is a generally acknowledged 
loading control.  
  
115 
 
  
1 2 3 4 5 6 7 8 
170kDa 
Figure 3.1a. The top panel demonstrates the presence of PALB2 in each 
sample at ~170kDa using PALB2 246A antibody. The bottom panel shows the 
presence of a band at ~100 kDa in lanes 3, 4 and 7, thought to represent the 
presence of the del/ins mutant in these samples. Lanes 1 and 8 are control 
samples, Lane 2 is the Father and lane 3 is the Mother. Lanes 4, 5, 6 and 7 
represent protein expression from the compound heterozygous FA child, the 
homozygous un-mutated child, the X6 carrier and del/ins carrier, respectively. 
PALB2 246A 
~100kDa 
1 2 3 4 5 6 7 8 
40 kDa 
Figure 3.1b. Aprataxin was used as a 50 µg loading control per sample. A 
band at approximately 40 kDa is seen in lanes 1 – 8, above.  
Aprataxin 
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170kDa 
Figure 3.2a. Demonstrates the presence of PALB2 in each sample at 
~170kDa using PALB2 247A antibody. Lanes 1 and 8 are control samples, 
Lane 2 is the father and lane 3 is the mother. Lanes 4, 5, 6 and 7 represent 
protein expression from the compound heterozygous FA child, the 
homozygous un-mutated child, the X6 carrier and del/ins carrier, respectively. 
1 2 3 4 5 6 7 8 
PALB2 247A 
1 2 3 4 5 6 7 8 
40 
kDa Figure 3.2b. Aprataxin was used as a 50 µg loading control per sample. A 
band at approximately 40 kDa is seen in lanes 1 – 8, above.  
Aprataxin 
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Figure 3.1a shows 2 panels, antibody PALB2 246A has been used to detect the 
presence of full length PALB2 (top panel) and a truncated (~100kDa) PALB2 mutant 
(bottom panel). Figure 3.2a illustrates PALB2 expression at ~170 kDa using antibody 
PALB2 247A. In all figures lanes 1 and 8 are the normal control samples loaded for 
comparison purposes. It should be noted that the Bradford assay was used to 
achieve loading of 50 µg of cell lysate per well, however as observed in figure 3.1b 
and 3.2b loading of these samples varies.  
Lanes 1 and 8 are control samples which show unequal loading (figure 3.1b) 
however, figure 3.1a shows abundant expression of full length PALB2 in each of 
these lanes therefore, confirming that PALB2 should be abundantly expressed in 
‘normal’ lymphoblastoid cells.  
As observed in figure 3.1b, lane 2 was loaded with a higher concentration of cell 
lysate than that in lanes 3, 5, 6 and 7 which appear to be loaded equally. This has 
been taken in to account when analysing the rest of this blot. Lane 4 in the top panel 
of figure 3.1a shows no full length PALB2 expression, yet in the bottom panel of 
figure 3.1a a band can be observed within the orange box at ~100 kDa when 
compared with the control in lane 1. Additionally, figure 3.1b shows that loading in 
lane 4 is acceptable, and therefore the absence of full length PALB2 expression in 
lane 4, Fig 3.1a (top) is genuine as is the truncated version of approximately 100 kDa 
in Fig1a (bottom). The top panel of figure 3.1a shows abundant expression of full-
length PALB2 in lanes 2, 3 and 5 with slightly reduced expression observed in lanes 
6 and 7. The bottom panel of figure 3.1a (~100 kDa) shows a lot of background 
antibody binding however, it is possible to see additional bands at approximately 100 
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kDa in lanes 3, 4 and 7 all containing lysates of cells from individuals carrying a 
mutation that could give rise to this truncated form.  
 
Similar to the loading control found in figure 3.1b, figure 3.2b also shows a loading 
disparity. In lanes 1 and 2 of figure 3.2b aprataxin is more abundantly expressed 
whereas lanes 3-8 display more equal loading of cell lysates. There is acceptable 
level of loading in lane 4 in figure 3.2b suggesting that the absence of full length 
PALB2 in lane 4 of figure 2a is genuine. Figure 3.2a aims to demonstrate the loss of 
some full-length PALB2 expression in samples 2 and 6, known from previous 
sequencing experiments to be the X6 carriers. However since the loss of exon 6 is 
only a small in-frame, 24 amino acid deletion, detection of this small reduction in 
band size is difficult. Lanes 2, 3 and 5. 6 and 7 in figure 3.2a show unevenness in the 
resolution of this X6 band however lane 4 shows a band in the appropriate place 
(highlighted) which could be this 24 amino acid deletion. When taking in to account 
the blots in figure 3.1a and 3.2a as well as the unequal loading controls in 3.1b and 
3.2b,  mutant PALB2 is implicated as being expressed at similar levels to the wild-
type. This, in addition to the data collected from sequencing confirms the presence of 
mutant PALB2 in our patient samples. 
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3.2 Analysis of transfected and selected U2OS Flp-In/T-REx™ cell lines to 
confirm the presence of the expected PALB2 construct 
The wild type and mutant cDNA copies of PALB2 (whose sequences were verified 
before this project began) had been cloned into the pcDNA5/FRT/TO-FLAG vector. 
Five experimental cell lines containing pcDNA5/FRT/TO-FLAG-PALB2 (pcDNA5-
PALB2) mutants and wild type vector, one pcDNA5/FRT/TO only cell line (U2OS 
transfected cells with the construct not containing any PALB2, known as vector only) 
and one parental (U2OS host cells not transfected with any construct) were analysed 
after transfection and cellular cloning. The vector only and parental cell lines were 
used as controls; if amplicons were generated from either control sample it would 
show non- specific primer annealing to genomic DNA outside of the construct. Two 
cDNA constructs contained representations of the two mutations found in the patient 
(X6 and del/ins) two mutations from EUFA1341 (Y551X and revertant X4) (Xia et al. 
2006b) and one un-mutated wild-type PALB2. After transfection the mutant colonies 
were left to grow until they were stable enough for experimental use (confirmation 
was made by visual inspection). As an initial assessment, an agarose gel was run 
following PCR amplification (figure 3.3). Three primer pairs were specifically created 
for their location within the sequence. First, the binding site of forward primer 77143F 
is located at the 5’ end of PALB2 cDNA sequence. By pairing this with PALB2 
reverse primer at base pair 1975R, amplicons from WT sequence would be expected 
to be ~1975 bp long and include the vector/PALB2 sequence junction (including the 
whole of exon 4) (lanes 1 – 8) (see appendix 10). This primer pair is particularly 
useful for identifying the X4 deletion (lane 4); since this mutant deletes approximately 
1.5 kb we would expect to see a band at ~500 bp. As predicted lane 4 produced a 
band in the desired location preliminarily confirming X4 mutagenesis. X6, del/ins, 
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Y551X and WT amplicons using the same primers are shown in lanes 5 – 8, their 
respective bands show a 2000 bp amplicon proving that, each of these did not have 
the exon 45 deletion. The second primer pair (1513F and 1803R) (lanes 9 – 16) 
confirmed the loss of exon 4 in X4 only mutant cells. The large deletion removes the 
binding site of forward primer 1513F (lane 11), when combined with the reverse 
primer, located at position 1803R, a 337 bp amplicon was generated in all other 
mutants (lanes 12 – 15), which gave further confirmation of presence of PALB2 in 
each cell line (further sequence details of primer pair 1513F/ 1803R can be found in 
appendix 8). The third and final primer pair’s amplicon included exon 6.  With the 
exon 6 deletion mutation a smaller product, by 72bp, was expected and indeed was 
observed, (lane 21). With forward and reverse annealing sites at 2143F and 2764, 
respectively, the successful mutants from X4, del/ins and Y551X  were predicted to 
produce a normal ~664 bp amplicon, as seen in lanes 20, 22, 23 and 24 (further 
details on primer sequence are available in appendix 9). The parental cell line 
(without the construct), vector only (cells transfected with just the vector, no PALB2) 
and no template control were used as controls for each primer pair. These results 
show correct amplification of PALB2 sequence in the respective cell lines consistent 
with the presence of the individual PALB2 mutations. 
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Mutant Primer pair required Figure 
Del/ins (our patient) 1513F, 1803R 3.4 
Y551X (EUFA 1341)  1513F, 1803R 3.6 
X4 (EUFA 1341) 77143F, 1975R 3.8 
X6 (our patient) 2143F, 2763R 3.9 
Wild type 1513F, 1803R; 77143F, 
1975R; 2143F, 2763R 
3.5, 3.7 and 3.10 
Table 3.1. A Table to show the correct use of primer pair to view PALB2 mutant sequences 
during gel electrophoresis and DNA sequencing. 
L 1 2 3 4 5 
16
0 
13 14 15 17 18 19 20 21 
L 
L 
8 7 6 
10 12 9 11 
Figure 3.3 Aragose gel electrophoresis after site directed mutagenesis. 
Lanes 1-8 represent amplicons produced using primer pair 77143F and 1975R, 
in order they are: 1= No template control, 2 =parental U2OS cells, 3 = vector 
only, 4= revertant X4, 5 = patient X6, 6 = patient del/ins, 7 = Y551X, and 8 = 
WT. Lanes 9-15 illustrate the amplicons replicated using primer pair 1513F and 
1803R, in order they are: 9 = parental U2OS cells, 10 = vector only, 11 = X4, 12 
= X6, 13 = del/ins, 14 = Y551X, 15 = WT, 16 = no template control. Lanes 17-
24 represent PCR products using primer pair 2143F and 2763R, in order they 
are: 17 = NTC, 18 = parental U2OS cells, 19 = vector only, 20 = X4, 21 = X6, 
22 = del/ins, 23 = Y551X, 24 = WT. 
1, 500 bp 
1, 000 bp 
500 bp 
22 23 24 
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To further validate the correct transfections, Sanger sequencing was carried out. 
Table 3.1 presents the primer pairs which were specifically chosen to detect PALB2 
mutated regions for each cell line. Figures 3.5, 3.7 and 3.10 showing sequencing in 
normal cells across the regions of the mutations 559, Y551X and revertant (exon 4 
del) and exon 6 del reveal normal sequence in each case. Full electropherograms 
are available in appendix 1 (for figure 3.10), appendix 2 (for figure 3.5), appendix 3 
(for figure 3.7), appendix 4 (for figure 3.8), appendix 5 (for figure 3.4), appendix 6 (for 
figure 3.9). Figure 3.8 demonstrates the correct sequence of the exon 4 deleted 
mutation (X4) by showing exon 3 reading directly into exon 5 in the electropherogram 
position 457. Similarly, figure 3.9 shows the correct sequencing indicating deletion of 
exon 6; exon 5 transcribes directly into exon 7 close to position 361 in the 
electropherogram. Correct insertion of the del/ins was confirmed by sequencing in 
figure 3.4, where two adenines have been replaced with a guanine close to position 
169 in the electropherogram. Similarly, for Y551X, figure 3.6 displays the point at 
which one thymine residue has been mutated to an adenine, truncating the protein at 
a.a position 551, close to position 133 on the electropherogram. The full 
electropherograms are available in the appendix along with a BLAST analysis for 
each of the data sets to confirm that no other mutants were present. Use of 
sequencing has therefore, showed the presence of the correct sequence in the 
correct cell lines. 
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Exon 4 
Figure 3.6 
Electropherogram of 
mutant, Y551X. The 
highlighted adenine 
replaces the two original 
thymine, in turn producing 
the codon ‘TAA’, a stop 
codon at residue 551. 
Exon 4 
Exon 5 
Figure 3.5 Electropherogram 
of wild type displaying the 
unmutated adenine residue 
at position 1676 (a.a. 559. 
The highlighted adenine is 
not replaced by two guanine 
residues, as with the del/ins 
mutant. 
Figure 3.7 Electropherogram 
of wild type displaying the 
unmutated form of residue 
551 where codon TAT codes 
for tyrosine. The highlighted 
thymine is not replaced by an 
adenine in this mutant. 
Exon 4 
Figure 3.4 
Electropherogram of 
mutant, del/ins. The 
highlighted guanine 
replaces the two original 
adenines 7 bases before 
exon 5. 
Exon 4 Exon 5 
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Figure 3.8 Electropherogram 
of mutant X4, displaying the 
skipped exon 4. The codon 
CAG of exon 3 leading, in 
frame, straight into GGA of 
exon 5 
Exon 3 Exon 5 
Figure 3.9 Electropherogram 
of mutant X6, displaying the 
skipped exon 6. The codon 
CAG of exon 5 leading, in 
frame, straight into AAT of 
exon 7. 
Exon 5 Exon 7 
Exon  
4 
Exon  
5 
Exon  5 Exon  
6 
Exon  
7 
Exon  
6 
Figure 3.10 Electropherogram of wild type displaying the presence 
of exon 4 and exon 6. In figure A, exon 4 leads into exon 5. B 
shows exon 5 leading into exon 6 and exon 6 into exon 7 in figure 
3.8C. 
A B C 
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3.3 Testing the tetracycline-controlled transcriptional activation system using a 
time course of doxycycline induction. 
PALB2 mutant proteins were expressed in genetically identical cells i.e. isogenic 
cells, in order that genetic differences in the cells would not be a confounding factor 
when comparing the properties of the PALB2 mutations. The system used for this 
purpose was based on the Flp-In U2OS T-REx™ (Invitrogen 2011) human 
osteosarcoma cell line. These cells contain an Flp Recombination Target (FRT) site 
stably integrated into the human genome. Co-transfection of these cells with an 
expression vector containing the gene of interest (PALB2) and an FRT site linked to 
the hygromycin resistance gene (selectable marker), together with a Flp-recombinase 
plasmid results in targeted integration of the expression vector at the FRT site in the 
human genome. Regulation of expression of the integrated gene of interest (PALB2) 
is controlled by two copies of the tet operator 2 (TetO2) elements of the E. Coli Tn10-
encoded tetracycline (Tet) resistance operon embedded in the cytomegalovirus 
(CMV) promoter (Gossen and Bujard 1992, Yao et al. 1998). 
The efficiency of the induction system was tested by harvesting the cells following 
induction with doxycycline (a tetracycline derivative) for 24 and 48 hours alongside 
an un-induced control for each cell line. Using Western blotting with anti-FLAG Ab, 
PALB2 protein expression levels were analysed against induction time in order to 
assess whether the transfections were successful, and also to assess the optimal 
timing of doxycycline induction. Figure 3.11a shows the results of PALB2 expression 
in WT (lanes 1-3), X6 (lanes 4-6), del/ins (lanes 7-9), Y551X (lanes 10-12), X4 (lanes 
13-15) and a control cell line transfected with pcDNA5/FRT/TO vector only (lanes 16-
18) without the PALB2 sequence by Western blot analysis after doxycycline 
induction. The blot has been split into two, the top panel shows location at ~170 kDa 
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where endogenous, WT and X6 PALB2 are expected; bands at ~100 kDa are shown 
in the lower panel where Y551X, del/ins and X4 were predicted to be; vector only 
would not be expected to respond in this blot since there is no PALB2 protein in the 
construct. In figure 3.11b, senataxin was used to validate results as a 50 µg loading 
control. Figure 3.11a clearly illustrates a successful induction of PALB2 in the exon 4 
deleted cell line as it is highly responsive to the induction system. A similar yield is 
also shown from the Y551X cell line, and strong bands can be seen ~100 kDa. The 
del/ins cells (lanes 7-9) show bands at the expected (~100 kDa) location however, 
the WT and X6 bands also show similar bands at ~100 kDa, it is therefore unclear as 
to whether or not these bands are a consequence of cross-reactivity from the FLAG 
anti-body or the induced expression as a direct result of doxycycline induction. The 
observed band in lane 7 is less abundant than that which can been seen in lanes 8 
and 9, therefore it can be assumed that this doxycycline induction was successful in 
the del/ins mutant cell line, however further testing will be needed to confirm this. 
Induction in the X6 and WT cell lines is less consistent and further analysis would 
need to be undertaken to investigate their lack of expression after both 24 and 48 
hour doxycycline induction.  
This test has shown that two of the mutants, X4 and Y551X, had effective 
tetracycline induction systems and are able to express large amounts of PALB2 
mutant protein. Induction of the del/ins mutant potentially shows some increased 
expression after doxycycline induction. Finally the WT and X6 cell lines did not 
respond in this experiment. 
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Full-
length 
PALB2  
170 kDa 
UN 24 48 
100 
kDa 
Mutant 
PALB2  
UN 24 48 UN 24 48 UN 24 48 UN 24 48 UN 24 48 
WT X4 Y551X Del/in
s 
X6 
Vector 
only 
Figure 3.11a Western blot using anti-FLAG after doxycycline induction. All 
mutants have an un-induced control, a 24 and a 48 hour induced sample. Lanes 
1-3, 4-6, 7-9, 10-12, 13-15 and 16-18 represent samples from WT, X6, del/ins, 
Y551X, X4 and pcDNA vector, respectively.  
1 2 13 14 15 16 17 18 6 7 8 9 10 11 1
2 
3 4 5 
Endogenous PALB2  
Anti-FLAG 
cross reacting 
bands 
260 kDa 
1 2 13 14 1
5 
16 17 18 6 7 8 9 10 11 1
2 
3 4 
Figure 3.11b Western blot using anti-sentataxin as the 50 µg loading control 
during doxycycline induction analysis. All mutants have an un-induced control, 
a 24 and a 48 hour induced sample. Lanes 1-3, 4-6, 7-9, 10-12, 13-15 and 16-
18 represent samples from WT, X6, del/ins, Y551X, X4 and pcDNA vector, 
respectively.  
5 
Senataxin  
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3.4 Choosing mutant cell lines 
To enable further experimentation with cell lines displaying similar expression levels, 
colonies were picked based on varied morphologies, size and location within the petri 
dish. All colonies were picked in sterile conditions within a tissue culture hood. 
Following stable growth, 18 of these colonies from each mutant were chosen, 
induced and analysed on a Western blot using aprataxin as a 50 µg loading control 
and an un-induced aliquot as a control. Firstly, in figure 3.12 the deleted exon 4 
revertant shows variable levels at the expected (~100 kDa) size using antibody 
PALB2 247A. This antibody was chosen because PALB2 246A epitope binding 
(residues 200-250) site was lost with the deletion of exon 4 (412-1884). From this, 
three cell lines were chosen and kept for further experimental use, lanes 4, 6, and 17 
show cells kept for this purpose. Fig 3.13 shows X6 responding to doxycycline 
despite not doing so previously. Blotting with anti-FLAG, this experiment showed a 
defined band (the lower band of the two present), which is not visible in the un-
induced control, in all induced samples, just below the PALB2 band, at ~160 kDa 
(figure 3.13). The anti-FLAG antibody was used because mutant X6 is difficult to 
differentiate from endogenous PALB2 on the blot as X6 is only 24 a.a shorter, anti-
FLAG however will not bind with endogenous PALB2 therefore X6 can be clearly 
identified. Using this blot the parental cell lines from lanes 3, 11 and 12 were chosen 
as ‘normal’ expressers. Similarly, the blot for the del/ins mutant (figure 3.14) revealed 
mixed expression levels from all induced samples and, as expected, no expression 
from the un-induced control (lane C) using antibody PALB2 246A, chosen because 
the epitope binding site (residues 200-250) was present in this cell line. The three 
chosen cell lines include 2, 15 and 18 which were grown up and utilised during 
further experiments. The Y551X mutant, as shown in figure 3.15, illustrates eighteen 
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successful inductions and one, lesser expressed un-induced control (lane C) after 
blotting with antibody PALB2 246A, chosen because the epitope binding site 
(residues 200-250) was present. In keeping with the other mutants three ‘normal 
expressers’ were chosen using the blot, here cell lines from lanes 4, 6 and 10 were 
kept for further experimental use. Finally, in contrast to the other mutants the WT cell 
lines showed no indication of increased expression (figure 3.16) after blotting with 
anti-FLAG. Anti-FLAG had to be used as, similar to mutant X6, when using 
antibodies PALB2 246A or 247A it becomes impossible to differentiate between 
endogenous and mutant PALB2. Nonetheless, three cell lines were chosen from 
these cell lines in order to establish a cause for these expression issues, the cell 
lines came from lanes 6, 11 and 17.  
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1 2 3 4 5 6 13 12 11 10 9 8 7 16 15 14 17 18 C 
Figure 3.12 Western blot using antibody PALB2 247A (the deletion removes 
the epitope detected by PALB246A) showing expression of mutant cells X4 
after doxycycline induction. Full-length (top) and truncated (bottom) PALB2 
bands can be seen, X4 band lies 491 amino acids below the endogenous at 
~100 kDa. Lane C illustrates the un-induced control cell line and lanes 1-18 
represent colonies 1-18, respectively.  
 
170 kDa 
100 kDa 
X
4 
Endogenous 
PALB2 
1 2 3 4 5 6 13 12 11 10 9 8 7 16 15 14 17 18 C 
Figure 3.13 Western blot using anti-FLAG showing expression of mutant cells 
X6 after doxycycline induction. Mutant X6 PALB2 bands can be seen, 24 amino 
acids below where the wild type would express. Anti-FLAG generates large 
amounts of background activity, here a band lies at ~170 kDa where PALB2 
would be expected. Lane C illustrates the un-induced control cell line and lanes 
1-18 represent colonies 1-18, respectively.  
X
6 
Anti-FLAG 
background  
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Figure 3.14 Western blot using antibody PALB2 246A showing expression of 
mutant cells del/ins after doxycycline induction. Full length (top) and truncated 
(bottom) PALB2 bands can be seen, del/ins band lies 627 amino acids below full 
length at ~100 kDa (bottom). Lane C illustrates the un-induced control cell line 
and lanes 1-18 represent colonies 1-18, respectively.  
 
1 2 3 4 5 6 13 12 11 10 9 8 7 16 15 14 17 18 C 
170 kDa 
Endogenous 
PALB2 
100 kDa 
Del/ins 
1 2 3 4 5 6 13 12 11 10 9 8 7 16 15 14 17 18 C 
170  
kDa 
WT 
PALB2 
Figure 3.16 Western blot using anti-FLAG showing expression of cell line WT 
after doxycycline induction. WT PALB2 bands can be seen ~170 kDa. Lane C 
illustrates the un-induced control cell line and lanes 1-18 represent colonies 1-18, 
respectively.  
 
1 2 3 4 5 6 13 12 11 10 9 8 7 16 15 14 17 18 C 
170 kDa 
Endogenous 
PALB2 
100 kDa 
Y551
X 
Figure 3.15 Western blot using antibody PALB2 246A showing expression of 
mutant cells Y551X after doxycycline induction. Full length (top panel) and 
truncated (lower panel) PALB2 bands can be seen, Y551X band lies 635 
amino acids below the full length at ~100 kDa (lower panel. Lane C illustrates 
the un-induced control cell line and lanes 1-18 represent colonies 1-18, 
respectively.  
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3.5 Knockdown of endogenous PALB2 using siRNA to the 3’ UTR. 
Endogenous PALB2 is present in each mutant cell line therefore it is essential to 
knockdown the endogenous protein leaving only the mutant  variants to ensure that 
all binding activity seen in further experiments is a direct cause of the mutant PALB2. 
Initially, the protocol was optimised with respect to duration of treatment and 
concentration of siRNA. To do this the del/ins cell line was used as it was 
straightforward to separate endogenous (~170 kDa) and mutant expression (~100 
kDa).  After siRNA transfection cells were lysed and run on a Western blot to assess 
how effective treatment had been. The membrane was blotted with PALB2 246A 
(figure 3.17a) with aprataxin as a 50 µg loading control (figure 3.17b) and developed 
using ECL. As seen in figure 3.17a endogenous PALB2 was successfully knocked 
down in all siRNA treated samples (lanes 2-13) as all control samples (lanes 1 and 
14-17) were still displaying endogenous PALB2 expression, confirming that this 
siRNA is specific to our protein of interest, PALB2.  
3.6 Anti-FLAG immunoprecipitation using mutant cell line del/ins. 
Immunoprecipitation using anti-FLAG to pull down the FLAG containing PALB2 
mutant protein and other proteins in complex was achieved as seen in figure 3.18. 
Protein expression is seen at ~100 kDa in lanes 3 and 4, and faint bands in lanes 5 
and 6, all of which represent successful pull down of the del/ins mutant 
immunoprecipitating with 2, 4, 6 and 8 µg of FLAG antibody (lanes 3-6, respectively). 
Lane 1, 2 and 7 represent the control samples, lane 1 is a doxycycline induced whole 
cell lysate, lane 2 shows an un-induced lysate with antibody and protein G sepharose 
beads, and lane 7 shows the induced lysate with protein G beads and no antibody. 
The expression of endogenous PALB2 in the no-bead control validates the specificity 
of the antibody to the mutant since endogenous PALB2 is expressed in this sample 
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and not in the rest. Lane 2, where the un-induced control is present shows a faint 
band within the 100 kDa region, this control was used to compare how much protein 
was available for IP before doxycycline induction. Lane 7 proves the specificity of the 
antibody to the protein since no antibody was added to the solution no protein would 
be expected to pull-down. This experiment has proved that immunoprecipitation of 
mutant proteins is possible using anti-FLAG. Furthermore, it also shows that 4 µg of 
anti-FLAG is the optimal concentration to immunoprecipitate using this protocol. 
Moving on from this it would be possible to use this Western and blot for BRCA1 and 
BRCA2 to assess whether the complex has changed to accommodate this mutant.  
Protein interaction analysis using immunoprecipitation with anti-FLAG enabled the 
identification of the optimal treatment conditions before carrying out additional 
experiments. Four separate reactions with incrementally higher antibody 
concentration (2, 4, 6 and 8 µg) were set up and precipitated using protein G 
sepharose beads. Western blot analysis was used to assess which proteins were 
pulled down in complex with the FLAG containing PALB2 (Figure 3.18). Three 
controls are present, one doxycycline induced del/ins mutant whole cell lysate (lane 
1) and one un-induced del/ins mutant with protein G sepharose bead precipitation 
(Lane 2) and a beads only control used without any antibody (lane 7). The no-bead 
control displays a band at the location of endogenous PALB2 (~170 kDa) whereas 
the un-induced control with beads only shows a band in the 100 kDa region. The 
immunoprecipitated cells incubated at an antibody concentration of 2, 4, 6 and 8 µg 
are shown in lanes 3, 4, 5, and 6, respectively. The upper panel on figure 3.18 
displays the protein ~170 kDa, the position of endogenous PALB2. Lanes 2-7 show a 
lack of antibody binding at this location which proves that the FLAG antibody used to 
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pull down PALB2 is specific to the mutant protein rather than the endogenous. The 
lower panel in figure 3.18 represents the length of the protein immunoprecipitated 
with anti-FLAG at approximately 100 kDa, in keeping with the length of the target 
del/ins mutant. Despite the higher concentration of antibody used for 
immuniprecipitation in lanes 5 and 6, it seems there has been a loss in binding 
efficiency in these samples, it could be assumed that this is consequence of an 
artefact or loading error. Since this was an optimisation step, it can be confirmed that 
4 µg of antibody is sufficient to produce the desired protein binding over 48 hour 
incubation period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17a Western blot using FLAG antibody after siRNA knockdown of 
endogenous PALB2 in del/ins mutant cell line. Lanes 2-4 show knockdown 
efficiency using 22.5nM of siRNA after 24, 48 and 72 hours, respectively. 
Lanes 5-7 show knockdown efficiency with 45nM siRNA after 24, 48 and 72 
hours, respectively. Lanes 8-10 show knockdown efficiency with 90 nM after 
24, 28 and 72 hours, respectively. Lanes 11-13 show knockdown after 24, 48 
and 72 hours, respectively, when using 180 nM of siRNA. Lanes 1 and 15-17 
demonstrate a positive control using scrambled siRNA with doxycycline 
induced del/ins cells. Lane 14 shows the negative, uninduced control. X marks 
a cross reacting band. 
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Aprataxin 
40kDa 
Figure 3.17b Aprataxin loading control during Western blot after siRNA 
knockdown. 
1 2 3 4 5 6 7 
Del/ins     
100 kDa 
Endogenous 
PALB2 
 
170 kDa   
Figure 3.18. Western blot using antibody PALB2 246A after 
immunoprecipitation with anti-FLAG. Lane 1 displays a whole cell 
lysate, lane 2 shows a second un-induced control with beads, lanes 
3-6 are protein samples using 2, 4, 6 and 8 µg of antibody during 
immunoprecipitation and lane 7 represents the ‘beads only’ control. 
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4 Discussion 
 
Described here is a case of Fanconi anaemia with compound heterozygous alleles 
for PALB2/FANCN (identified as patient 10). The paternal mutation is c.2586+1G>A 
that leads to skipping of exon 6 in the mRNA and the in frame deletion of all 24 
amino acids of exon 6 (abbreviated here as ‘X6’). Transcripts from this allele are 
translated from exon 5 into exon 7 in-frame (See figure 4.1). The maternal mutant 
allele deletes two adenosines at nucleotides 1676 and 1677, replacing them with a 
guanine (1676_1677delAAinsG, abbreviated here as ‘del/ins’). This results in a 
translational frame shift that truncates the PALB2 protein at amino acid 559, which is 
also changed from glutamine to arginine (p.Gln559Argfs*2). 
Figure 4.1 A figure to show the open 
reading frame with and without exon 6 
Results acquired from NCBI: ORF Finder 
Figure 4.2. A figure to show the frame shift 
incurred by the del/ins mutant. Results 
acquired from NCBI: ORF Finder. 
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4.1 Assessing PALB2 protein level in 6 family members 
 
 
I tested PALB2 expression in patient whole cell lysates using Western blot and 
antibody PALB2 246A (figure against antibody PALB2 246A figure 3.1b) and PALB2 
247A (figure against antibody PALB2 247A figure 3.1b). Figure 3.1 and 3.2 confirmed 
the presence of PALB2 from two mutant alleles in the patient, from different single 
mutations in each parental cell line and two other children.  A fourth child had normal 
PALB2 consistent with homozygosity for wild type alleles. 
Figure 3.1b and 3.2b show a variation in sample loading which caused difficulty when 
observing the relevant bands, since this was the first Western blot performed in the 
laboratory my knowledge was limited, therefore I was unaware that this Western blot 
should have been repeated. This has taught me that checking the loading controls 
during a Western blot is imperative during future experiments. 
4.2 Generation of Cell Lines Expressing Individual Mutant or WT PALB2 
Proteins 
In keeping with previous Fanconi anaemia related PALB2 experiments (Xia et al. 
2006a, Zhang et al. 2009b) cell lines were generated by site directed mutagenesis in 
order to study the separate PALB2 mutations in the patients. The pcDNA5-FLAG 
construct used here was specifically chosen for its tetracycline induction system. 
Using an efficient induction system expression of the recombinant protein can be 
monitored and controlled. Cell lines that contained mutations (Including a revertant 
sequence) from another patient EUFA1341 (Xia et al. 2006b) were also generated for 
comparison with the germline PALB2 mutations of my patient (patient 10). The 
EUFA1341 mutation Y551X and a revertant mutation from the same cell line that 
deletes exon 4 (X4) were chosen instead of the other 6 previously published cases 
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for a number of reasons; first, the Y551X allele resulted in a truncated protein 
whereby the C-terminal WD40 repeats are removed, the consequence of which is 
similar to that of the del/ins mutation in my patient which suffers a frame shift and 
truncation at codon 559. Second, the in-frame exon 4 deletion revertant mutation of 
EUFA1341 retains both the N-terminus and the C-terminus, including the WD40 
repeats, and retains BRCA1 and BRCA2 binding capacity and some PALB2 activity. 
Finally, the EUFA1341 mutants are a good reference for comparison with other 
studies because they have been used widely in the literature. 
4.3 Sanger Sequencing 
Proof of successful mutagenesis was shown by DNA sequencing (figure 3.3) 
showing that amplicons are a result of the transfected pcDNA5-PALB2 construct 
rather than endogenous PALB2. The importance of sequencing was demonstrated 
during the first attempt of sequencing where some colonies were found to have 
random mutated artefacts, in addition to un-mutated regions where mutations were 
expected. It is unclear whether this is a result of sample mix-up, mutagenesis failure 
or inaccurate sequencing however further sequencing of alternative colonies proved 
that mutagenesis had been successful in the picked colonies. Sequencing analysis, 
as seen in figures 3.4 – 3.10, identified the correct mutations in the correct cell lines 
and therefore, successful mutagenesis. From this stable U2OS cell lines expressing 
the correct PALB2 mutants in the correct sample have been confirmed.  
4.4 Doxycycline Induction 
The tetracycline-controlled transcriptional activation system, as part of the original 
pcDNA5-PALB2 vector, was used to control expression of each mutant. This 
induction system was first described by Gossen and Bujard (1992), by manipulating 
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the Tn10 tetracycline repressor system found in E.coli. The tetracycline repressor 
(tetR) controls expression of the tetracycline resistance genes. In the presence of 
tetracycline (or a suitable derivative) tetR is left unbound to promoters within the 
operon therefore, resistance genes are allowed to overexpress. A construct was 
developed whereby any core promoter fused to this system would be stimulated into 
over expression of the target gene. Protein translation will lie almost dormant until the 
concentration of tetracycline is rapidly increased in the cell. Once induced this 
system can increase expression to over five orders of magnitude. 
Figure 3.11 displays varied responses to the tetracycline induction system. For the 
over expressers, in particular X4, the difference in expression between the un-
induced (lane 13) and induced (lanes 14 and 15) clearly shows that not only does the 
construct work, but that it is extremely efficient in this cell line. A similar pattern was 
found in the Y551X (lanes 10-12) mutant which again, showed effective expression in 
this cell line between induced (lanes 11 and 12) and uninduced (lane 10). The 
construct seemed to be less active in the X6 (lanes 4-6) and del/ins (lanes 7-9) cells, 
although bolder bands are seen at ~170 kDa and ~100 kDa, respectively, in some 
cell lines on the Western blots. Results from X6 (lanes 4-6) and del/ins (lanes 7-9) 
indicate a partially inducible construct as the increase in expression is not as notable 
as that from X4 (lanes 13-15) and Y551X (lanes 10-12) cell lines. Induction of WT 
(lanes 1-3) indicated little to no change in expression compared to that over the un-
induced control. This is somewhat of a concern as the wild type cell line was to be 
used as a control against the other mutants. Further testing was required to be able 
to provide resolution of this problem. There are a number of reasons why all cell lines 
displayed varied results after doxycycline induction; firstly, the stability of the host cell 
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lines is a major factor since an unstable lineage can cause ineffective transcription 
and inevitably, cell death. However, the U2OS host, as used in all mutant cell lines, is 
one recommended by the T-REx™ user manual (Invitrogen 2011) making this an 
unlikely cause. Additionally, the expression levels of the protein also rely on the 
number of cells available, the fewer the cells, the less available DNA to transcribe 
from. Inadequate volume of cells is an unlikely cause for lack of expression as a 50 
µg loading control was used (figure 3.11b), showing equal expression across all 
lanes. Furthermore, cells were visually assessed for confluence in the tissue culture 
dish before doxycycline induction (Berens and Hillen 2003). Figure 3.4 outlines how 
effective the doxycycline induction was using cell lines containing a truncated PALB2 
mutant construct (Y551X and X4), whereas the longer proteins were less susceptible 
to induction (WT and X6). Taken together it would seem that there is another reason 
for the lack of expression in certain cell lines, proposing the question whether over 
expression of full-length PALB2 is toxic to the cell.  
4.5 Choosing mutant cell lines 
It is important for further experiments that all cell lines are expressing PALB2 at 
similar levels. Figures 3.12 – 3.16 display the various expression levels shown 
between different cultures in all five experimental cell lines. In keeping with the 
Western blot shown in figure 3.11, expression varied between cultures within the 
same cell line after 48 hour doxycycline induction. X4 (figure 3.12, lanes 1-18) and 
Y551X (figure 3.15, lanes 1-18) constructs displayed high levels of protein 
expression after doxycycline induction compared to the un-induced control (lane C), 
these results are similar to the expression levels shown in figure 3.11. X6 induction 
(figure 3.13) indicated expression at the expected band (~160kDa) in all induced 
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cultures (lanes 1-18) with no expression in the un-induced (lane C), confirming the 
success of the construct in this cell line. In contrast to the previous induction test 
(figure 3.11) where del/ins displayed weak induction efficiency, figure 3.14 proved 
certain strains of del/ins were inducible using this construct. Again, there was no 
notable change in WT expression after doxycycline induction in all 18 colonies, 
further supporting the theory that over expression of WT PALB2 could be toxic to the 
cell. Other explanations include the use of antibody when using PALB2 246A or 
PALB2 247A during Western blotting. With the exception of wild type all other 
mutants are expressed at different sizes to endogenous PALB2 (~170kDa), therefore 
making it impossible to differentiate between the expression of the WT and 
endogenous PALB2 when using one of these antibodies. Additionally, the M2 FLAG 
antibody used to blot during these experiments generated a lot of background ‘noise’ 
on the blots, it is therefore difficult to differentiate between what is a direct effect of 
our induction system and a result of this ‘noise’.  
4.6 Small Interfering RNA 
By knocking down endogenous PALB2, it was possible to ensure any further 
interactions between PALB2 and other proteins within the cell were a direct effect of 
the recombinant, mutant protein. Firstly, the optimal treatment conditions needed to 
be established, including concentration of siRNA and duration of treatment. Using the 
del/ins cell line siRNA concentration levels were staggered at 22.5 nM, 45 nM, 90 nM 
and 180 nM for 24, 48 and 72 hours. Five controls included, four scrambled RNA 
samples transfected with 22.5 nm, 45 nm, 90 nm and 180 nm for 48 hours each and 
one un-induced control. To test this protocol the del/ins mutant was chosen as it is 
distinctively smaller than endogenous PALB2 and, therefore, there would be no 
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dispute whether or not any interaction was a reflection of mutant or endogenous 
PALB2 activity. Successful knockdown using this siRNA was achieved, as shown in 
figure 3.17, lanes 2 - 13. Using antibody PALB2 246A, high levels of del/ins 
expression was detected at ~100kDa. Additionally, absence of knockdown is 
displayed in all control samples (lanes 1, 14-17). These results suggest a successful 
knockdown of endogenous PALB2 with simultaneous induction of mutant del/ins. 
Using these results optimal conditions for further experiments were established and it 
was concluded that transfection of siRNA in a 45 nM concentration for 48 hours 
produced the required level of PALB2 knockdown. Figure 3.18 shows equal loading 
of 50 µg using aprataxin (~40 kDa). 
4.7 Immunoprecipitation  
Immunoprecipitation using anti-FLAG to pull down the FLAG containing PALB2 
mutant protein and other proteins in complex was achieved as seen in figure 3.19. 
Protein expression is seen at ~100 kDa in lanes 3 and 4, and faint bands in lanes 5 
and 6, all of which represent successful pull down of the del/ins mutant 
immunoprecipitating with 2, 4, 6 and 8 µg of FLAG antibody (lanes 3-6, respectively). 
Lane 1, 2 and 7 represent the control samples, lane 1 is a doxycycline induced whole 
cell lysate, lane 2 shows an un-induced lysate with antibody and protein G sepharose 
beads, and lane 7 shows the induced lysate with protein G beads and no antibody. 
The expression of endogenous PALB2 in the no-bead control validates the specificity 
of the antibody to the mutant since endogenous PALB2 is expressed in this sample 
and not in the rest. Lane 2, where the un-induced control is present shows a faint 
band within the 100 kDa region, this control was used to compare how much protein 
was available for IP before doxycycline induction. Lane 7 proves the specificity of the 
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antibody to the protein since no antibody was added to the solution no protein would 
be expected to pull-down. This experiment has proved that immunoprecipitation of 
mutant proteins is possible using anti-FLAG. Furthermore, it also shows that 4 µg of 
anti-FLAG is the optimal concentration to immunoprecipitate using this protocol. 
Moving on from this it would be possible to use this Western and blot for BRCA1 and 
BRCA2 to assess whether the complex has changed to accommodate this mutant.  
4.8 Troubleshooting 
Time was a difficult factor from the outset of this project, 17 weeks to create and grow 
five stable mutant cell linages with similar expression levels and perform numerous 
experimental methods was ambitious. With this in mind preliminary and optimisation 
experiments were used to avoid spending time constructing the same experiment 
numerous times. For instance, after site directed mutagenesis the cells were allowed 
to grow up on a petri dish, after days of growth twelve colonies were picked in to 
wells of a 96 well plate. PCR and DNA sequencing was performed on one of the 
twelve colonies picked, when one of the sequence analyses returned unsuccessful 
another colony was promptly chosen from the 96 well plate, PCR amplified and 
sequenced, this time round analysis proved a successful mutant was present. Having 
these additional colonies ready created a more efficient process whereby the mutant 
cells were available without going through the lengthy mutagenesis and transfection 
processes again. Additionally, during DNA sequencing each mutant was sequenced 
with both the forward and the reverse primer for the relevant pair to provide two 
separate results for the same mutant to ensure the correct mutants were in place. 
This proved to be useful during analysis when identifying the unsuccessful mutant by 
checking both electropherograms for confirmation.  
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Other preliminary experiments undertaken included the doxycycline induction, a test 
which identified the optimal time needed to induce the cells. Establishing optimal 
conditions of doxycycline treatment early on meant cells were not induced for longer 
than necessary, therefore saving time. More importantly, optimisation of induction 
conditions meant the construct was induced long enough to be able to effectively 
increase PALB2 expression. As shown in figure 3.11, cells treated for 48 hours did 
not display much increase in expression compared to those treated for 72 hours, this 
result indicates a plateau effect therefore underlying the importance of this 
experiment in enabling optimal use of time and efficiency of the construct. Similarly, 
the siRNA transfection was performed with two variables, concentration of siRNA and 
duration of treatment. The same principle applies here, by optimising these two 
variables both time and resources would be saved upon completion of further siRNA 
treatments. Optimisation of IP experiments by staggering antibody concentration 
during immunoprecipitation meant resources could be saved by not overusing the 
antibody during each IP. Finally, further troubleshooting was addressed by using 
different antibodies depending on the mutant strain used, for example the deleted 
exon 4 in mutant X4 removes a 491 amino acid sequence (residues 412-1884) which 
also deleted the epitope to PALB2 246A antibody, located at residues 200-250. It 
was not until one Western blot failed to show any X4 activity after doxycycline 
induction that this was brought to light, however PALB2 247A provided an epitope 
available for X4 binding. As previously addressed other antibody issues arose during 
the course of this project, mostly from the unspecific binding of FLAG. Figure 4.3 
shows a blot run after siRNA transfection using the same lysates as those shown in 
figure 3.17 using PALB2 246A.  However in Fig 4.3 instead of indicating knockdown 
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of endogenous PALB2 this blot suggests that there is still protein expression. The 
conclusion is that the 170kDa band in Fig 4.3 is a consequence of non-specific 
binding by the FLAG Ab. In order to avoid this issue arising again another FLAG 
antibody was ordered for future experiments.  
4.9 Applications to the Field 
4.9.1 Is PALB2 toxic to the cell? 
Although it is unfinished, this work has brought to light many questions regarding the 
functionality of PALB2 and its mutants. Firstly, the over expression of full-length 
PALB2 has been indicated as potentially toxic to the cell, after evaluating the 
available literature it would seem that overexpression of PALB2 has not previously 
been reported as being toxic to the cell; furthermore, Reid et al. (2007), Xia et al. 
(2006b), Zhang et al. (2009a) and Zhang et al. (2009b) all published results where 
recombinant PALB2 was over expressed in U2OS host cells, in each case their 
experiments were successful and produced valid data. In addition, PALB2 was also 
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Figure 4.3. Western blot after knockdown of endogenous PALB2 
and detection of induced PALB2 using anti-FLAG. The bands at 
~170 kDa, where the endogenous PALB2 would be expected, are not 
present using PALB2 246A (Fig 3.17) but appear to be present here 
using FLAG Ab. The signal here at ~170kD in Fig 4.3 is a 
consequence of unspecific binding of FLAG Ab.  
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expressed in HeLa, 293/293T cells, non-neoplatic, epithelial cells, fibroblasts, LCLs, 
SF9 insect cells, and lymphocytes without any mention of any toxic responses to the 
cell (Oliver et al. 2009).  
4.9.2 Does del/ins function in the FA pathway? 
Serra et al (2012) recently published a case from a FA patient homozygous for 
mutant del/ins (1676_1677DelAA/InsG), the same as the mutation in my patient the 
investigated here. Their patient exhibited the most severe form of FA phenotype with 
embryonal tumours, Wilms, neuroblastoma and a medulloblastoma as well as 
abnormal thumbs, horseshoe kidney, sacral dysplasia and uterine bicorn. 
Importantly, Serra et al. (2012) noted that they did not detect any notable 
PALB2/FANCN activity in patient cells as measured by MMC induced chromosome 
breakage analysis (100% of the metaphase cells showed >10 breaks after MMC 
exposure). However, their report lacked much information on the functionality and 
activity of this mutant. Located at the C-terminus of PALB2, seven WD40 repeats 
form a seven bladed locking mechanism whereby the N-terminus of the first blade 
binds to the C-terminal tiers of the seventh blade, thereby stabilising PALB2. Both 
patients 8 and 9 (see table 1.1) exhibit heterozygous Y1183X alleles, a mutant 
PALB2 protein which truncates 3 codons upstream of the termination codon. Y1183X 
causes the loss of WD40 repeat domain and in turn, the locking mechanism, since 
the loss of only the final 3 codons is enough to destabilise PALB2 in these patients, it 
would seem logical to assume that del/ins produces similar, destabilising effects. 
Despite this, research into the effect of embryonic development in PALB2 knockout 
mice suggests that although these truncated proteins are no longer stable, they are 
still generating some form of activity from the N-terminal, coiled coil region. Both 
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studies by Rantakari et al. (2010) and Bouwman et al. (2011) clearly suggest that 
embryonic lethality within early gestation was a direct result of PALB2 knockout. All 
10 patients listed in table 1.1 present either homozygous or compound heterozygous 
mutants of PALB2 but yet survived passed birth, taken together this data suggests 
that hypomorphic PALB2 activity is present in the identified mutants.  
4.10 Future Work 
Firstly, to further test the efficiency of the induction construct in WT cell lines Western 
blot would be used using a different branded FLAG antibody if, as before, there is no 
change in the expression of un-induced compared with the induced samples. If this 
antibody also proves to be unspecific, another option would be to siRNA treat WT to 
knockdown endogenous PALB2 since we have already proved that the siRNA 
transfections work, Western blot analysis with antibody PALB2 246A or 247A would 
generate bands at ~170 kDa where WT expression should lie, since endogenous 
PALB2 would be knocked down the resulting bands would be an effect of doxycycline 
induction, representing the induced expression of WT PALB2. 
By inducing cells with siRNA and doxycycline, knockdown of endogenous PALB2 
and expression of the mutant PALB2, followed by subsequent reciprocal co-
immunoprecipitation and Western blot experiments, it will be possible to study the 
implications of X6, X4, Y551X and del/ins expression on PALB2 binding affinity with 
all known binding partners of PALB2. To check the integrity of our experimental 
procedures our results would be compared to that published by Xia et al. (2006b) 
Sequential experiments would involve understanding whether the PALB2 mutants 
retain their ability to localise to the nucleus after IR/MMC treatment. 
Immunofluorescence would visualise the movements of any tagged protein both 
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before and after IR/MMC treatment, using the two results to compare PALB2 
concentration in the nucleus with results from wild-type. Subcellular fractionation 
could further aid in assessing the localisation of mutant PALB2 within the nucleus, for 
example, does the complex locate to the foci of DNA double stranded breaks like WT 
PALB2? (Xia et al. 2006a, Sy et al. 2009, Zhang et al. 2009b). Flowcytometry can 
separate cells by size and position in the cell cycle, if DNA DSBs remain unrepaired 
when the cell reaches the G2 check point it will remain in G2 until the DSB is 
repaired and only then will it progress onto mitosis. An ineffective DSB repair 
pathway caused by inactive mutant PALB2 would result in a high volume of cells at 
G2 arrest after IR/MMC treatment, as shown by the flowcytometer. Analysis of 
PALB2 expression and other interacting partners can also be achieved using a 
flowcytometer. Additionally, cell apoptosis and proliferation using fluorescent 
antibodies bound to cell surface proteins can be monitored with using flowcytometry.  
After assessing the effect of mutant PALB2 on the cells, testing for protein binding 
sites, checking localisation, expression levels, and effect on homologous 
recombination, WT will be transfected into the same cell lines as the mutant to see if 
PALB2 functions and binding partners are restored, thereby confirming the loss of 
function from mutant alleles. 
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5. Conclusion 
PALB2/FANCN is one of the 15 currently known FA associated proteins, functionally 
involved in the DNA double stranded break repair pathway via homologous 
recombination (Xia et al. 2006a, Sy et al. 2009a, Zhang et al. 2009a, Zhang et al 
2009b). Of the 15 currently known FA complementational groups, FA-N is one of the 
more recently described. Of the mutants used here, X4 and Y551X have been 
previously described in several publications and their consequences upon cellular 
activity have been well documented (Xia et al.2006a, Sy et al. 2009a, Zhang et al. 
2009a, Zhang et al. 2009b). Cells from the PALB2 Del/ins and X6 from a patient was 
investigated here. Mutant del/ins has previously been reported (Serra et al. 2012) in 
a homozygous PALB2 patient, however the impact this mutation had on PALB2 
function was not studied fully by these authors. Interestingly, my patient was 
diagnosed with lymphoma, a disease not recognised as being associated with FA. 
My project set out to create five cell line each carrying a different PALB2 mutation 
mutant in order to evaluate their effect on the DSB repair pathway at the cellular 
level, paying particular attention to the patient 10 copied PALB2 mutants (X6 and 
del/ins). The size and expression of PALB2 mutants from patient 10, both parents 
and two siblings, and the homozygous wild-type alleles in one sibling were confirmed 
using Western blot. Site directed mutagenesis followed by transfection of the 
construct, that included a tetracycline-controlled transcriptional activation system, in 
frame FLAG sequence and one of four mutant or the wild-type PALB2 alleles, was 
confirmed using PCR amplification as well as DNA sequencing. Activity of the 
tetracycline regulatory system was established and cell lines were chosen based on 
their PALB2 mutant expression. Endogenous PALB2 knockdown was achieved in 
del/ins cell line using siRNA and confirmed with Western blotting against antibody 
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PALB2 246A. Immunoprecipitation of the del/ins mutant protein using anti-FLAG in 
knocked down del/ins cell lines was confirmed using Western blot with antibody 
PALB2 246A. All experimental results are preliminary and much work is still to be 
done to be able to draw a definitive conclusion on the impact each mutant has upon 
PALB2 activity and, in turn, how this affects the DSB pathway. Moreover, this 
information can be used to further understand the link between PALB2 activity and 
lymphoma development in the two affected individuals described here.  
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Appendix 1 – WT electropherogram using primer 2143F 
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WT 2143F BLAST sequence 
 
Range 1: 2372 to 2986  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
1136 bits(615) 0.0() 615/615(100%) 0/615(0%) Plus/Plus 
 
 
Features: 
Query  1     TTCACCTGCTTTCCCCATCTTAGGTACTACTCCAGCCTTTGGCCCTCAAGGCTCCTATGA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2372  TTCACCTGCTTTCCCCATCTTAGGTACTACTCCAGCCTTTGGCCCTCAAGGCTCCTATGA   
 
Query  61    AAAAGCATCTACAGAAGTTGCTGGACGAACTTGCTGCACACCCCAACTTGCTCATTTGAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2432  AAAAGCATCTACAGAAGTTGCTGGACGAACTTGCTGCACACCCCAACTTGCTCATTTGAA   
 
Query  121   AGACTCAGTCTGTCTTGCCAGTGATACTAAACAATTCGACAGTTCAGGCAGCCCAGCAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2492  AGACTCAGTCTGTCTTGCCAGTGATACTAAACAATTCGACAGTTCAGGCAGCCCAGCAAA   
 
Query  181   ACCACATACCACCCTGCAAGTGTCAGGCAGGCAAGGACAACCTACCTGTGACTGTGACTC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2552  ACCACATACCACCCTGCAAGTGTCAGGCAGGCAAGGACAACCTACCTGTGACTGTGACTC   
 
Query  241   TGTCCCGCCAGGAACACCTCCACCCATTGAGTCATTCACTTTTAAAGAAAATCAGCTCTG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2612  TGTCCCGCCAGGAACACCTCCACCCATTGAGTCATTCACTTTTAAAGAAAATCAGCTCTG   
 
Query  301   TAGAAACACATGCCAGGAGCTGCATAAACATTCCGTCGAACAGACTGAAACAGCAGAGCT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2672  TAGAAACACATGCCAGGAGCTGCATAAACATTCCGTCGAACAGACTGAAACAGCAGAGCT   
 
Query  361   TCCTGCTTCTGATAGCATAAACCCAGGCAACCTACAATTGGTTTCAGAGTTAAAGAATCC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2732  TCCTGCTTCTGATAGCATAAACCCAGGCAACCTACAATTGGTTTCAGAGTTAAAGAATCC   
 
Query  421   TTCAGGTTCCTGTTCCGTAGATGTGAGTGCCATGTTTTGGGAAAGAGCCGGTTGTAAAGA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2792  TTCAGGTTCCTGTTCCGTAGATGTGAGTGCCATGTTTTGGGAAAGAGCCGGTTGTAAAGA   
 
Query  481   GCCATGTATCATAACTGCTTGCGAAGATGTAGTTTCTCTTTGGAAAGCTCTGGATGCTTG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2852  GCCATGTATCATAACTGCTTGCGAAGATGTAGTTTCTCTTTGGAAAGCTCTGGATGCTTG   
 
Query  541   GCAGTGGGAAAAACTTTATACCTGGCACTTCGCAGAGGTTCCAGTATTACAGATAGTTCC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2912  GCAGTGGGAAAAACTTTATACCTGGCACTTCGCAGAGGTTCCAGTATTACAGATAGTTCC  
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Appendix 2 – WT electropherogram using primer 1513F  
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WT 1513F BLAST sequence 
 
 
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
518 bits(280) 8e-146() 290/294(99%) 4/294(1%) Plus/Plus 
 
 
Features: 
Query  15    CACAGG--AAAG-AAATCAGCCTGCACCCCAGCATCAGATCATTGTGAACCACTTTTGCC  
71 
             ||||||  |||| ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1736  CACAGGAAAAAGAAAATCAGCCTGCACCCCAGCATCAGATCATTGTGAACCACTTTTGCC  
1795 
 
Query  72    AACTTCTAGCCTGTCGATTGTTAACAGGTCCAAGGAAGAAGTCACCTCACACAAATATCA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1796  AACTTCTAGCCTGTCGATTGTTAACAGGTCCAAGGAAGAAGTCACCTCACACAAATATCA  
1855 
 
Query  132   GCACGAAAAATTATTTATTCAAGTGAAAGGGAAGAAAAGTCGTCATCAAAAAGAGGATTC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1856  GCACGAAAAATTATTTATTCAAGTGAAAGGGAAGAAAAGTCGTCATCAAAAAGAGGATTC  
1915 
 
Query  192   CCTTTCTTGGAGTAATAGTGCTTATTTATCCTTGGATGATGATGCTTTCACGGCTCCATT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1916  CCTTTCTTGGAGTAATAGTGCTTATTTATCCTTGGATGATGATGCTTTCACGGCTCCATT  
1975 
 
Query  252   TCATAGGGATGGAATGCTGAGTTTAAAGCAACTACTGTCTTTTTCTCAGTATCA  305 
             ||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct  1976  TCATAGGGATGGAATGCTGAGTTTAAAGCAACTACTGTCTTTT-CTCAGTATCA  2028 
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WT 77143F BLAST sequence 
 
Range 1: 201 to 878  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
1223 bits(662) 0.0() 675/680(99%) 5/680(0%) Plus/Plus 
 
 
 
Features: 
Query  228  ATGGACGAGCCTCCCGGGAAGCCCCTCAGCTGTGAGGAGAAGGAAAAGTTAAAGGAGAAA 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  201  ATGGACGAGCCTCCCGGGAAGCCCCTCAGCTGTGAGGAGAAGGAAAAGTTAAAGGAGAAA   
 
Query  288  TTAGCATTCTTGAAAAGGGAATACAGCAAGACACTAGCCCGCCTTCAGCGTGCCCAAAGA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  261  TTAGCATTCTTGAAAAGGGAATACAGCAAGACACTAGCCCGCCTTCAGCGTGCCCAAAGA   
 
Query  348  GCTGAAAAGATTAAGCATTCTATTAAGAAAACAGTAGAAGAACAAGATTGTTTGTCTCAG   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321  GCTGAAAAGATTAAGCATTCTATTAAGAAAACAGTAGAAGAACAAGATTGTTTGTCTCAG   
 
Query  408  CAGGATCTCTCACCGCAGCTAAAACACTCAGAACCTAAAAATAAAATATGTGTTTATGAC   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  381  CAGGATCTCTCACCGCAGCTAAAACACTCAGAACCTAAAAATAAAATATGTGTTTATGAC   
 
Query  468  AAGTTACACATCAAAACCCATCTTGATGAAGAAACTGGAGAAAAGACATCTATCACACTT   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  441  AAGTTACACATCAAAACCCATCTTGATGAAGAAACTGGAGAAAAGACATCTATCACACTT   
 
Query  528  GATGTTGGGCCTGAGTCCTTTAACCCTGGAGATGGCCCAGGAGGATTACCTATACAAAGA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  501  GATGTTGGGCCTGAGTCCTTTAACCCTGGAGATGGCCCAGGAGGATTACCTATACAAAGA   
 
Query  588  ACAGATGACACCCAAGAACATTTTCCCCACAGGGTCAGTGACCCTAGTGGTGAGCAAAAG   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  561  ACAGATGACACCCAAGAACATTTTCCCCACAGGGTCAGTGACCCTAGTGGTGAGCAAAAG   
 
Query  648  CAGAAGCTGCCAAGCAGAAGAAAGAAGCAGCAGAAGAGGACATTTATTTCACAGGAGAGA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  621  CAGAAGCTGCCAAGCAGAAGAAAGAAGCAGCAGAAGAGGACATTTATTTCACAGGAGAGA   
 
Query  708  GACTGTGTCTTTGGCACTGATTCACTCAGATTGTCTGGGAAAAGACTAAAGGAACAGGAA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  681  GACTGTGTCTTTGGCACTGATTCACTCAGATTGTCTGGGAAAAGACTAAAGGAACAGGAA   
 
Query  768  GAAATCAGTAGCAAAAATCCTGCTAGATCACCAGTAACTGAAATAAGAACTCACCTTTTA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  741  GAAATCAGTAGCAAAAATCCTGCTAGATCACCAGTAACTGAAATAAGAACTCACCTTTTA   
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X4 77143F BLAST sequence 
 
 
201 to 411  
Score Expect Identities Gaps Strand Frame 
390 bits(211) 5e-107() 211/211(100%) 0/211(0%) Plus/Plus 
 
 
Features: 
Query  245  ATGGACGAGCCTCCCGGGAAGCCCCTCAGCTGTGAGGAGAAGGAAAAGTTAAAGGAGAAA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  201  ATGGACGAGCCTCCCGGGAAGCCCCTCAGCTGTGAGGAGAAGGAAAAGTTAAAGGAGAAA   
 
Query  305  TTAGCATTCTTGAAAAGGGAATACAGCAAGACACTAGCCCGCCTTCAGCGTGCCCAAAGA   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  261  TTAGCATTCTTGAAAAGGGAATACAGCAAGACACTAGCCCGCCTTCAGCGTGCCCAAAGA   
 
Query  365  GCTGAAAAGATTAAGCATTCTATTAAGAAAACAGTAGAAGAACAAGATTGTTTGTCTCAG   
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  321  GCTGAAAAGATTAAGCATTCTATTAAGAAAACAGTAGAAGAACAAGATTGTTTGTCTCAG   
 
 
Query  425  CAGGATCTCTCACCGCAGCTAAAACACTCAG  455 
            ||||||||||||||||||||||||||||||| 
Sbjct  381  CAGGATCTCTCACCGCAGCTAAAACACTCAG  411 
 
 
 
Score Expect Identities Gaps Strand Frame 
568 bits(307) 2e-160() 307/307(100%) 0/307(0%) Plus/Plus 
 
 
Features:  
Query  454   AGGGAAGAAAAGTCGTCATCAAAAAGAGGATTCCCTTTCTTGGAGTAATAGTGCTTATTT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1883  AGGGAAGAAAAGTCGTCATCAAAAAGAGGATTCCCTTTCTTGGAGTAATAGTGCTTATTT   
 
Query  514   ATCCTTGGATGATGATGCTTTCACGGCTCCATTTCATAGGGATGGAATGCTGAGTTTAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1943  ATCCTTGGATGATGATGCTTTCACGGCTCCATTTCATAGGGATGGAATGCTGAGTTTAAA   
 
Query  574   GCAACTACTGTCTTTTCTCAGTATCACAGACTTTCAGTTACCTGATGAAGACTTTGGACC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2003  GCAACTACTGTCTTTTCTCAGTATCACAGACTTTCAGTTACCTGATGAAGACTTTGGACC   
 
Query  634   TCTTAAGCTTGAAAAAGTGAAGTCCTGCTCAGAAAAACCAGTGGAGCCCTTTGAGTCAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2063  TCTTAAGCTTGAAAAAGTGAAGTCCTGCTCAGAAAAACCAGTGGAGCCCTTTGAGTCAAA   
Exon 3 Exon 5 
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Appendix 5 – del/ins electropherogram using primer 1513F 
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Del/ins 1513F BLAST Sequence 
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
508 bits(275) 5e-143() 282/285(99%) 2/285(0%) Plus/Plus 
 
 
 
Features: 
Query  42    AAAG-AAATCAGCCTGCACCCCAGCATCAGATCATTGTGAACCACTTTTGCCAACTTCTA   
             |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1744  AAAGAAAATCAGCCTGCACCCCAGCATCAGATCATTGTGAACCACTTTTGCCAACTTCTA   
 
Query  101   GCCTGTCGATTGTTAACAGGTCCAAGGAAGAAGTCACCTCACACAAATATCAGCACGAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1804  GCCTGTCGATTGTTAACAGGTCCAAGGAAGAAGTCACCTCACACAAATATCAGCACGAAA   
 
Query  161   AATTATTTATTCG-GTGAAAGGGAAGAAAAGTCGTCATCAAAAAGAGGATTCCCTTTCTT   
             ||||||||||||  |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1864  AATTATTTATTCAAGTGAAAGGGAAGAAAAGTCGTCATCAAAAAGAGGATTCCCTTTCTT   
 
Query  220   GGAGTAATAGTGCTTATTTATCCTTGGATGATGATGCTTTCACGGCTCCATTTCATAGGG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1924  GGAGTAATAGTGCTTATTTATCCTTGGATGATGATGCTTTCACGGCTCCATTTCATAGGG   
 
Query  280   ATGGAATGCTGAGTTTAAAGCAACTACTGTCTTTTCTCAGTATCA  324 
             ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1984  ATGGAATGCTGAGTTTAAAGCAACTACTGTCTTTTCTCAGTATCA  2028 
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Appendix 6 – X6 electropherogram using primer 2143F 
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X6 2143F BLAST sequence 
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
638 bits(345) 0.0() 347/348(99%) 0/348(0%) Plus/Plus 
 
 
Features: 
Query  19    TGTATTCACCTGCTTTCCCCATCTTAGGTACTACTCCAGCCTTTGGCCCTCAAGGCTCCT   
             ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2368  TGTGTTCACCTGCTTTCCCCATCTTAGGTACTACTCCAGCCTTTGGCCCTCAAGGCTCCT   
 
Query  79    ATGAAAAAGCATCTACAGAAGTTGCTGGACGAACTTGCTGCACACCCCAACTTGCTCATT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2428  ATGAAAAAGCATCTACAGAAGTTGCTGGACGAACTTGCTGCACACCCCAACTTGCTCATT   
 
Query  139   TGAAAGACTCAGTCTGTCTTGCCAGTGATACTAAACAATTCGACAGTTCAGGCAGCCCAG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2488  TGAAAGACTCAGTCTGTCTTGCCAGTGATACTAAACAATTCGACAGTTCAGGCAGCCCAG   
 
Query  199   CAAAACCACATACCACCCTGCAAGTGTCAGGCAGGCAAGGACAACCTACCTGTGACTGTG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2548  CAAAACCACATACCACCCTGCAAGTGTCAGGCAGGCAAGGACAACCTACCTGTGACTGTG   
 
Query  259   ACTCTGTCCCGCCAGGAACACCTCCACCCATTGAGTCATTCACTTTTAAAGAAAATCAGC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2608  ACTCTGTCCCGCCAGGAACACCTCCACCCATTGAGTCATTCACTTTTAAAGAAAATCAGC   
 
Query  319   TCTGTAGAAACACATGCCAGGAGCTGCATAAACATTCCGTCGAACAGA  366 
             |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2668  TCTGTAGAAACACATGCCAGGAGCTGCATAAACATTCCGTCGAACAGA  2715 
 
 
 
Alignment statistics for match #2 
Score Expect Identities Gaps Strand Frame 
374 bits(202) 4e-102() 202/202(100%) 0/202(0%) Plus/Plus 
 
 
Features: 
Query  364   AGAATCCTTCAGGTTCCTGTTCCGTAGATGTGAGTGCCATGTTTTGGGAAAGAGCCGGTT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2785  AGAATCCTTCAGGTTCCTGTTCCGTAGATGTGAGTGCCATGTTTTGGGAAAGAGCCGGTT   
 
Query  424   GTAAAGAGCCATGTATCATAACTGCTTGCGAAGATGTAGTTTCTCTTTGGAAAGCTCTGG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2845  GTAAAGAGCCATGTATCATAACTGCTTGCGAAGATGTAGTTTCTCTTTGGAAAGCTCTGG   
 
Query  484   ATGCTTGGCAGTGGGAAAAACTTTATACCTGGCACTTCGCAGAGGTTCCAGTATTACAGA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2905  ATGCTTGGCAGTGGGAAAAACTTTATACCTGGCACTTCGCAGAGGTTCCAGTATTACAGA   
 
Query  544   TAGTTCCAGTGCCTGATGTGTA  565 
             |||||||||||||||||||||| 
Sbjct  2965  TAGTTCCAGTGCCTGATGTGTA  2986 
Exon 5 Exon 7 
Exon 5 Exon 7 
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Appendix 7 – Y551X electropherogram using primer 1513F 
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Y551X 1513F BLAST Sequence 
 
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
520 bits(281) 2e-146() 293/298(98%) 4/298(1%) Plus/Plus 
 
 
Features: 
Query  12    AGAT-CACAGG--AAAG-AAATCAGCCTGCACCCCAGCATCAGATCATTGTGAACCACTT   
             |||| ||||||  |||| |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1731  AGATACACAGGAAAAAGAAAATCAGCCTGCACCCCAGCATCAGATCATTGTGAACCACTT  
1790 
 
Query  68    TTGCCAACTTCTAGCCTGTCGATTGTTAACAGGTCCAAGGAAGAAGTCACCTCACACAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1791  TTGCCAACTTCTAGCCTGTCGATTGTTAACAGGTCCAAGGAAGAAGTCACCTCACACAAA   
 
Query  128   TAACAGCACGAAAAATTATTTATTCAAGTGAAAGGGAAGAAAAGTCGTCATCAAAAAGAG   
             || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1851  TATCAGCACGAAAAATTATTTATTCAAGTGAAAGGGAAGAAAAGTCGTCATCAAAAAGAG  
1910 
 
Query  188   GATTCCCTTTCTTGGAGTAATAGTGCTTATTTATCCTTGGATGATGATGCTTTCACGGCT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1911  GATTCCCTTTCTTGGAGTAATAGTGCTTATTTATCCTTGGATGATGATGCTTTCACGGCT  
1970 
 
Query  248   CCATTTCATAGGGATGGAATGCTGAGTTTAAAGCAACTACTGTCTTTTCTCAGTATCA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1971  CCATTTCATAGGGATGGAATGCTGAGTTTAAAGCAACTACTGTCTTTTCTCAGTATCA  
2028 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exon 4 
Exon 5 
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Appendix 8 - Primer pair 1513F/1803R within the PALB2 sequence.  
 
Sequence also shows in bold where each mutation lies within the amplicon.  
 
The each exon is separated with an underline. 
 
atggacgagcctcccgggaagcccctcagctgtgaggagaaggaaaagttaaaggagaaattagcattcttgaaa
agggaatacagcaagacactagcccgccttcagcgtgcccaaagagctgaaaagattaagcattctattaagaaa
acagtagaagaacaagattgtttgtctcagcaggatctctcaccgcagctaaaacactcagaacctaaaaataaa
atatgtgtttatgacaagttacacatcaaaacccatcttgatgaagaaactggagaaaagacatctatcacactt
gatgttgggcctgagtcctttaaccctggagatggcccaggaggattacctatacaaagaacagatgacacccaa
gaacattttccccacagggtcagtgaccctagtggtgagcaaaagcagaagctgccaagcagaagaaagaagcag
cagaagaggacatttatttcacaggagagagactgtgtctttggcactgattcactcagattgtctgggaaaaga
ctaaaggaacaggaagaaatcagtagcaaaaatcctgctagatcaccagtaactgaaataagaactcacctttta
agtcttaaatctgaacttccagattctccagaaccagttacagaaattaatgaagacagtgtattaattccacca
actgcccaaccagaaaaaggtgttgatacattcctaagaagacctaatttcaccagggcgactacagttccttta
cagactctatcagatagcggtagtagtcagcaccttgaacacattcctcctaaaggtagcagtgaacttactact
cacgacctaaaaaacattagatttacttcacctgtaagtttggaggcacaaggcaaaaaaatgactgtctctaca
gataacctccttgtaaataaagctataagtaaaagtggccaactgcccacaagttctaatttagaggcaaatatt
tcatgttctctaaatgaactcacctacaataacttaccagcaaatgaaaaccaaaacttaaaagaacaaaatcaa
acagagaaatctttaaaatctcccagtgacactcttgatggcaggaatgaaaatcttcaggaaagtgagattcta
agtcaacctaagagtcttagcctggaagcaacctctcctctttctgcagaaaaacattcttgcacagtgcctgaa
ggccttctgtttcctgcagaatattatgttagaacaacacgaagcatgtccaattgccagaggaaagtagccgtg
gaggctgtcattcagagtcatttggatgtcaagaaaaaagggtttaaaaataaaaataaggatgcaagtaaaaat
ttaaacctttccaatgaggaaactgaccaaagtgaaattaggatgtctggcacatgcacaggacaaccaagttca
agaacctctcagaaacttctctcattaactaaagtcagctctcccgctgggcccactgaagataatgacttgtct
aggaaggcagttgcccaagcacctggtagaagatacacaggaaaaagaaaatcagcctgcaccccagcatcagat
cattgtgaaccacttttgccaacttctagcctgtcgattgttaacaggtccaaggaagaagtcacctcacacaaa
tatcagcacgaaaaattatttattc[aa/g]gtgaaagggaagaaaagtcgtcatcaaaaagaggattccctttc
ttggagtaatagtgcttatttatccttggatgatgatgctttcacggctccatttcatagggatggaatgctgag
tttaaagcaactactgtcttttctcagtatcacagactttcagttacctgatgaagactttggacctcttaagct
tgaaaaagtgaagtcctgctcagaaaaaccagtggagccctttgagtcaaaaatgtttggagagagacatcttaa
agagggaagctgtatttttccagaggaactgagtcctaaacgcatggatacagaaatggaggacttagaagagga
ccttattgttctaccaggaaaatcacatcccaaaaggccaaactcgcaaagccagcatacaaagacgggcctttc
ttcatccatattactttatactcctttaaatacggttgcgcctgatgataatgacaggcctaccacagacatgtg
ttcacctgctttccccatcttaggtactactccagcctttggccctcaaggctcctatgaaaaagcatctacaga
agttgctggacgaacttgctgcacaccccaacttgctcatttgaaagactcagtctgtcttgccagtgatactaa
acaattcgacagttcaggcagcccagcaaaaccacataccaccctgcaagtgtcaggcaggcaaggacaacctac
ctgtgactgtgactctgtcccgccaggaacacctccacccattgagtcattcacttttaaagaaaatcagctctg
tagaaacacatgccaggagctgcataaacattccgtcgaacagactgaaacagcagagcttcctgcttctgatag
cataaacccaggcaacctacaattggtttcagagttaaagaatccttcaggttcctgttccgtagatgtgagtgc
catgttttgggaaagagccggttgtaaagagccatgtatcataactgcttgcgaagatgtagtttctctttggaa
agctctggatgcttggcagtgggaaaaactttatacctggcacttcgcagaggttccagtattacagatagttcc
agtgcctgatgtgtataatctcgtgtgtgtagctttgggaaatttggaaatcagagagatcagggcattgttttg
ttcctctgatgatgaaagtgaaaagcaagtactactgaagtctggaaatataaaagctgtgcttggcctgacaaa
gaggaggctagttagtagcagtgggaccctttctgatcaacaagtagaagtcatgacgtttgcagaagatggagg
aggcaaagaaaaccaatttttgatgccccctgaggagactatactaacttttgctgaggtccaagggatgcaaga
agctctgcttggtactactattatgaacaacattgttatttggaatttaaaaactggtcaactcctgaaaaagat
gcacattgatgattcttaccaagcttcagtctgtcacaaagcctattctgaaatggggcttctctttattgtcct
gagtcatccctgtgccaaagagagtgagtcgttgcgaagccctgtgtttcagctcattgtgattaaccctaagac
gactctcagcgtgggtgtgatgctgtactgtcttcctccagggcaggctggcaggttcctggaaggtgacgtgaa
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agatcactgtgcagcagcaatcttgacttctggaacaattgccatttgggacttacttctcggtcagtgtactgc
cctcctcccacctgtctctgaccaacattggtcttttgtgaaatggtcgggtacagactctcatttgctggctgg
acaaaaagatggaaatatatttgtataccactattcataagttagggtaaagtgaaaacacaattttctggatat
attgggcctcttagtattttttggagttttaaatataaaggagaatatctgaatgacacttaaaatgattgcttg
tttatgtccagacagacttattttttattctaatgatggtagcaccactgatcttggatgtacatttatgtatac
tttgagaaaaagggttttaggttgatttttgtaatttcccacatttgtacatgtgcttttaaaggtgtacataaa
gcttcaaatggcaataaatatttatttttatacattcaaaaaaaaaaa 
 
 
 
Forward Primer:    C T T G T C T A G G A A G G C A G T T G 
 
 
Reverse Primer:    T T T A A A C T C A G C A T T C C A T C C  
 
 
 
 
 
Total sequence length: 313 bp 
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Appendix 9 - Primer pair 2413/2763R within the PALB2 sequence.  
 
The each exon is separated with an underline. 
 
gcaggccgaatggtggatttaattggccggagtttagggcgcgcttggcccgcgtgggtcagctgatcgcgcact
gagggtgcgatcccgggctccccattccttcctggggcgcctccccggcccagggccaactgggtcccggtgtcg
gcaggcctggggtcggcgacggctgctcttttcgttctgtcgcctgcccgatggacgagcctcccgggaagcccc
tcagctgtgaggagaaggaaaagttaaaggagaaattagcattcttgaaaagggaatacagcaagacactagccc
gccttcagcgtgcccaaagagctgaaaagattaagcattctattaagaaaacagtagaagaacaagattgtttgt
ctcagcaggatctctcaccgcagctaaaacactcagaacctaaaaataaaatatgtgtttatgacaagttacaca
tcaaaacccatcttgatgaagaaactggagaaaagacatctatcacacttgatgttgggcctgagtcctttaacc
ctggagatggcccaggaggattacctatacaaagaacagatgacacccaagaacattttccccacagggtcagtg
accctagtggtgagcaaaagcagaagctgccaagcagaagaaagaagcagcagaagaggacatttatttcacagg
agagagactgtgtctttggcactgattcactcagattgtctgggaaaagactaaaggaacaggaagaaatcagta
gcaaaaatcctgctagatcaccagtaactgaaataagaactcaccttttaagtcttaaatctgaacttccagatt
ctccagaaccagttacagaaattaatgaagacagtgtattaattccaccaactgcccaaccagaaaaaggtgttg
atacattcctaagaagacctaatttcaccagggcgactacagttcctttacagactctatcagatagcggtagta
gtcagcaccttgaacacattcctcctaaaggtagcagtgaacttactactcacgacctaaaaaacattagattta
cttcacctgtaagtttggaggcacaaggcaaaaaaatgactgtctctacagataacctccttgtaaataaagcta
taagtaaaagtggccaactgcccacaagttctaatttagaggcaaatatttcatgttctctaaatgaactcacct
acaataacttaccagcaaatgaaaaccaaaacttaaaagaacaaaatcaaacagagaaatctttaaaatctccca
gtgacactcttgatggcaggaatgaaaatcttcaggaaagtgagattctaagtcaacctaagagtcttagcctgg
aagcaacctctcctctttctgcagaaaaacattcttgcacagtgcctgaaggccttctgtttcctgcagaatatt
atgttagaacaacacgaagcatgtccaattgccagaggaaagtagccgtggaggctgtcattcagagtcatttgg
atgtcaagaaaaaagggtttaaaaataaaaataaggatgcaagtaaaaatttaaacctttccaatgaggaaactg
accaaagtgaaattaggatgtctggcacatgcacaggacaaccaagttcaagaacctctcagaaacttctctcat
taactaaagtcagctctcccgctgggcccactgaagataatgacttgtctaggaaggcagttgcccaagcacctg
gtagaagatacacaggaaaaagaaaatcagcctgcaccccagcatcagatcattgtgaaccacttttgccaactt
ctagcctgtcgattgttaacaggtccaaggaagaagtcacctcacacaaatatcagcacgaaaaattatttattc
aagtgaaagggaagaaaagtcgtcatcaaaaagaggattccctttcttggagtaatagtgcttatttatccttgg
atgatgatgctttcacggctccatttcatagggatggaatgctgagtttaaagcaactactgtcttttctcagta
tcacagactttcagttacctgatgaagactttggacctcttaagcttgaaaaagtgaagtcctgctcagaaaaac
cagtggagccctttgagtcaaaaatgtttggagagagacatcttaaagagggaagctgtatttttccagaggaac
tgagtcctaaacgcatggatacagaaatggaggacttagaagaggaccttattgttctaccaggaaaatcacatc
ccaaaaggccaaactcgcaaagccagcatacaaagacgggcctttcttcatccatattactttatactcctttaa
atacggttgcgcctgatgataatgacaggcctaccacagacatgtgttcacctgctttccccatcttaggtacta
ctccagcctttggccctcaaggctcctatgaaaaagcatctacagaagttgctggacgaacttgctgcacacccc
aacttgctcatttgaaagactcagtctgtcttgccagtgatactaaacaattcgacagttcaggcagcccagcaa
aaccacataccaccctgcaagtgtcaggcaggcaaggacaacctacctgtgactgtgactctgtcccgccaggaa
cacctccacccattgagtcattcacttttaaagaaaatcagctctgtagaaacacatgccaggagctgcataaac
attccgtcgaacag[actgaaacagcagagcttcctgcttctgatagcataaacccaggcaacctacaattggtt
tcagagttaaag]aatccttcaggttcctgttccgtagatgtgagtgccatgttttgggaaagagccggttgtaa
agagccatgtatcataactgcttgcgaagatgtagtttctctttggaaagctctggatgcttggcagtgggaaaa
actttatacctggcacttcgcagaggttccagtattacagatagttccagtgcctgatgtgtataatctcgtgtg
tgtagctttgggaaatttggaaatcagagagatcagggcattgttttgttcctctgatgatgaaagtgaaaagca
agtactactgaagtctggaaatataaaagctgtgcttggcctgacaaagaggaggctagttagtagcagtgggac
cctttctgatcaacaagtagaagtcatgacgtttgcagaagatggaggaggcaaagaaaaccaatttttgatgcc
ccctgaggagactatactaacttttgctgaggtccaagggatgcaagaagctctgcttggtactactattatgaa
caacattgttatttggaatttaaaaactggtcaactcctgaaaaagatgcacattgatgattcttaccaagcttc
agtctgtcacaaagcctattctgaaatggggcttctctttattgtcctgagtcatccctgtgccaaagagagtga
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gtcgttgcgaagccctgtgtttcagctcattgtgattaaccctaagacgactctcagcgtgggtgtgatgctgta
ctgtcttcctccagggcaggctggcaggttcctggaaggtgacgtgaaagatcactgtgcagcagcaatcttgac
ttctggaacaattgccatttgggacttacttctcggtcagtgtactgccctcctcccacctgtctctgaccaaca
ttggtcttttgtgaaatggtcgggtacagactctcatttgctggctggacaaaaagatggaaatatatttgtata
ccactattcataagttagggtaaagtgaaaacacaattttctggatatattgggcctcttagtattttttggagt
tttaaatataaaggagaatatctgaatgacacttaaaatgattgcttgtttatgtccagacagacttatttttta
ttctaatgatggtagcaccactgatcttggatgtacatttatgtatactttgagaaaaagggttttaggttgatt
tttgtaatttcccacatttgtacatgtgcttttaaaggtgtacataaagcttcaaatggcaataaatatttattt
ttatacattcaaaaaaaaaaa 
 
 
Forward Primer:    C T T T A A A T A C G G T T G C G C C T G A T G 
 
Reverse Primer:    C T A T C A A G G T C A C G G A C T A C A 
 
Total sequence length: 664bp 
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Appendix 10 - Primer pair 77143F/1975R within the PALB2 sequence 
The each exon is separated with an underline. The region 
identified by capital letters is a sequence added by the 
77143F primer containing restriction enzymes EcoRI and AscI. 
gcaggccgaatggtggatttaattggccggagtttagggcgcgcttggcccgcgtgggtcagctgatcgcgcact
gagggtgcgatcccgggctccccattccttcctggggcgcctccccggcccagggccaactgggtcccggtgtcg
gcaggcctggggtcggcgacggctgctcttttcgttctgtcgcctgcccgGTTGTTGAATTCGGCGCGCCA
atggacgagcctcccgggaagcccctcagctgtgaggagaaggaaaagttaaaggagaaattagcattcttgaaa
agggaatacagcaagacactagcccgccttcagcgtgcccaaagagctgaaaagattaagcattctattaagaaa
acagtagaagaacaagattgtttgtctcagcaggatctctcaccgcagctaaaacactcagaacctaaaaataaa
atatgtgtttatgacaagttacacatcaaaacccatcttgatgaagaaactggagaaaagacatctatcacactt
gatgttgggcctgagtcctttaaccctggagatggcccaggaggattacctatacaaagaacagatgacacccaa
gaacattttccccacagggtcagtgaccctagtggtgagcaaaagcagaagctgccaagcagaagaaagaagcag
cagaagaggacatttatttcacaggagagagactgtgtctttggcactgattcactcagattgtctgggaaaaga
ctaaaggaacaggaagaaatcagtagcaaaaatcctgctagatcaccagtaactgaaataagaactcacctttta
agtcttaaatctgaacttccagattctccagaaccagttacagaaattaatgaagacagtgtattaattccacca
actgcccaaccagaaaaaggtgttgatacattcctaagaagacctaatttcaccagggcgactacagttccttta
cagactctatcagatagcggtagtagtcagcaccttgaacacattcctcctaaaggtagcagtgaacttactact
cacgacctaaaaaacattagatttacttcacctgtaagtttggaggcacaaggcaaaaaaatgactgtctctaca
gataacctccttgtaaataaagctataagtaaaagtggccaactgcccacaagttctaatttagaggcaaatatt
tcatgttctctaaatgaactcacctacaataacttaccagcaaatgaaaaccaaaacttaaaagaacaaaatcaa
acagagaaatctttaaaatctcccagtgacactcttgatggcaggaatgaaaatcttcaggaaagtgagattcta
agtcaacctaagagtcttagcctggaagcaacctctcctctttctgcagaaaaacattcttgcacagtgcctgaa
ggccttctgtttcctgcagaatattatgttagaacaacacgaagcatgtccaattgccagaggaaagtagccgtg
gaggctgtcattcagagtcatttggatgtcaagaaaaaagggtttaaaaataaaaataaggatgcaagtaaaaat
ttaaacctttccaatgaggaaactgaccaaagtgaaattaggatgtctggcacatgcacaggacaaccaagttca
agaacctctcagaaacttctctcattaactaaagtcagctctcccgctgggcccactgaagataatgacttgtct
aggaaggcagttgcccaagcacctggtagaagatacacaggaaaaagaaaatcagcctgcaccccagcatcagat
cattgtgaaccacttttgccaacttctagcctgtcgattgttaacaggtccaaggaagaagtcacctcacacaaa
tatcagcacgaaaaattatttattcaagtgaaagggaagaaaagtcgtcatcaaaaagaggattccctttcttgg
agtaatagtgcttatttatccttggatgatgatgctttcacggctccatttcatagggatggaatgctgagttta
aagcaactactgtcttttctcagtatcacagactttcagttacctgatgaagactttggacctcttaagcttgaa
aaagtgaagtcctgctcagaaaaaccagtggagccctttgagtcaaaaatgtttggagagagacatcttaaagag
ggaagctgtatttttccagaggaactgagtcctaaacgcatggatacagaaatggaggacttagaagaggacctt
attgttctaccaggaaaatcacatcccaaaaggccaaactcgcaaagccagcatacaaagacgggcctttcttca
tccatattactttatactcctttaaatacggttgcgcctgatgataatgacaggcctaccacagacatgtgttca
cctgctttccccatcttaggtactactccagcctttggccctcaaggctcctatgaaaaagcatctacagaagtt
gctggacgaacttgctgcacaccccaacttgctcatttgaaagactcagtctgtcttgccagtgatactaaacaa
ttcgacagttcaggcagcccagcaaaaccacataccaccctgcaagtgtcaggcaggcaaggacaacctacctgt
gactgtgactctgtcccgccaggaacacctccacccattgagtcattcacttttaaagaaaatcagctctgtaga
aacacatgccaggagctgcataaacattccgtcgaacagactgaaacagcagagcttcctgcttctgatagcata
aacccaggcaacctacaattggtttcagagttaaagaatccttcaggttcctgttccgtagatgtgagtgccatg
ttttgggaaagagccggttgtaaagagccatgtatcataactgcttgcgaagatgtagtttctctttggaaagct
ctggatgcttggcagtgggaaaaactttatacctggcacttcgcagaggttccagtattacagatagttccagtg
cctgatgtgtataatctcgtgtgtgtagctttgggaaatttggaaatcagagagatcagggcattgttttgttcc
tctgatgatgaaagtgaaaagcaagtactactgaagtctggaaatataaaagctgtgcttggcctgacaaagagg
aggctagttagtagcagtgggaccctttctgatcaacaagtagaagtcatgacgtttgcagaagatggaggaggc
aaagaaaaccaatttttgatgccccctgaggagactatactaacttttgctgaggtccaagggatgcaagaagct
ctgcttggtactactattatgaacaacattgttatttggaatttaaaaactggtcaactcctgaaaaagatgcac
attgatgattcttaccaagcttcagtctgtcacaaagcctattctgaaatggggcttctctttattgtcctgagt
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catccctgtgccaaagagagtgagtcgttgcgaagccctgtgtttcagctcattgtgattaaccctaagacgact
ctcagcgtgggtgtgatgctgtactgtcttcctccagggcaggctggcaggttcctggaaggtgacgtgaaagat
cactgtgcagcagcaatcttgacttctggaacaattgccatttgggacttacttctcggtcagtgtactgccctc
ctcccacctgtctctgaccaacattggtcttttgtgaaatggtcgggtacagactctcatttgctggctggacaa
aaagatggaaatatatttgtataccactattcataagttagggtaaagtgaaaacacaattttctggatatattg
ggcctcttagtattttttggagttttaaatataaaggagaatatctgaatgacacttaaaatgattgcttgttta
tgtccagacagacttattttttattctaatgatggtagcaccactgatcttggatgtacatttatgtatactttg
agaaaaagggttttaggttgatttttgtaatttcccacatttgtacatgtgcttttaaaggtgtacataaagctt
caaatggcaataaatatttatttttatacattcaaaaaaaaaaa 
 
Forward Primer:  
G T T G T T G A A T T C G G C G C G C C A A T G G A C G A G C 
C T C C C G G G A A G C 
 
 
Reverse Primer:G A C T C A G G A T T T G C G T A C C T A T G T  
 
 
 
 
 
Fragment length: 2019 bp 
 
 
 
 
 
 
 
 
 
